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 Due to the aggregated impact of rising chronic disease prevalence and increasing 
demand for better quality of health care, disease management has been increasingly 
emphasized across Asia to achieve optimal health outcomes at affordable 
expenditures. In order to ensure that disease management programs are realizing their 
value-adding capacities to health care systems, it is essential to apply economic 
evaluations like cost-utility analysis (CUA) as a decision making tool to improve 
resource allocation and optimization.  
Currently, the number of high-quality CUA studies in this region is quite limited 
compared to that in Western countries; and, direct CUA result generalization from 
Western studies could not be substantiated due to differences in socio-cultural, socio-
economic, and various other factors. Hence, in order to reduce the need to replicate 
CUA performed in western countries, it is necessary to identify the factors influencing 
the generalization of CUA to ensure its role in assessing efficiency of disease 
management programs in Asian countries.   
Within this framework, this thesis is organized to achieve the following 
objectives:  
• To evaluate whether there is any linguistic or cultural barrier in the adaptation of 
an English health-related quality of life (HRQoL) or utility instrument into a non-
English version, as this may influence the results of CUA analyses which require a 
HRQoL instrument. 
•  To review the factors found to influence the application, and hence its 
generalization of CUA in the published literature.  
• To explore other new factors that may potentially influence the application of 
CUA of disease management programs in Asia. 
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      The performed studies revealed the following findings:  
• First, minor linguistic and cultural differences did exist between original English 
version and the translated Chinese version. More importantly, we demonstrated 
that it was essential to adopt the universalist approach to ensure all important 
equivalences, namely, conceptual, item, semantic, operational, measurement and 
functional equivalences were all sequentially and adequately demonstrated during 
the adaptation process.  
• Second, we identified altogether 20 factors from the published literature, which 
could be used as a reference list by Asian researchers and decision-makers when 
conducting or adopting CUA analyses.  These factors could be further grouped 
into five categories as treatment-related (duration, efficacy, and frequency), 
disease-related (severity level, risk level, incidence rate, prevalence rate, disease 
progression rate and survival length), patient-related (age, gender, race/ethnicity 
and compliance), cost-related (treatment cost variation, incorporation of indirect 
cost), and methodology-related factors (discount rate, QALY elicitation method, 
statistical uncertainty, handling of confounding variables and reliability of data 
source). 
• Third, health psychology-related factors such as response shift and expectancy-
value could significantly influence the measurement of HRQoL and utility values, 
thus impacting CUA results. Comparatively, patient empowerment-related factors 
such as health literacy and disease knowledge had minimal impact on these values. 
We also developed and validated two new scales (the generic functional health 
literacy test and patient's trust in pharmacists scale), which demonstrated high 
reliability and good construct validity. Their impact on CUA would need further 
investigation.  
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In conclusion, we would suggest that if impossible or infeasible to replicate CUA 
performed in Western countries in an Asian environment, the decision makers need to 
consider the potential impact of at least the factors we identified when adopting CUA 
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1.1 What is disease management? 
With the ultimate aim to improve the quality of healthcare delivery, disease 
management is a knowledge-based integrative process intended to continuously 
maximize the effectiveness of health care delivery at lowest possible expenditures 
from the perspectives of those who receive, purchase, provide, supply and evaluate it 
(Couch, 1998; Fritzner et al., Quality and Research Committee, Disease Management 
Association of America, 2004). In the new millennium, disease management has been 
increasingly emphasized due to the high prevalence rate of chronic diseases, the 
pressure of cost containment and the need to improve quality of health care (Fritzner 
et al., 2004; Fernandes, 2002; Ofman et al., 2004). In Asia, as projected by the United 
Nations in 2001, the aging population (i.e., the number of people aged 65 and above) 
in this region will increase by 314 percent, from 207 million in 2000 to 857 million in 
2050 (United Nations, 2001). Such a dramatic increase in aging population has been 
shown to exert ever increasing health and economic burdens on the health care 
systems across Asia (World Health Organization, 2007).  This phenomenon has forced 
reconsideration about the mode of health care delivery to ensure that acceptable health 
outcomes can be achieved with affordable expenditure. 
 
Previously, health care was delivered in a so-called “component management 
system”, which often led to increased total treatment cost without the expected 
improvement in patient outcomes (Todd et al., 1997). Comparatively, in the system of 
disease management, patients themselves together with other various stakeholders 
(e.g., policy makers, purchasers, payers, providers, practitioners and product 
producers, etc.) are included in the value chain of health care delivery with the aims to 
optimize clinical, economic, humanistic (including quality of life and satisfaction) 
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outcomes at the lowest possible expenditure (Couch, 1998).  This represents a shift 
from the “piece-meal” approach of health care delivery by individual providers to a 
more coordinated and streamlined approach aiming to achieve an outcome agreed by 
all stakeholders. Therefore, the sustainable success of disease management requires 
refined evidence-based practice guidelines for practitioners, enhanced capability of 
self-management of patients, valid and reliable outcomes measures by researchers and 
robust decision-making models for policy makers.  
 
A comparison of the processes of implementing disease management shows that 
the advocates of disease management approach of health care delivery have borrowed 
the practices and concepts of total quality management from the business world and 
applied it to health care with the focus on outcome-based care (Gilmour et al., 1995; 
Rall et al., 1997; Grol, 2000). As such, the disease management approach also 
incorporates a feedback loop mechanism to complete the quality improvement cycle 
known as “Plan-Do-Check-Act” (PDCA) cycle (Figure 1.1). In the Plan-Do-Check-
Act loop, assessing disease management could be considered as the procedure of 
“Check”. Therefore, the assessment of disease management not only answers whether 



















   
 
 
1.2 How to assess disease management?  
       Despite the theoretical benefits of disease management approach over the 
traditional mode of health care delivery, any disease management program needs to be 
evaluated to ascertain whether it is realizing its value adding capacity to the health 
care system. Disease management could be assessed by three major categories of 
indicators, namely, structure, process and outcomes indicators (Donabedian, 1966). As 
defined, structure indicators are used to examine physical and organizational 
properties of health care settings. Process indicators reflect what and how well disease 
management is executed. Outcomes indicators are applied to show the end results of 
disease management, such as changes in health status, life expectancy, health-related 
quality of life (HRQoL) and health care costs (Donabedian, 1980). 
 
        Theoretically, outcomes indicators have been regarded as the most 
comprehensive and representative indicators of the three types. It has been argued that 
outcomes indicators could directly evaluate the efficiency of disease management 
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programs, in terms of cost and effectiveness. If designed properly, they are able to 
reflect all aspects of structure and process, including those that are not measurable or 
have not been measured yet (Steuten et al., 2006). 
 
 However, in reality, it has been found that process indicators were predominantly 
chosen to assess efficiency of disease management programs, which should have been 
properly co-examined by outcomes indicators (Mant, 2001). Such phenomenon could 
be due to the reason that processes are generally easier to measure than outcomes 
because measuring outcomes requires development and application of new 
instruments/methods and it usually takes much more time and efforts (Donaldson et 
al., 2004; Bratzler et al., 2007). Furthermore, outcomes especially from patients’ 
perspectives have not been assessed in a holistic approach, which may lead to 
potential misinterpretation of the efficiency of a disease management program 
(Steuten et al., 2006; Ritterband, 2000). 
 
       In order to ensure that disease management programs deliver the best outcomes 
with minimal economic resources, that is, to achieve efficiency in delivery, it is 
necessary for decision makers to apply systematic economic evaluations to appraise 
both costs and benefits in a balanced way with no outcome being maximized to the 
detriment of the other (Gunter, 1999). Based on the guideline issued by the Disease 
Management Association of America (DMAA) on the "principles of assessing disease 
management outcomes", it was emphasized that all three types of outcomes, namely, 
economic, clinical and humanistic outcomes should be evaluated in the assessment of 
disease management Fritzner et al., Quality and Research Committee, Disease 
Management Association of America, 2004). One of the most comprehensive 
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approaches proposed to evaluate outcomes in disease management has been known as 
ECHO model, which stands for a model evaluating economic, clinical and humanistic 
outcomes (Reeder, 1995; Gunter, 1999; Kemp, 2006). Clinical outcomes measure the 
end-points of medical events that occur as a result of disease or treatment and have 
been used routinely without any controversy in health care settings. Economic 
outcomes refer to direct, indirect and intangible costs associated with the 
consequences of medical treatment alternatives or preventions.  In the age of cost 
containment in the realization that resource available for health care is limited, the 
inclusion of economic outcomes in the assessment of a disease management program 
is deemed necessary to address the concern of accountability.  Humanistic outcomes 
are consequences of disease or treatment on patient’s functional status or quality of 
life (e.g. physical functioning, social functioning, general health and well-being, and 
life satisfaction). Additionally, satisfaction with health care services and results of 
treatment were also an integral part of humanistic outcomes. Comparatively, this is a 
newer concept of outcome indicator used in measuring the efficiency of a disease 
management program. Nevertheless, considering that the health care delivery 
occurring in any disease management program can be conceptualized as a humanistic 
exchange between the providers and the receivers (patients in this case), it would be 
logical to include the impact from the perspective of the receiver. Hence, the ECHO 
model of assessing outcomes in disease management has been gaining increasing 
acceptance since its proposal.   
 
Since the adoption of ECHO model, apart from continuous efforts in seeking 
better clinical indicators, there have been increasing research endeavors in the 
development and validation of patient-reported outcome measures (e.g. HRQoL, 
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functioning and satisfaction measures) to evaluate humanistic outcomes, which could 
further contribute to the accurate assessment of either benefit or effectiveness in 
economic evaluations (Kind, 2001; Korolija, 2007).  
 
The other equally important issue in the application of ECHO model to assess 
disease management is to enhance the robustness of economic modeling, which has 
been heavily pursued by developing and refining guidelines, consolidating individual 
approaches, and seeking appropriate application of these approaches for various 
purposes (Fleurence et al., 2007; Mason et al., 2006; Inadomi, 2004; Siegel et al., 
1997).   
 
       Nevertheless, for a brief summing up, the outcome indicators from the ECHO 
model are being increasingly used in economic evaluation of disease management 
program worldwide and signify a philosophical shift in assess efficiency of health 
care delivery. 
 
1.3 What is the role of cost-utility analysis (CUA) in assessing disease 
management?  
      Currently, there are altogether four basic economic evaluations used to assess 
disease management programs, namely, cost-minimization analysis (CMA), cost-
benefit analysis (CBA), cost-effective analysis (CEA) and cost-utility analysis (CUA) 
(Johannesson,1996). Collectively speaking, all of these four economic evaluations 
generate results by comparing both the cost and health outcomes of two or more 
interventions using one formula, with difference in costs presented in the nominator 
and difference in health outcomes in the denominator.  
 8
       As shown in Table 1.1, the four economic analyses share one commonality, that is, 
to measure costs in monetary value. Except for CMA which assumes the health 
outcomes to be the same and thus requires no measurement, all the other three types 
of economic evaluations measure health outcomes in different ways. CBA measures 
health outcomes in monetary value, which has generated argument that it is 
inappropriate and difficult to place a dollar value on human life. Comparatively, both 
CEA and CUA measure benefits in non-monetary units such as quantity or quality of 
life, which are more acceptable and make clinical sense in the assessment of health 
care (Muenning, 2002).  
 
Table 1.1  The four basic economic analyses to assess disease management programs 
 
Type of analysis Costs Outcomes Comments 
Cost Benefit 
Analysis (CBA)  
In monetary units In monetary terms Less commonly used as it 
is difficult to quantify 




Analysis (CMA)  
In monetary units Assuming 
equivalence in 
outcomes 
To identify the cheapest 
program when the 
outcomes are assumed to 




In monetary units In physical or 
natural units 
Mainly used to compare 











       However, more specifically, the unit of health outcome measures also differs 
between CUA and CEA, whereby CUA measures health outcomes in utility-weighted 
life years and computes a cost per utility-measure ratio for comparisons across 
different interventions (Gerard, 1992). Consequently, CUA has been recommended as 
the preferred form of reporting health economic evaluation results by the Panel on 
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Cost-Effectiveness in Health and Medicine (Siegel et al., 1996).  
       
       In CUA, the utility-weighted life years could be either calculated as Quality-
Adjusted Life Years (QALYs) or Disability-Adjusted Life Years (DALYs) (Gold, 2002; 
Torrance, 1997; Sassi, 2006). 
 
       Congruent with the purpose of maximizing allocative efficiency in disease 
management, the use of such a standardized index in CUA would allow not only 
comparison of cost-effectiveness among interventions for the same disease or 
condition, but also comparison across interventions for different diseases or cost-
effectiveness of different health service programs. This is a distinct advantage over 
the use of CEA where the major concern would be that of technical efficiency.   
 
        Regarding the standard index commonly used in CUA, besides quantity of life 
(life expectancy), QALYs also incorporate quality of life (health utilities), which has 
been shown to be a very useful and important humanistic endpoint to assess the 
effectiveness of treatment, particularly in chronic diseases where mortality is not the 
major issue or when the primary purpose of the intervention is palliative rather than 
curative (Burger, 2003; Merhrez et al., 1989; Raisch, 2000). Health utilities could be 
either elicited by direct measurement using Time Trade-Off (TTO), Standard Gamble 
(SG) and Rating Scale (RS) (Morimoto et al., 2002), or by indirect measurement 
using utility-based Health-related Quality of Life (HRQoL) instruments such as SF-
6D (Brazier et al., 2002), EQ-5D (The EuroQol Group, 1990), Health Utilities Index 
Mark 2 (HUI2) (Torrance et al., 2002) and Mark3 (HUI3) (Feeny et al., 2002).  
 
 10
        In comparison, DALYs can be viewed as a form of unequally weighted QALYs, 
which assign different weights to different age groups when quantifying the burden of 
disease (Murray, 1994). Yet, all other non-health characteristics of an individual are 
arbitrarily ignored, which is based on Murray and Acharya’s ethical principle that all 
other factors should play no part in deciding health care priorities (Murray, 1997). 
Due to the increased complexity in DALYs calculations and widely challenged 
conceptual and technical soundness, DALYs are much less adopted than QALYs as a 
standardized form to measure benefits in CUA (Fox-Rushby, 2001), but used more 
commonly in assessment of burden of illness. 
 
          Hence, this near univocal acceptance of QALY as the outcome indicator in 
CUA should promote the application of CUA in evaluating disease management at 
least theoretically. 
  
1.4 Why explore factors influencing the application of CUA to assess disease 
management among Asian patients?  
       Despite heterogeneities, health care systems across Asia are facing unprecedented 
and unparalleled increase in health care expenditure, due to the aggregated impact of 
rapid growth in aging population, rising prevalence in chronic diseases and increasing 
demand of better quality of health care (Clark, 2004; Cheah, 2001; East West Center, 
2002). For most of the countries in the region (as shown in Table 1.2), although the 
total expenditure on health as percentage of Gross domestic product (GDP) is seen to 
be more or less stable, yet when GDP growth is factored in, the per capita total 
expenditure on health is found to be subject to continual growth at relatively high 
rates (World Health Organization, 2007). With the rapidly ageing of populations in the 
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region as previously mentioned, this trend is likely to continue if not escalated in the 
next few decades. Some sort of systematic approach, such as the adoption of disease 
management would be necessary to ensure that the increased health care expenditure 
is delivering the required outcomes. Hence, economic evaluations like CUA would 
play a significant role in improving the rationality of disease management in terms of 
resource allocation and optimization.  
 
Probably due to the fact that disease management assessment is still a relatively 
emerging area in Asia, the number of high-quality CUA studies is quite limited in this 
region compared with that in Western countries. Direct generalization of CUA results 
from studies in the West could not be substantiated, as variations in the CUA results 
have been found even across different locations in those countries (Sculpher et al., 
2004). Hence, it is deemed necessary to perform CUA based on local populations and 
health care settings to generate more accurate appraisal of the locally implemented 
disease management programs.  
 
However, for the successful application of CUA to assess the efficiency of disease 
management programs in Asian countries, there are a number of factors either as 
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                                          Table 1.2 National Health Accounts of Selected Asian Countries* 
Total expenditure on health as % of 
 Gross domestic product (GDP) Per capita total expenditure on health at average exchange rate (US$) 
Country 
2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 
Average 
annual Growth 
rate     (2000-
2004) 
Cambodia 5.9 6.6 7.1 7.3 6.7   17   19   22   24   24 8.5% 
            
China† 4.6 4.6 4.8 4.8 4.7   44   48   54   62   71 12.9% 




3.6 3.5 3.5 3.5 3.5   17   18 21.2 21.2 21.2 6.1% 
            
India 4.3 4.5 4.8 4.9 5   19   21   23   27   31 12.9% 
            
Indonesia 2.3 2.7 2.8 2.9 2.8   18   20   25   31   33 16.4% 
            
Japan 7.6 7.8 7.9 8 7.8  2 828  2 558  2 450  2 694  2 831 0.3% 
            
Lao People's  
Democratic 
Republic 
3.2 3.3 3.3 4.5 3.9   11   11   11   15   17 13.5% 
            
Malaysia 3.3 3.7 3.7 4.2 3.8   130   138   146   177   180 8.8% 
            
Mongolia 7.9 8.2 8 6.5 6   30   33   35   32   37 5.9% 
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Table 1.2 (Continued) 
Total expenditure on health as % of 
 Gross domestic product Per capita total expenditure on health at average exchange rate (US$) 
Country  
2000 2001 2002 2003 2004 2000 2001 2002 2003 2004 
Average 
annual Growth 
rate     (2000-
2004) 
Myanmar  2.1 2.1 2.3 2.2 2.2   3   3   3   4   5 10.9% 
            
Philippines 3.5 3.2 3 3.4 3.4   34   30   29   34   36 2.0% 
            
Republic of Korea 4.8 5.4 5.3 5.5 5.6   518   553   607   703   787 11.1% 
            
Singapore 3.6 4.3 4.2 4.2 3.7   820   888   894   921   943 3.6% 
            
Thailand 3.4 3.3 3.7 3.5 3.5   68   62   75   80   88 7.3% 
            
Viet Nam 5.3 5.5 5.1 5.2 5.5   21   23   22   25   30 9.8% 
*: Source: World Health Organization. NHA ratios and per capita levels (Excel). Available from: http://www.who.int/nha/country/en/index.html. Accessed on 
January 27, 2008.  
†: The estimates do not include expenditures of Hong Kong and Macao Special Administrative Regions. 
‡: Exchange rate was changed from 2.15 Won in 2001 to 152 Won in 2002. For comparison, the figures in the table were all based on the exchange rate of 
2.15 Won.  
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  First and foremost among these factors is the linguistic barrier. Although a 
variety of reliable disease-specific and generic HRQoL and utility measures were 
available for use in CUA, most of them have been developed in Western countries (in 
particularly English speaking countries) in languages and contexts that are different 
from those of Asian countries. Ideally, it would be necessary to develop HRQoL 
instruments for use in different Asian countries and cultures, but the resource 
requirements would be overwhelming and the comparability of results across 
countries using country-specific instruments would be problematic. As a trade-off, in 
order to avoid the time and efforts of developing a new instrument, translating and 
adapting suitable ones in an Asian population is a wiser choice but it requires 
comprehensive validation process to ensure their reliability and validity.   
 
Secondly, in order to perform high-quality CUA to assist decision-making in 
uncertainties, it is important to generate a list of potential factors that need to be 
incorporated into sensitivity analyses to examine their impact on the robustness of 
CUA results.  
 
Thirdly, in view of additional impact of differences in socio-cultural, socio-
economic and socio-epidemiological differences between the East and the West, it is 
necessary and important to explore new factors that could potentially influence CUA 
to enhance its comprehensiveness and robustness in assessing disease management 
among Asian patients.  
 
These are some of the pertinent concerns that need to be addressed properly in 
order to facilitate the proper application of CUA in disease management assessment in 
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Asian countries. The studies performed and reported in this thesis are  to address these 
concerns.   
 
         In the studies presented in this thesis, Singapore was selected to provide a 
demonstrative study population within the Asian region due to three major reasons 
which are listed as follows:  
(1) Singapore is one of the leading countries in Asia adopting disease management 
(Cheah, 2001), which has greater needs to have robust economic analysis like CUA 
studies to be in place;  
(2) Singapore has a multiethnic and multilingual population of Chinese (76% of the 
total population), Malays (14% of the total population) and Indians (8% of the total 
population), most of whom may share similar socio-cultural background and values 
with their counterparts in China, Malaysia and India; hence, with this unique position, 
the results generated from Singapore are expected to serve as better references for 
researchers in the Asian region to further investigate the factors influencing the 
application of CUA in their own countries; and  
(3) Singapore is among the most westernized of all the Asian countries, but at the 
same time maintains a very strong root in traditional Asian values and culture. Hence 
Singapore would provide an ideal transitional site for studying of the various factors 
impacting on CUA. Analogous to a filtering system to save energy and efforts, any 
factors found not to be impacting on CUA in Singapore would be unlikely to be 





1.5   Research objectives  
In general, the current thesis aims to provide a reference list of the factors that 
may have potential impact on the application of CUA to assess disease management 
in Asian countries.   
 
Specifically, in line with the barrier and concerns as mentioned in Section 1.4, the 
subsequent eight chapters were designed to answer the following research questions:  
1. Is there any linguistic or cultural barrier in the adaptation of an English 
HRQoL or utility instrument into a non-English version among Singaporeans? As 
generic HRQoL and utility measures such as EQ-5D and SF-6D have already been 
adapted into Chinese, Malay and Tamil for EQ-5D (Luo et al., 2003; Wee et al., 2007) 
and into Chinese for SF-6D (Wee et al., 2004) in Singapore, hence the efforts were 
focused on the demonstration of adaptation of disease-specific HRQoL instruments, 
which had been found to be more responsive and accurate to measure HRQoL or 
utility changes compared with those generic measures (Mishoe et al., 2001; Hart et al., 
2007; Eurich et al., 2006) Furthermore, items in the disease-specific HRQoL 
instruments were recommended to be used as a reservoir for selection of different 
health profiles for the direct elicitation of utility values by SG, TTO or RS (Buxton et 
al., 2007; Krahn et al., 2007; Casey et al., 2006), the validity and feasibility of which 
have been shown among a multiethnic Asian population in Singapore (Wee et al., 
2008). The studies as presented in Chapter 2 would illustrate as an example of how to 
translate and validate the English Audit of Diabetes-Dependent Quality of life 
(ADDQoL) into a Chinese version based on a systematic approach that could evaluate 
all six types of equivalences, namely, conceptual, item, semantic, operational, 
measurement and functional equivalences. 
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      2. What are the factors that have been found to influence the application of CUA 
in the published literatures so far? A qualitative literature review on such factors 
would be presented in Chapter 3. Factors identified from the literature review could 
be used by researchers or decision makers in Asia as a fundamental reference list to 
verify and evaluate their potential impacts on future Asian CUA studies. Moreover, 
the availability of such list also serves as a stepping stone for us to explore other new 
factors that would potentially influence the CUA in the Asian populations and 
contexts.  
3. Are there any other new factors that may potentially influence the application 
of CUA of disease management programs in Asia? In this thesis, patient 
empowerment-related and health psychology-related factors would be the two major 
categories to be explored.  
 
As patient empowerment strategies were found to be another key factor that 
might enhance the effectiveness and efficiency of disease management programs 
(Thiel de Bocanegra and Gany, 2004; Day, 2000; Anderson, 1996), therefore it was 
deemed necessary to explore the correlation between patient empowerment factors 
such as disease knowledge and health literacy with health utility values. If a 
significant relationship between those factors with health utility values is identified, 
the magnitudes of impact of these two factors on CUA results would also be discussed 
at the end of each chapter.  
 
 Correspondingly, the study presented in Chapter 4 aims to investigate the impact 
of disease knowledge using diabetes knowledge as an example, while the study in 
Chapter 5 focuses on the correlation between health literacy with health utility values, 
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using patients with rheumatic diseases as an example.  
 
In the study presented in Chapter 5, a widely used word recognition test, called 
the Rapid Estimate of Adult Literacy in Medicine (REALM), was used to assess 
patients' health literacy levels. However, there have been debates around whether 
REALM could assess patients' comprehension capabilities of the medical information, 
or the functional health literacy levels of the patients (Friedman and Hoffman-Goetz, 
2006). Consequently, it actually generated research interests to develop and validate a 
few functional health literacy tests by researchers in the West [e.g. the Newest Vital 
Sign (NVS), the Test of Functional Health Literacy in Dentistry (TOFHLiD) and the 
Test of Functional Health Literacy among Adults (TOFHLA)] (Parker et al., 1995; 
Weiss et al., 2005; Gong et al., 2007).  
 
However, due to the lack of content validity of those available functional health 
literacy measure for use among patients or general public in Singapore, a generic 
functional health literacy test was therefore developed and validated (presented in 
Chapter 6) for further investigation of the impact of functional health literacy on CUA 
in future studies.  
 
Chapter 7 to Chapter 9 are dedicated to the studies of three health psychology-
related factors, namely, response shift, health preference and trust in pharmacists. The 
study in Chapter 7 uses the total knee replacement patients as an example to explore 
the impact of response shift on the longitudinal measurement of health utilities, as the 
presence of response shift may directly affect the robustness of CUA results. 
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   The study in Chapter 8 presents a comprehensive psychological model named as 
“expectancy-value model” to better explain the differences in health preferences to 
facilitate the understanding of health utility values across different populations. Last 
but not least, the study in Chapter 9 focused on the development and validation of a 
new scale to measure patient's trust in pharmacists, as trust in pharmacists may 
influence patient's satisfaction and adherence to disease management programs. The 
availability of such scale could therefore contribute to the further investigation of its 





















Chapter Two  
 
Translating and culturally adapting the English 
version of Audit of Diabetes-Dependent Quality of 
Life (ADDQoL) into Chinese-- 












 2.1 Introduction  
        Diabetes mellitus has become one of the most daunting public health problems in 
the world, because of its alarmingly increasing prevalence, significant impairment on 
patients’ quality of life (QoL), and tremendous burden on healthcare resources. The 
global number of individuals with diabetes in 2006 was estimated to be 180 million, a 
figure projected to be more than doubled by 2030 [World Health Organization (WHO), 
2006]. According to the estimate by the International Diabetes Federation (IDF) in 
2006, China was ranked as the country with the highest prevalence in diabetes with a 
disease population of 39 million (IDF, 2006). With such high prevalence rates 
internationally, diabetes and its related complications impose significant economic 
consequences on individuals, families, health systems and countries. WHO estimates 
that over the period of 10 years from 2006 to 2015, in China alone, a loss up to $ 558 
billion in foregone national income would be incurred due to heart disease, stroke and 
diabetes (WHO, 2006).  
  Singapore, another Southeast Asian country, also has a higher diabetes 
prevalence of 8% among its predominant Chinese ethnic group compared with other 
parts of the world (Ministry of Health of Singapore, 1998). With such a high 
prevalence, diabetes is causing significant morbidity and mortality in Singapore, and 
the implementation of disease management programs for diabetes would be a cost-
effective way to reduce health and economic burdens and improve patients' QoL, in 
particular their health-related quality of life (HRQoL). 
 
  HRQoL is a subset of QoL, which describes patient–perceived functional effect 
of an illness and its consequent therapy. With the international trend of ageing of the 
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populations and the resultant increasingly prevalence of chronic diseases requiring 
often life-long treatment, the adoption of HRQoL as an outcome indicator in addition 
to the conventional biochemical outcome indicators has been gaining acceptance 
clinically. Similarly, due to the chronic nature of diabetes, HRQoL has been 
increasingly used as a supplementary outcome measure in addition to the traditional 
biomarkers like HbA1c values. Furthermore, HRQoL has been incorporated into 
utility assessment and has become an important parameter for assessing the cost-
effectiveness of such programs either by CEA or CUA. With regards to HRQoL 
measurement, the major challenge to researchers, clinicians and decision-makers alike 
is to find a suitable HRQoL instrument that is both reliable and sensitive. 
 
  For diabetes, there are several HRQoL instruments available (Luscombe, 2000; 
El Achhab et al., 2008; Brazier et al., 1998; EuroQol Group, 1990). Among these, the 
Audit of Diabetes-Dependent Quality of life (ADDQoL) is a valid and reliable 
diabetes-specific HRQoL measure originally developed in U.K. It has two 
distinguished and unique features: one is to allow patients to indicate which aspects of 
life apply to them by using the “not applicable” (N/A) options; the other is the 
application of importance ratings of each domain so as to give a weighted score in the 
end (Bradley et al., 1999). Compared with other generic measures like EQ-5D and 
SF-6D, these two features make the ADDQoL both a more sensitive HRQoL 
instrument and a valuable candidate to be further developed for utility assessment in 
CUA of diabetes programs.  
 
 The English version of the ADDQoL has been culturally adapted for use in 
Singapore without any modification and the equivalence between the adapted and the 
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original version was also demonstrated recently (Wee et al., 2006). However, to date, 
a Chinese version of ADDQoL is not available. In Singapore itself, about 32% of the 
local ethnic Chinese is monolingual in Chinese (Singapore Census of Population, 
2000). Given the large number of monolingual Chinese-speaking diabetic patients in 
the world and the importance of HRQoL and utility measurement to evaluate cost-
effectiveness of diabetes management programs, a culturally adapted and validated 
Chinese version of ADDQoL would contribute significantly to the management of 
DM in Chinese patients.  
 
    A universalist approach to the cross-cultural adaptation of HRQoL instruments 
proposed by Herdman et al (1998) suggests that conceptual equivalence and item 
equivalence should be examined and demonstrated before we start to translate a 
questionnaire into the target language. The universalist model of cross cultural 
adaptation criticized a commonly used approach, where translation is completed first 
and then post hoc analysis is performed to demonstrate equivalence especially the 
measurement equivalence.  Such commonly used approach overlooks the evaluation 
of the conceptual and item equivalences, which is of fundamental significance in 
identifying any potential cultural barriers in the cross cultural adaptation process.  
 
         According to the universalist approach, six types of equivalence should be 
investigated in sequence as follows:  
 
(1) Conceptual equivalence to investigate which domains are important to the 
concept in the target culture and the relationships between them, which can be 
achieved by reviewing local literature, consulting experts in the target culture and 
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discussing with target group;   
(2) Item equivalence to examine critically the items used to tap those domains as 
the relevance of items may vary across cultures which can also be achieved by 
literature review, expert judgment and assessment by target population;  
(3) Semantic equivalence to ensure that any translation which takes place leads to 
semantically equivalent items with the recommended translation process is to be done 
according to the following steps: initial discussion with the developer about the 
underlying concept (this step should be completed in the phase of “conceptual 
equivalence”), forward translation, cognitive debriefing, backward translation, 
cognitive debriefing, harmonization review, feedback by developer, revision, 
proofread and approval of final version by the developer (Acquadro et al., 2004);  
(4) Operational equivalence to ensure that the measurement methods used are 
appropriate to the culture in question which can be investigated by using similar 
methods as mentioned in “item equivalence”;  
(5) Measurement equivalence to examine the outcome of the process in terms of 
instrument behavior; reliability, responsiveness, construct validity (convergent and 
divergent validity, known group validity) tests are often used; and  
(6) Functional equivalence to summarize the above-mentioned types of equivalence. 
 
   The purpose of the study was to translate and culturally adapt the English-
ADDQoL into Chinese for use in Singapore with the universalist approach. As the 
English-ADDQoL was previously adapted in Singapore without any modification, 
therefore the one used for adaptation in our study was actually the same as the 
original U.K. version. The Chinese version developed in this study was aimed to be 
used in Singapore first. The possibility of adaptation to other Chinese-speaking 
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population could be assessed in future studies. 
 
  As for the tests of construct validity, the following 4 a-priori hypotheses were 
generated based on literature review:  
(A) Convergent and Divergent validity 
1. An assumption that the “Present HRQoL” score will correlate moderately with 
the EQ-5D utility, SF-6D and Visual Analogue Scale (VAS) scores. The 
assumption is based on literature reports that disease specific instruments 
correlated moderately with utility-based instruments (Luo et al., 2003; Revivki 
and Kaplan, 1993). 
2. The ADDQoL mean weighted score will correlate moderately with “HRQoL 
without diabetes” and correlate weakly with “Present HRQoL” score 
(Nunnally, 1978).  
 
(B) Known group validity  
1. Subjects who are more depressed (as shown by the score in the mental health 
in SF-6D) will have poorer ADDQoL scores (Paschalides et al., 2004)  
2. Subjects who have better family functioning [as shown by higher score in 
Family Functioning Measure (FFM)] will have better ADDQoL mean 
weighted scores (Sawyer et al., 2001). 
 
2.2 Methods 
2.2.1  Subjects and study design 
        This study was carried out in two phases. The first phase was to use the 
universalist approach in translating and culturally adapting the English version of 
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ADDQoL into a Chinese version. The second phase of the study involved pilot testing 
the adapted Chinese version and evaluation of its equivalence with the English 
version.  
 
 During the first part of the study, as suggested by the universalist approach, steps 
were taken to investigate conceptual equivalence, item equivalence, semantic 
equivalence and operational equivalence, through which translation was integrated. 
Conceptual, item and operational equivalence was assessed by local literature review, 
expert judgment and cognitive debriefing among target subjects. Semantic 
equivalence was studied according to the recommended translation procedure which 
will be described in the translation part of the methodology. Two local bilingual 
(Chinese and English) clinical experts in diabetes were involved in the judgment. 
  
 Five native Chinese-speaking diabetic patients were recruited for the cognitive 
debriefing during the whole process of the first part. They were members of Diabetes 
Society of Singapore (DSS) who attended two government polyclinics. These 
recruited patients differed in their gender, type of diabetes (diagnosed by physician) 
and treatment method to better represent the diabetic patients in Singapore. Of the 5 
patients, there were 1 male and 1 female patient each with Type-1 diabetes; the other 
patients consisted of 2 male and 1 female Type-2 diabetics who were undergoing 
medication, diet control, and insulin injection respectively. Their consents to 
participate ion the study were sought through a consent form before the interview.  
 
   After the above four kinds of equivalence were demonstrated, measurement 
equivalence was investigated by a pilot cross-sectional study during the second phase 
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of the study. It was undertaken at the World Diabetes Day 2004 commemorative event 
organized by DSS at the exhibition hall of a major shopping center in Singapore on 
Oct 17, 2004. Participants were approached by research assistants to identify whether 
they were eligible for the study. Inclusion criteria were English-speaking or Chinese-
speaking Singaporean diabetic patients (type 1 or type 2) aged 21 and above, who 
were able to complete questionnaires without any assistance. All subjects who agreed 
to participate in the study were asked to sign a written informed consent. Then they 
were asked to complete a booklet containing a demographic datasheet, diabetes 
knowledge test sheet (the results of which were used and reported for another study), 
FFM and a battery of HRQoL instruments including ADDQoL and two other generic 
HRQoL measures (SF-6D and EQ-5D).  
 
   A week later, those who had indicated in the consent form that they were willing 
to take part in the retest, received a similar set of questionnaires, excluding the 
demographic sheet by mail together with a stamped returned envelope. A reminder 




2.2.2.1   Initial discussion with the developer 
   The developer was contacted and asked to provide descriptions of ideas behind the 
language used in original ADDQoL. 
 
2.2.2.2   Forward translation (FT) 
       In the first stage, a preliminary Chinese version from the original English 
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ADDQoL was developed. Two Singaporean translators, both fluent in writing and 
speaking Chinese and English, did the initial forward translation independently. After 
the two forward translations were completed, the translators met with the project 
coordinator to produce a preliminary consensus version of the ADDQoL in Chinese 
(C-ADDQoL FT). A forward translation report was produced at the end of the 
meeting. 
 
2.2.2.3   Cognitive debriefing 
        After the forward translation was produced, cognitive debriefing was carried out. 
Conceptual equivalence, item equivalence and operational equivalence were 
discussed with participants during the interview. Participants were asked about their 
view of health and QoL (conceptual equivalence), relevance of each item to 
themselves (item equivalence). Besides, they were asked whether items were difficult 
to understand or to answer (for translation purpose). Operational equivalence was 
assessed in two steps: first, participants were asked whether they were able to finish 
the self-administered ADDQoL; then, they were required to complete the 
questionnaire and discuss with interviewer about the appropriateness of the 
questionnaire format, instructions and mode of administration. The cognitive 
debriefing report was generated after the debriefing. It included items that had been 
changed from the tested version and the reason for such a change. The edited version 
of the ADDQoL FT was produced and subjected to backward translation (BT).  
 
After backward translation has been completed, another cognitive debriefing was 
carried out before a preliminary version of Chinese ADDQoL (C-ADDQoL pre) was 
produced.  
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2.2.2.4   Backward translation (BT) 
       After the first cognitive debriefing, another two bilingual Singaporean translators 
were recruited to back translate the C-ADDQoL pre from the forward translation into 
English independently. Once the back translation was completed, the project 
coordinator met up with the translators to discuss the problems during the translation. 
The Chinese-ADDQoL Backward Translated version (C-ADDQoL BT) was produced 
after all discrepancies were dealt with. Next, a backward translation report was 
compiled to indicate the differences between the two back translations and the 
differences between the latter BT version and the original one was noted and recorded. 
This C-ADDQoL BT was then subjected to the second cognitive debriefing. 
 
2.2.2.5   Harmonization review, feedback and approval by original developer 
       Finally, all the translators met up with coordinator and discussed to compose the 
C-ADDQoL pre by settling down any discrepancy or disagreement before submitting 
the version and all the forward translation, backward translation, cognitive debriefing 
reports to the original developer for a final review. The original developer then did a 
review to ensure the authenticity of the translation. After the approval had been 
obtained, the final version of the C-ADDQoL was produced.  
 
2.2.3 Instrument  
2.2.3.1   ADDQoL 
ADDQoL-13.3.03 is a 19-domian disease-specific instrument designed to 
measure individual’s perception of the impact of diabetes on their quality of life (See 
Appendix 2.1). It begins with two items assessing “present HRQoL” and “HRQoL 
without diabetes”. The former is a measure of general HRQoL, while the latter is a 
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measure of diabetes-specific HRQoL. The subsequent items are related to the 19 
domains of physical functioning, symptoms, psychological well-being, social well-
being, role activities, personal constructs, etc (Bradley et al., 1999). Impact of each 
domain is scored on a 5-point scale (from -3 to 1) and the corresponding importance 
is rated on a 4-point scale (0 to 3). The weighted score of each domain is calculated 
by multiplying the impact and importance rating (-9 to +3).                 
 
Out of the 19 domains, there are five with N/A (not applicable) options. These 
N/A items were scored as missing values. As a result, domains that are not important 
to respondent are excluded from the mean ADDQoL weighted score. Lastly, the mean 
weighted score is converted to a final score on a 0-100 scale. A higher score indicates 
a better HRQoL.  
 
2.2.3.2   EQ-5D 
       The EQ-5D questionnaire is a 5-item (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) questionnaire for respondents to self-classify 
and rate their health on the day of administration of the instrument (Brooks, 1996; 
Rabin and de Charro, 2001). For each item, there are three response levels (with no 
problem, with some problems, with extreme problems). Theoretically, 243 unique 
health states could be identified by the descriptive system of the instruments.  
 
Scoring methods have been developed to assign each of these health states a 
utility score, in which 1 represents full health (no problem with all 5 items) and 0 
represents being dead (Dolan, 1997; Dolan and Roberts, 2002). The range of the final 
score is from -0.594 to 1.00. The validity and equivalence of the EQ-5D in English 
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and Chinese versions were previously demonstrated in a sample of rheumatic patients 
in Singapore (Luo et al., 2003). 
 
2.2.3.3   SF-6D  
       The SF-6D is a 6 dimensional health classification system assessing physical 
functioning, role limitations, social functioning, pain, mental health and vitality, with 
4 to 6 level per dimension (Brazier et al., 1998; Brazier et al., 2002). An SF-6D health 
state is defined by selecting 1 level from each dimension. The SF-6D score is scaled 
from 0.26 to 1.00 continuously, with 0.26 representing the worst health state (all 
dimensions being at the worst level) and 1.00 representing full health (all dimensions 
being at full functional level).  
 
The validity and equivalence of the SF-6D in English and Chinese versions were 
previously demonstrated in a population-based study in Singapore (Wee et al., 2004).  
 
2.2.3.4  Family functioning measure (FFM) 
       The family functioning measure is a 3-item instrument designed to measure the 
quality of interaction among family members (Sherbourne and Kamberg, 1992). It has 
a 5-point Likert scale, with higher scores reflecting better family functioning.  
 
Several studies have shown that family functioning was associated with HRQoL 
scores (Thumboo et al., 1999; Sawyer et al., 2001). The validity for use among 




2.2.4   Statistical analysis  
       Data collected from the second phase of the study were entered into an Excel 
spreadsheet (Microsoft Corporation, Redmond, Washington) and analyzed using the 
Statistical Package for the Social Sciences, version 12.0 (SPSS Inc, Chicago, Ill). 
Subjects with ≥6 missing items in ADDQoL or ≥ 1 missing value in EQ-5D or SF-6D 
were excluded from all analyses.  
 
 Group comparisons were made using non-parametric tests with Mann-Whitney U 
tests for quantitative data and Chi-square tests for qualitative data. For reliability tests, 
Cronbach’s α and the intraclass correlation coefficient were calculated for internal 
consistency and test-retest reliability, respectively. Response distribution for each item, 
use of N/A options and item ranking (weighted, unweighted and change in order of 
ranking) were compared between two language groups as responsiveness tests, during 
which descriptive analyses and group comparisons were carried out. Spearman’s 
correlation coefficients were used to investigate construct validity (convergent and 
divergent validity, known group validity) by correlation analyses among ADDQoL 
(“present HRQoL” score, ADDQoL mean weighted score, “HRQoL without diabetes” 
score), SF-6D and EQ-5D scores. Statistical significance was set at p<0.05 for the 
data analysis and p<0.01 or <0.001 was also reported where applicable.  
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2.3   Results  
2.3.1  Characteristics of the subjects 
Altogether 56 eligible English-speaking patients and 32 eligible Chinese-speaking 
patients participated in the study. During data analysis, 14 English-speaking subjects 
and 6 Chinese-speaking subjects were dropped due to incomplete responses as 
defined previously, leaving 68 subjects (42 English-speaking subjects and 26 Chinese-
speaking subjects) with complete responses for analysis. Table 2.1 shows respondents’ 
characteristics and scores of FFM and HRQoL measures.  
 
Respondents who completed the Chinese-ADDQoL were more likely to be 
unemployed (p<0.01), have received fewer years of education (p<0.05), lived in 
public housing (p<0.01) and poorer family functioning (p<0.01). Although statistical 
significance was not demonstrated, English-speaking patients appeared to have higher 
























Table 2.1.  Characteristics of  study subjects 
 N (%) unless stated   
 English (n=42) Chinese(n=26) p-value 
Age [Mean (SD)] 53.5 (9.64) 55.8 (11.09) 0.479 
       
Female  18 (45.0) 12(46.2) 0.068 
    
Chinese ethnicity  36(85.7) 26 (100)  
    
Years of education   <0.05 
≤6 4 (10) 22 (84.6)  
7-10 18 (45) 2 (7.7)  
≥11 18 (45) 2 (7.7)  
    
Employed 23 (54.8) 4 (15.4) <0.01 
    
Smoking 3 (7.1) 3 (11.5) 0.535 
    
Presence of acute medial conditions* 23 (54.8) 15 (57.7) 0.813 
    
Presence of chronic medical conditions 
other than diabetes† 
27 (64.3) 14 (53.8) 0.393 
    
Presence of diabetes complications‡ 17 (40.5) 13 (50.0) 0.442 
    
Housing type   <0.01 
  Public    
    Lower cost 1 (2.4) 16 (61.5)  
    Regular 32 (76.2) 6 (23.1)  
  Private 9 (21.4) 4 (15.4)  
    
Type of diabetes    0.287 
  Type I 13 (31.0) 5 (19.2)  
  Type II 29 (69.0) 21(80.8)  
    
Mean Family function score (SD)  63.5 (16.21) 47.0 (17.46) <0.01 
    
Median (Interquartile range)  
EQ-5D utility  
1.00 (0.81, 1.00) 1.00 (0.78, 1.00) 0.331 
Median (Interquartile range)  
SF-6D   
0.80 (0.70, 0.95)  0.77 (0.65, 0.94)  0.303 
    
Median (Interquartile range)  
weighted ADDQoL  
-3.05 (-4.38, -1.26) -4.31 (-6.10, -2.24) 0.238 
    
Median (Interquartile range) 
converted ADDQoL  
49.57 (38.53, 64.47) 39.15 (25.00, 56.40) 0.241 
*: Acute medical conditions included running a nose, sore throat or cough, vomiting or diarrhea, 
headache lasting more than one day, sleeping problems and body injuries. 
†: Chronic medical conditions other than diabetes included hypertension, heart disease, stroke, asthma 
or other lung disease, cancer, rheumatism, back pain or other bone or muscle illness, mental illness, 
other illness like kidney problems on dialysis.  
‡: Diabetes complications included eye disease, foot problems, kidney disease, heart disease, stroke, 








2.3.2 Conceptual equivalence  
  The perception of HRQoL among Chinese-speaking Singaporeans has been well 
demonstrated by several local studies (Thumboo et al., 2002; Luo et al., 2003; Wee et 
al., 2004). Relevance of 19 domains to the Chinese-speaking Singaporean diabetes 
patients was confirmed by two local diabetes experts and respondents during the 
cognitive debriefing. As domains are weighted in ADDQoL, the importance of the 
domains is allowed to vary between two cultures.  
 
2.3.3 Item equivalence  
        Initial qualitative examination of relevance of items was carried out using the 
same procedures as described in the “conceptual equivalence”. The results suggested 
that items can be used in the Chinese version without modification other than 
translation (See Appendix 2.2 for the Chinese-ADDQoL). Quantitative investigation 
of item equivalence will be reported in the “measurement equivalence” section later.  
 
2.3.4 Semantic equivalence  
        No significant problem surfaced during the translation process except for a few 
minor lexical issues. Among them, one issue was that sometimes an English word or 
phrase possesses multiple explanations in Chinese. During forward translation, the 
word “close” (in the context of “close personal relationship”) and another phrase 
“working life” were translated into two different Chinese terms respectively. Similar 
problems were also encountered in the backward translation for the word “physically” 
and the phrase “living condition”. Such problems were then resolved by selecting the 
most appropriate Chinese term, which could convey the original meaning indicated by 
the developer.   
 
        Some other discrepancies were due to the difference in word order between the 
Chinese and English expressions. In the first cognitive debriefing, all five respondents 
found the translation of “much easier” for the impact scale option to be awkward. 
Nevertheless, it was used in order to maintain the thematic meaning (consistent word 
order with other impact scale options). In the second cognitive debriefing, the same 
problem was brought up again. After much lengthy discussion, in the end the 
translation was deemed suitable as consistency with the English version should be 
adhered to. 
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       No major problem arose during the harmonization review. The C-ADDQoL pre 
together with all the necessary reports were then sent to the original developer for 
final review. Since the version was approved without any change, it was thus adopted 
as the final C-ADDQoL.  
 
2.3.5 Operational equivalence 
      The previous study of the English-ADDQoL adaptation in Singapore and other 
studies of similar questionnaires used among Singaporeans have shown that the 
format of ADDQoL and the mode of self-completion would be feasible in Singapore 
(Wee et al., 2006; Thumboo et al., 2002; Luo et al., 2003; Thumboo et al., 1999; Koh 
et al., 1998). Apart from literature review, this was also confirmed by researchers in 
outcomes research field in Singapore. Additionally, respondents were able to complete 
the questionnaire without any trouble during cognitive debriefings, which predicted 
the success of the testing methods.  
 
2.3.6 Measurement equivalence  
2.3.6.1 Reliability of the Chinese-ADDQoL  
Cronbach’s alpha indicates how much the items on a scale are measuring the same 
underlying dimension, that is, a measure of internal consistency (Pilot, 1996).  In this 
study, the Cronbach’s alpha for the overall items is 0.94. When two items of “self-
confidence” and “financial situation” were deleted individually, the Cronbach’s alpha 
reduced to 0.93. However, if the item of “freedom to drink” was deleted, the alpha 
increased to 0.95. As for the separate deletions of other items, the Cronbach’s alpha 
remained at 0.94 (See Table 2.2). All of the above coefficient alphas suggested 
excellent reliability, because according to the rule of thumb that applies to most 
situations, a value exceeding 0.9 would demonstrate excellent reliability (George and 
Mallery, 1999). 
 
      The time of completion for the re-administration varied from two to four weeks 
and the response rate was 42.3 %( n=11). One respondent who did not specify his/her 
name was omitted from the test-retest reliability study. This lowered the response rate 
to 38.5% (n=10). The intra-class correlation coefficient was 0.65, slightly lower than 
the commonly accepted level for group comparison. 
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2.3.6.2 Comparison of responsiveness between the Chinese and English ADDQoL 
2.3.6.2.1 Response distribution  
     Table 2.3 shows the response distribution of unweighted impact scores, importance 
ratings, weighted impact scores of each domain by two languages. Unweighted 
impact scores of 4 domains, namely, “family life” [English vs. Chinese:  -2.00 (-2.00, 
0.00) vs. -2.00 (-2.88, -2.00)], “friendship and social life” [English vs. Chinese:  
-1.00 (-2.00, 0.00) vs. -2.00 (-2.00, -2.00)], “close personal relationship” [English vs.  
Chinese: -1.00 (-2.00, 0.00) vs. -2.00 (-2.00, -1.00)] and “dependence on others” 
[English vs. Chinese: -1.00 (-2.00, 0.00) vs. -2.00 (-2.00, -1.00)] were statistically 
different (p<0.05) between the two language versions with Chinese-speaking 
respondents reporting lower scores.   
 
Statistically significant difference (p<0.05) in importance ratings was only 
detected in the domain of “employment” with Chinese-speaking respondents 
reporting higher ratings [English vs. Chinese: 2.00 (0.00, 3.00) vs. 2.00 (2.00, 3.00)]. 
For weighted impact scores, no statistically significant difference was found between 
the two languages. In addition, the ranges of responses in terms of “unweighted 
impact score” and “importance ratings” were quite similar between the two language 
groups. Interestingly, positive impact of diabetes was reported in the domains of 
“physical appearance” and “freedom to drink” by one (English-speaking) and three 
















Table 2.2  Reliability of the Chinese -ADDQOL. 














alpha  if item 
deleted 
Family life -65.11 1419.23 0.36 0.51 0.94 
      
Friendship and social 
life 
-66.33 1385.02 0.60 0.88 0.94 
      
Close personal 
relationship 
-66.65 1371.92 0.60 0.88 0.94 
      
Sex life -67.44 1410.69 0.42 0.86 0.94 
      
Physical appearance -65.85 1346.78 0.66 0.83 0.94 
      
Physical health -66.52 1381.10 0.73 0.91 0.94 
      
Work (Employment)  -67.10 1368.00 0.57 0.88 0.94 
Holiday -66.73 1369.09 0.71 0.93 0.94 
      
Leisure activities -66.90 1375.88 0.67 0.96 0.94 
      
Local or long 
distance journeys 
-66.29 1336.44 0.82 0.90 0.94 
      
Self-confidence -65.54 1286.34 0.90 0.96 0.93 
      
Motivation -66.12 1337.87 0.75 0.93 0.94 
      
People’s reaction -66.62 1312.41 0.81 0.97 0.94 
      
Feelings about the 
future 
-65.42 1335.29 0.82 0.94 0.94 
      
Financial situation -65.31 1295.02 0.90 0.97 0.93 
      
Dependence on 
others 
-66.48 1338.85 0.67 0.77 0.94 
      
Living condition -66.33 1314.90 0.80 0.95 0.94 
      
Freedom to eat -65.25 1384.91 0.48 0.93 0.94 
      
Freedom to drink -66.29 1422.88 0.33 0.96 0.95 
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Table 2.3: Comparison of response distribution between the English and the Chinese sample 
Domain  Impact scores unweighted  Importance ratings Impact scores weighted by importance 
 Median (Interquartile range)  Median (Interquartile range)  Median (Interquartile range)  
 English  Chinese  p-value  English  Chinese  p-value  English  Chinese  p-value  
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Table 2.3 (Continued) 
Domain Impact scores unweighted Importance ratings Impact scores weighted by importance 
 Mean (SD) Mean (SD) Mean (SD) 
 English Chinese p-value English Chinese p-value English Chinese p-value 













          













          
People’s reaction -1.00 
(-2.00, 0.00) 
-1.50 










          













          













          













          













          













          


















The one who reported positive impact of diabetes on “physical appearance” rated “my 
physical appearance” to be “very important”. As for the three respondents who 
reported positive impact of diabetes on “freedom to drink”, two respondents (one 
English speaking and one Chinese speaking respectively) rated such domain as 
“somewhat important” while the other English-speaking respondents rated it as “not 
important at all.”  
 
2.3.6.2.2 Use of N/A options  
      The N/A option was provided for 5 domains, namely, “family life”, “close 
personal relationship”, “sex life”, “work (employment)” and “holiday”. The rank of 
N/A option use was similar between the two groups with domains of “sex” and “work 
(employment)” being the top 2. Percentages were also similar in 4 domains except for 
the domain of “holiday” (English-speaking: 2 (4.8%); Chinese-speaking: 4 (15.4%)) 
by two languages. (See Table 2.4) 
 
Table 2.4. Use of N/A options between the English and the Chinese samples 
 N (%) 
Domain English Chinese 
Family life 3 (7.1) 3 (11.5) 
   
Close personal relationship 6 (14.3) 4 (15.4) 
   
Sex life 12 (28.6) 7 (26.9) 
   
Work (Employment) 11 (26.2) 8 (30.8) 
   
Holiday 2 (4.8) 4 (15.4) 
 
2.3.6.2.3 Effect of weighting impact ratings 
Weighting impact scores by importance ratings apparently changes the ranking of 
domains, which were originally demonstrated by unweighted scores (see Table 2.5). 
Except for the two domains of “sex life” and “feeling about future”, all the other 17 
domains showed slight (1 notch) to distinctive (10 notches) changes in both directions, 
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Table 2.5. Comparison of item ranking with and without importance weighting by language 
Item  English  Chinese  




Change in  






Change in  
order of  
ranking 
Family life 9 5 4 2 1 1 
       
Friendship and social life 13 9 4 3 11 -8 
       
Close personal 
relationship 
15 15 0 10 15 -5 
       
Sex life 19 19 0 19 19 0 
       
Physical appearance 14 14 0 13 6 7 
       
Physical health 7 11 -4 12 13 -1 
       
Work (Employment)  18 16 2 16 18 -2 
       
Holiday 8 10 -2 6 16 -10 
       
Leisure activities 10 12 -2 18 17 1 
       
Local or long distance 
journeys 
4 8 -4 7 9 -2 
       
Self-confidence 6 4 2 9 5 4 
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Table 2.5 (Continued) 
Item  English  Chinese  




Change in  






Change in  
order of  
ranking 
People’s reaction 17 18 -1 17 14 -3 
       
Feelings about the future 3 3 0 4 4 0 
       
Financial situation 5 6 -1 8 3 5 
Dependence on others 16 17 -1 14 12 2 
       
Living condition 11 7 4 15 10 5 
       
Freedom to eat 1 1 0 1 2 -1 
       
Freedom to drink 2 2 0 5 8 -3 
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2.3.6.3   Construct validity  
      All four a-priori hypotheses were fulfilled in the study although not all of the 
results were statistically significant (See Table 2.6). 
 
      Convergent and divergent validity was demonstrated by the following correlations: 
“Present HRQoL” scores correlated moderately with EQ-5D utility scores (r=0.268, 
p=0.185), and SF-6D index scores (r=0.351, p=0.078). As predicted, ADDQoL 
median weighted scores correlated moderately with “HRQoL without diabetes” scores 
(r=0.339, p=0.090) but weakly with “Present HRQoL” scores (r=0.027, p=0.896).  
 
 As for the known group validity, the results showed that lower ADDQoL median 
weighted scores moderately correlated with lower SF-6D mental scores (r=0.247, 
p=0.224), suggesting that those who were more depressed had a poorer HRQoL; and 
FFM scores positively correlated with ADDQoL scores (r=0.288, p=0.182), which 
provided the finding of “better HRQoL is associated with better family functioning” 
among the diabetes patients.  
 
Table 2.6: Spearman rank correlation among Chinese-ADDQOL weighted scores,” 
Present HRQoL”, “HRQoL without diabetes”, EQ-5D utility, SF-6D and FFM scores  
 
  ADDQOL scores SF-6D FFM 







scores Index  Mental   
ADDQoL         
  Present HRQoL 
scores 1.000  
     
 Weighted scores 0.027 1.000      
  HRQoL without  
diabetes scores  -0.015 0.339 
1.000     
        
EQ-5D utility 
scores 0.268 0.238 
0.021 1.000    
        
SF-6D        
Index score 0.351 0.256 -0.016 0.785** 1.000   
Mental score  0.287 0.247 -0.206 0.342 0.597 1.000  
        
FFM score -0.121 0.288 0.271 0.362 0.378 -0.148 1.000 




2.3.7   Functional equivalence 
       The results of the conceptual equivalence, item equivalence, semantic 
equivalence, operational equivalence and measurement equivalence listed above 
indicated that a reasonable degree of equivalence was achieved in all the 5 areas. 
Therefore, the functional equivalence between the Chinese-ADDQoL and English-
ADDQoL was demonstrated in this study. 
 
2.4 Discussion  
        Due to increasingly higher prevalence and huge economic burden of diabetes 
among Chinese-speaking population, it becomes important and urgent to implement 
cost-effective diabetes management programs to ensure the sustainability of 
healthcare and economic resources. Hence, a well translated and culturally adapted 
disease-specific HRQoL measure such as ADDQoL could contribute to the more 
accurate assessment of the effectiveness of the disease management programs, 
compared with generic HRQoL measures.  
 
      To the best of our knowledge, the current study is the first to translate and 
culturally adapt the original English-ADDQoL into the Chinese version. The 
promising findings of the Singapore-based study could contribute to further 
adaptation of this Chinese-ADDQoL among other Chinese-speaking populations in 
the world.  
 
Furthermore, the current study also serves as a pioneering yet important example 
to apply the systematic universalist approach to translate and adapt an English 
HRQoL instrument into a Chinese version to ensure equivalences in the full spectrum. 
Unlike some other equivalent studies, the current study emphasized the importance of 
conceptual equivalence and item equivalence as the prerequisite for the translation of 
ADDQoL, which is exceptionally important for the cross-cultural adaptation. The 
translation process was integrated into the whole adaptation process rather than 
simply heavily relying on translation techniques without cognitive debriefing. 
Therefore, the mistake of rigid assumption that HRQoL instruments would be equally 
valid in any culture was avoided. We thus carried out the investigation of 
measurement equivalence only when conceptual equivalence, item equivalence, 
semantic equivalence and operational equivalence had been demonstrated. 
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The main findings suggest that the Chinese-ADDQoL adapted in Singapore 
achieved all six types of equivalences with the original English-version developed in 
UK. In the mean time, it is worthwhile pointing out the following findings or issues, 
as they could provide either precautions or suggestions for future studies.  
 
       First, in this study, the test-retest reliability was relatively poor with its ICC (0.65) 
a little below the acceptability level of 0.7 (Nunnally, 1997). The relatively poorer 
test-retest reliability might be due to insufficient sample size (n=10) for data analysis 
and poor compliance of the second administration. Of the 10 respondents of test-retest 
reliability, 3 filled up the retest questionnaires at around the 4th week after the first 
administration, which violated the preset 2-week interval rule. It was also likely that 
some of their answers were different due to recall problem or certain change in the 
disease state, since the 4-week interval might be too long. Therefore, further test-retest 
reliability studies on Chinese-ADDQoL should be conducted for verification of the 
results. Moreover, methods to increase response rates to postal questionnaires as 
suggested by Edwards et al. (2007) could be used for retests, such as pre-notification, 
giving out small incentives, etc.  
 
      Second, we have observed interesting findings regarding the differences in 
response distributions as reported by the English-speaking and Chinese-speaking 
study subjects. It was shown that the unweighted impacts scores of four domains, 
namely, "family life", "friendship and social life", "close personal relationship" and 
"dependence on others" were rated as significantly worse by the Chinese-speaking 
subjects than their English-speaking counterparts. Such differences might be related 
to the differences in the subject characteristics as we have found, in which Chinese-
speaking subjects had a relatively poorer socioeconomic status especially in the areas 
of family functioning, education levels, employment status, and dwelling type. 
Similarly, the domain of "employment" was again found to be significantly more 
important as rated by Chinese-speaking subjects as compared to the English-speaking 
counterparts who had a much higher employment ratio. Yet when the comparisons 
were made by weighted ADDQoL scores, no statistically significant differences were 
detected between the two study groups.  We suggest that when the margin for the 
minimal clinically important difference is established for ADDQoL in other clinical 
studies, further analysis could be performed to examine whether the score differences 
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after adjustment for the confounding variables in baseline characteristics between the 
two study groups are clinically unimportant so as to demonstrate the measurement 
equivalence in the aspect of responsiveness (Drasgow and Kanfer, 1985).  
 
       Third, the use of N/A options and weighted scoring method were proven to be 
necessary and effective for Chinese-ADDQoL as well as English-ADDQoL. Such 
results further emphasized the importance of increasing relevance and sensitivity of a 
HRQoL questionnaire for better accuracy.  
 
       Last but not least, due to the nature as an exploratory study, we only recruited a 
small sample size as a start-off to explore the translation and adaptation process by the 
universalist approach. Hence, the small sample size would hamper generalizing our 
results to the general Chinese-speaking diabetic population in Singapore. Nevertheless, 
the preliminary study did provide conceptual background and encouraging results for 
using the universalist approach in the translation and cultural adaptation of HRQoL 
instrument from West to East in an effective and efficient manner. 
 
2.5   Conclusion 
       The results of this exploratory study suggest that this Singaporean Chinese-
ADDQoL has achieved functional equivalence with both the original and the 
Singaporean adapted English-ADDQoL by demonstrating conceptual equivalence, 
item equivalence, semantic equivalence, operational equivalence and measurement 
equivalence. It also shows the strength of using the universalist approach to ensure 
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3.1 Introduction  
       Despite the fact that health economic evaluation is a relatively new research area 
in Asia, its importance as a quantitative tool to assist decision-making in disease 
management has been increasingly recognized due to the escalating healthcare 
expenditures and tightening budget constraints. As mentioned in Chapter 1, cost-
utility analysis (CUA) is a special type of economic evaluation that measures health 
benefits in utility-weighted life years and computes a cost per utility-measure ratio, 
which has the crucial advantage over others to enable comparisons across different 
disease management programs (Gerard, 1992). Therefore, CUA has been 
recommended as the preferred form of reporting health economic evaluation results 
by the Panel on Cost-Effectiveness in Health and Medicine (Siegel et al., 1996). 
 
       However, surprisingly, even in Western countries, where CUA has been widely 
applied in evaluating disease management programs, its impact in real-world medical 
decision-making has been shown to be rather limited across various countries. 
According to a focus group research study among a panel of decision-makers from 
two UK health authorities, one of the key problems was the lack of generalizability or 
transferability of the results published in most of the medical literature (Hoffmann et 
al., 2002). Similarly, decisions-makers and researchers from other Western countries 
like Canada (PausJenssen et al., 2003), Australia (Salkeld et al., 1995), Sweden (Anell 
and Persson, 2005) have also identified such problems as a crucial barrier of using 
CUA as a valid and reliable tool in their decision-making processes. This lack of 
generalizability threatens the relevance of CUA, which has also been commented by 
researchers from Asian countries like Lee et al. (2005, Korea) and Ikegami et al. 
(2002, Japan). These findings challenged the opinion of CUA as a useful and accurate 
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decision informing tool that could be further widely applied in Asian countries. Hence, 
it is of paramount importance to explore what are the factors have jeopardized the 
generalizability of CUA results.  
 
        Actually, when trying to explore the reasons causing the perceived lack of 
generalizability among end-users of CUA or other economic evaluations in general, it 
becomes obvious that the uncertainties relating to the impact on outcomes caused by 
the various factors tested in CUA is a major hindrance. Hence, one major hurdle 
affecting the generalizability of CUA results is, therefore, the lack of consensus about 
factors that should be tested when examining the applicability in different settings of 
the results from a CUA.  
 
       Naturally, there are many factors and variables that could potentially affect the 
outcomes when conducting CUA to assess the cost-effectiveness of interventions or 
disease management programs; and their impact on outcomes are usually tested in 
sensitivity analyses. Although sensitivity analyses have been widely performed to 
examine uncertainties caused by the various factors in CUA, it was found that the set 
of parameters tested in sensitivity analysis was often limited and the overall reporting 
quality was far from satisfactory (Briggs and Sculpher,1995; Schakman et al., 2004).  
       
      In fact, Walker and Fox-Rushby (2001) commented that the very first step to 
design a well-justified sensitivity analysis was to identify all the potential parameters 
that are relevant to the model. Based on such list, researchers could then choose the 
parameters with uncertainties relevant to the case being evaluated to perform 
sensitivity analysis; and decision-makers can use the check list to assess the 
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generalizability of the results from the CUA and its sensitivity analyses. Such 
comment is deemed as valid for the CUA studies universally.  
 
       However, an extensive literature search revealed no published literature synthesis 
focusing on the factors influencing CUA. Hence, to fill in such knowledge gap, the 
current study was aimed to provide a qualitative literature review of all the influential 
factors identified in the published CUA studies, regardless of its origin.    
 
3.2 Methods  
3.2.1 Literature search strategy  
        Potentially relevant articles were identified by electronic database search as well 
as manual search. At first, search of several electronic databases, namely, Medline 
(1966 to May 2005), PsycINFO (1967 to May 2005), ISI Web of Knowledge (ISI) 
[including Web of Science (1980 to May 2005), Current Contents Connect (1998 to 
May 2005), ISI proceedings (2002 to May 2005)], EconLit (1969 to May 2005) and 
the Cochrane Library (1996-May 2005) was performed, where cost-utility analysis 
was entered as a free term in the text word search. At this stage, non-English 
publications whose abstracts were in English were also included as they were more 
likely to explore factors pertaining to different socio-cultural contexts. It was agreed 
by the candidate and the two supervisors that a brief summary of non-English 
publications would be given in this literature review for completeness. However, due 
to a lack of language proficiency other than English on the part of the candidate, non-
English articles were excluded from further full-text review.  
 
        Manual search of several key health economics journals including Value in 
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Health (May 1998-May 2005), Pharmacoeconomics (Jan 1992-May 2005), Health 
Economics (April 1992-May 2005) and Journal of Health Economics (1982-May 
2005) was also performed to identify any articles that were missed out in the 
electronic database search. As cost-utility analysis has also been referred to as cost-
effectiveness analysis or economic evaluation in titles of publications, all of the three 
terms were used as key words in the manual search. In addition, bibliographies of all 
articles selected for full-text review were also examined and potentially relevant 
articles were further selected for full-text review.    
 
3.2.2 Selection of articles for full-text review 
       All of the identified abstracts retrieved from each of the electronic databases were 
first downloaded into Reference Manager Version 11 and checked for duplication. All 
abstracts from the manual search and the modified Reference Manager Database were 
then examined by the candidate based on the predefined inclusion criteria to select 
articles for full-text review. Any uncertainties were brought up for discussion with the 
two supervisors and then finally resolved by reaching consensus after the discussion.   
 
      Inclusion criteria were as follows: (1) for empirical studies, factors affecting cost-
utility ratio should be clearly identified and quantitatively analyzed by sensitivity 
analysis; (2) for review articles, factors affecting cost-utility ratio should be clearly 
qualitatively analyzed in terms of why or how they affected results of CUA; (Denzin 
and Lincoln, 2000) (3) articles for full-text review should be written in English.   
 
3.3 Results  
3.3.1   A brief summary of non-English publications  
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        Fifteen non-English languages articles (4 in Japanese; 5 in Dutch; 2 in 
Norwegian; 1 each in Korean; German; Spanish and French respectively) were 
identified as articles dedicated to study of CUA. Based on their English-written 
abstracts, four articles mentioned about the factors or issues influencing CUA.  These 
were the articles by De Neeling (2004), Belouet et al. (1999), Kristiansen et al. (1997), 
and Rubeo-Terres et al. (2003) in Dutch, French, Norwegian and Spanish respectively.  
The factors affecting CUA identified by these articles are summarized in the next 
paragraph.  
 
        De Neeling (2004) argued that quite a few uncertainties restricted the application 
of CUA for direct comparisons of efficiency across all types of healthcare services. 
These uncertainties included QALY elicitation methods, QALY elicitation population 
(patients or the general public), types of costs to be incorporated, discounting of 
future cost and benefits, etc. In the other three abstracts, (Belouet et al., 1999; 
Kristiansen et al., 1997; and Rubeo-Terres et al., 2003], disease progression rate, risk 
of disease worsening or complications, cost of intervention, duration of treatment and 
discount rate were identified to affect cost-utility ratio in sensitivity analyses, but 
magnitude of impacts were not mentioned in detail.  
 
3.3.2   Identification of potentially relevant articles for full-text review 
       Figure 3.1 presents the article selection process together with the results. Before 
checking for duplication, 2,644 articles were identified from electronic database 
search (660 from Medline, 36 from Psycinfo, 734 from ISI, 19 from EcoLit and 1,195 
from Cochrane Library). After checking for duplication using Reference Manager, 
716 articles were identified without duplication. After reviewing the titles and 
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abstracts according to the predefined criteria, 93 articles were selected for full-text 
review. The other 622 articles were not included due to the following reasons: (1) it 
was not a CUA study or a CUA-related review (N= 275); (2) there was no sensitivity 
analysis reported (N=145); (3) there was no influential factor identified from 
sensitivity analysis (N=202).     
 
       As for the manual search, four additional articles were identified for full-text 
review. Hence, bibliographies of 97 articles were examined for full-text review, but no 
additional article was further identified which had not been identified through the 
electronic literature search.  
 
        Of the 97 articles included for full-text review, 5 were review articles and 92 
were empirical studies.  The majority was conducted in the United States of America 
(N=41), United Kingdom (N=28), and Canada (N=14). With the exception of one 
study performed in Hong Kong, the rest of the studies were carried out in other 
Western countries including the Netherlands (N=5), Germany (N=2), Spain (N=2) 
Australia, Switzerland, Belgium, Denmark  and Mexico (N=1 for each country).  
 
3.3.3   Factors affecting cost-utility ratio by categories 
       Altogether 20 factors that could potentially impact on the outcomes of a CUA 
were identified in this literature review. These factors could be categorized into 
several broad groupings as treatment-related, disease-related, patient-related, cost-




Figure 3.1 Article selection process  
*: Numbers refer to references identified  
†: Duplication was checked by Reference Manager.  
‡: Inclusion criteria were as follows: (1) for empirical studies, factors affecting cost-utility 
ratio should be clearly identified and quantitatively analyzed by sensitivity analysis; (2) for 
review articles, factors affecting cost-utility ratio should be clearly qualitatively analyzed in 
terms of why or how they affected results of CUA; (3) articles for full-text review should be 

















716 articles of 
no 
duplication† 
93 articles for  
full-text review‡ 
Manual search (1):  
z Journals: 
 Value in Health (n=13) 
 PharmacoEconomics  (n=109) 
 Health Economics (n=35) 
 Journal of Health Economics (n=22) 
4 additional articles for full-text 
review‡ 
Manual search (2):  
All bibliographies of 
97 articles (n=0) 
97 articles for  
full-text review‡ 
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3.3.3.1 Treatment-related factors  
       Efficacy (N=12), duration (N=4), and frequency of treatment (N=1) were the 
three treatment-related factors that have been found to directly influence cost-utility 
ratio in  a wide range of diseases such as myocardial infarction (Sanders et al., 2001), 
diabetes (Kiberd and Larson, 2000), breast cancer (Li et al., 2001), HIV (Pinkerton et 
al., 2000), etc. As shown in Table 3.1, duration and efficacy of treatment are the two 
factors that had negative impacts on cost-utility ratios, while the impact of frequency 
of treatment was reported to be positive (where negative impact denotes an increase in 
the value of factor led to a decrease in cost-utility ratio; while positive impact denotes 
an increase in the value of factor led to an increase in cost-utility ratio.) 
 
       Ten out of 12 studies reported that changes in the efficacy of treatment exerted 
minor and negative impacts on cost-utility ratios, but the impacts were not large 
enough to cross the preset thresholds (USD 20,000/QALY, or USD 50,000/QALY, or 
USD 100,000/QALY depending on individual cases) to alter the conclusion about 
cost-effectiveness of the interventions. On the contrary, increases in duration of 
treatment were mostly found to have major and negative impacts on cost-utility ratios  
(three out of four studies). For example, in a CUA of finasteride for treatment of 
benign prostatic hyperplasia, it was found that duration of treatment was the critical 
factor in judging cost-effectiveness of the drug. Finasteride was shown to be the 
dominant alternative compared with both transurethral resection of the prostate 
(TURP) and watchful waiting for patients with moderate symptoms, only when the 
duration of drug therapy was three years or less (Baladi et al., 1996).  
 
       Comparatively, although frequency of treatment was identified to be the 
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influential factor in only one comparative study assessing the cost-effectiveness of 
sildenafil versus papaverine-phentolamine injections for treatment of erectile 
dysfunction (Schleinitz and Heidenreich, 2005), the impact turned out to be quite 
critical. Doubling the frequency of use of sildenafil was shown to almost increase cost 
per QALY by two-fold. It was mainly because that doubling the dosing frequency 
doubled the drug acquisition cost, which was the major cost driver of the sum of cost 
in the study. However, comparatively, the effect on QALY turned out to be a just 
slight increase, which was far from being doubled.   
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Table 3.1. Treatment-related factors that affect cost-utility ratio 
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by 
author(s), if any  
Duration of treatment     
 Chronic myeloid leukemia Gordois et al., 2003 - Uncertainty regarding the duration of efficacy  
 HIV Pinkerton et al., 2000 -- Uncertainty regarding the duration of efficacy 
 Benign prostatic hyperplasia Baladi et al., 1996 -- Uncertainty regarding the duration of treatment  
 Dystonia Gudex et al., 1997 -- Uncertainty about the duration of treatment  
Efficacy of treatment     
 Myocardial infarction Sanders et al., 2001; -- Uncertainty about the efficacy 
 Breast cancer Hayman et al., 2000; - Uncertainty about the efficacy 
  Hutton et al., 1996 - Uncertainty about the efficacy 
  Verma and Rocch, 2003i - Uncertainty about the efficacy 
 Diabetes Czoski-Murray et al., 2004 - Uncertainty about the efficacy 
 Prostate cancer Krahn et al., 1994 - Uncertainty about the efficacy 
 Parkinson's disease Nuijten and Rutten, 2003 N.A.  Efficacy of treatment could be a potential source 
of uncertainty, so it should be incorporated into 
sensitivity analysis  
     
  59 
Table 3.1 (Continued)  
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by 
author(s), if any  
Efficacy of treatment     
 Back pain Rivero-Arias et al., 2005 - Uncertainty about the efficacy 
 coronary syndrome Schleinitz & Heidenreich, 
2005  
- Uncertainty about the efficacy 
 Hepatitis C Stein et al., 2004 - Uncertainty about the efficacy 
 Orbital foreign body Seidenwurum et al., 2000 - Uncertainty about the efficacy 
 chronic obstructive pulmonary 
disease 
Añón et al., 1999 - Uncertainty about the efficacy 
Frequency of treatment  Erectile dysfunction Stolk et al., 2000 ++ Uncertainty about the frequency of use  
*:  
+: minor positive influence, indicating that increase in the factor would also result in  minor increase in the cost-utility ratio but the impact was not 
large enough to change the conclusion regarding cost-effectiveness of the intervention ;  
++: major positive influence, indicating that increase in the factor would also result in a substantial increase in the cost-utility ratio and the impact 
was large enough to change the conclusion regarding cost-effectiveness of the intervention;  
-: minor negative influence, indicating that increase in the factor would result in minor decrease in cost-utility ratio but the impact was not large 
enough to change the conclusion regarding cost-effectiveness of the intervention ;  
--: major negative influence, indicating that increase in the factor would result in a substantial decrease in cost-utility ratio and the impact of the 
factor was large enough to change the conclusion regarding cost-effectiveness of the intervention;  
N.A.: Not available (magnitude of the impact was not presented in the publication).  
Unless indicated in the study, the threshold of cost-effectiveness was USD 50,000/QALY in this review.  
  60
3.3.3.2 Disease-related factors  
       There were altogether six disease-related factors identified as shown in Table 3.2, 
namely, risk level [N=18: including baseline risk of disease (N=7); and risk of disease 
worsening or complication or even death (N=11)], prevalence rate (N=3), severity 
level (N=5), survival length (N=3), disease progression rate (N=2) and incidence rate 
(N=1). Interestingly, these six factors could be further related to the type of 
intervention, that is, treatment or prevention. 
 
       For treatment programs, cost-utility ratios were shown to be affected by risk level 
(disease worsening or complication or even death), severity level, disease progression 
rate and survival length.  
 
       Among these four factors, risk level and severity level were reported to have 
minor or major and negative impacts on cost-utility ratios (Table 3.2). For example, a 
study on the cost-effectiveness of prophylactic use of the implantable cardioverter 
defibrillator (ICD) or amiodarone after myocardial infarction showed that risk of 
ejection fractions played a key role in determining cost-effectiveness of the treatment 
(Sanders et al., 2001).  For moderate efficacies, when the risk level was less than or 
equal to 0.3, 0.31 to 0.4, or greater than 0.4, the cost-effectiveness of amiodarone 
compared with no therapy was $43,100/QALY, $66,500/QALY, and $132,500/QALY, 
respectively. Under the same condition, the cost-effectiveness of ICD compared with 
amiodarone was $71,800/QALY, $195,700/QALY, and $557,900/QALY. As for 
severity level, in a CUA study conducted by Johnston et al. (1999), it was found that 
treatment of small, asymptomatic, unruptured cerebral aneurysms worsened clinical 
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outcomes, and thus was neither effective nor cost-effective, compared with the same 
treatment on patients with aneurysms that were ≥10 mm or symptomatic.  
       
       Comparatively, the other two factors, namely, disease progression rate and 
survival length were found to have minor and positive influences. It was found that 
reduced disease progression rate increased QALYs, but did not substantially reduce 
direct medical costs (Danese et al., 1996).  As for survival length, its positive impact 
might be more related with the increase of total medical cost due to the extension of 
survival length, while the improvement in QALY was not comparatively significant 
(Richards and Irving, 1996; Manns et al., 2003; Bakhai et al., 2003). 
 
       For disease prevention programs, cost-utility ratio was found to be influenced by 
baseline risk of disease, prevalence rate and incidence rate. All of the three factors had 
negative impacts on cost-utility ratios, the magnitude of which ranged from minor to 
major (Table 3.2). For example, in the CUA of a HIV prevention intervention for 
mentally ill adults, compared with other health promotion interventions, it was 
marginally cost-effective if the analysis was restricted to the subset of high-risk and 
sexually-active women (Pinkerton et al., 2001). In another study of the HIV risk 
reduction intervention among African-American male adolescents, the HIV 
prevalence rate in the community had a substantial impact on the cost-utility ratio. 
The program would no longer be cost-effective if the prevalence rate was less than 
0.58% for all youth despite past sexual experience or less than 0.35% for sexually 
active youth (Pinkerton et al., 2000). Similar impact was also indicated by incidence 
rate, which was identified to be the most influential parameter in the sensitivity 
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analyses of a screening test for hepatocellular carcinoma in patients with hepatitis C 
cirrhosis (Arguedas et al., 2003).  
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Table3.2. Disease-related factors that affect cost-utility ratio  
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by author(s), 
if any  
Severity level     
 Vestibular aqueduct 
syndrome 
Bichey et al., 2002 - Uncertainty about severity level 
 Severe proliferative 
vitreoretinopathy 
Brown et al., 2002 - Uncertainty about severity level 
 Pediatric cochlear 
implantation 
Bichey et al., 2002  - Uncertainty about severity level  
 Parkinson’s disease Nuijten and Rutten, 2003 N.A.  Severity level could be a potential confounding 
variable of the effectiveness of treatment, so it should 
be incorporated into sensitivity analysis  
 Cerebral aneurysms Johnston et al., 1999 -- Hypothesized that patients of different severity would 
lead to difference in cost-effectiveness of the 
treatment.  
Risk level      
(1) Disease worsening  
or complications  
       or death 
    
 Renal transplantation Keown et al., 2004 -- Uncertainty about the risk of rejection after renal 
transplantation; the higher the rejection possibility, 
the lower the cost-utility ratio 
  Keown et al., 2004, 2001 -- Uncertainty about the risk of rejection after renal 
transplantation 
 Abdominal aortic aneurysm 
(AAA) 
St Legar et al., 1996 - Uncertainty about the annual risk of rupture for AAA 
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Table3.2 (Continued) 
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by author(s), 
if any  
(1) Disease worsening  or 
complications or death 
    
 Diabetes Vijan et al., 2000 -- The risk reduction varies dramatically by age and 
level of glycemic control. 
 Myocardial infarction Sanders et al., 2001 -- Uncertainty about the risk of death   
 Allogeneic transfusion Sonnernburg et al., 1999 -- Uncertainty about the relative risk of bacterial 
infection following allogeneic transfusion 
 Appendectomy wounds Brasel et al., 1997 -- Uncertainty about the risk of primary infection 
 Rheumatic diseases Gabriel et al., 1995 -- Uncertainty about the risk of disease   
 Chronic arthritis Zabinski et al., 2001 - Uncertainty about the GI risk in the population  
 Pancreatitis, Gregor et al., 1996 -- Uncertainty about having an occult common duct 
stone 
  (2) Baseline risk of 
disease 
    
 Acute coronary syndrome Latour-Pérez et al., 2004 - Uncertainty about baseline risk of cardiovascular 
events 
 Meningeal signs Oosteinbrink et al., 2002 -- Uncertainty about the risk of bacterial meningitis or 
sequelae 
 HIV Pinkerton et al., 2000 -- Hypothesized that if the analysis was restricted to 
those youth who reported sexual activity in the 3 
months preceding the intervention 
  Pinkerton et al.,1997 - Uncertainty about the per-contact risk of HIV 
transmission 
  Pinkerton et al., 2001 - Uncertainty about risk of HIV  
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Table3.2 (Continued) 
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by author(s), 
if any  
(2) Baseline risk of 
disease 
    
 Chronic arthritis Spiegel et al., 2003  -- Uncertainty about the baseline risk as a having a 
history of bleeding ulcers  
 Diabetes  Ragnarson and Apelgvist, 
2001  
-- Uncertainty about the risk of foot ulcers and lower 
extremity amputations 
Incidence rate     
 Hepatitis C  Arquedas et al., 2003 -- Uncertainty about the incidence rate of hepatitis C  
Disease progression rate     
 Parkinson’s disease Nuijten and Rutten, 2003 N.A.  Disease progression rate  could be a potential 
confounding variable of the effectiveness of 
treatment, so it should be incorporated into sensitivity 
analysis  
 Diabetes Kiberd and Larson + Uncertainty about the progression rate to the end 
stage renal disease  
 Mild thyroid failure Danese et al., 1996  + Uncertainty about the disease progression rate  
Survival length     
 Coronary heart disease  Chau et al., 2001  + Uncertainty about the survival length  
 End-stage renal disease Kiberd and Larson, 2000 + Uncertainty about the survival length  
 Intestinal failure Richards and Irving, 1996 + Uncertainty about the survival length 
Prevalence rate      
 Orbital foreign body  Seidenwurum et al., 2000 - Uncertainty about the prevalence rate 
 Orthoptic screening König and Barry, 2004 - Uncertainty about the prevalence rate 
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Table3.2 (Continued) 
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by author(s), 
if any  
Prevalence rate     
 HIV Pinkerton et al., 2000 -- Uncertainty about the HIV prevalence in the 
community 
*:  
+: minor positive influence, indicating that increase in the factor would also result in  minor increase in the cost-utility ratio but the impact was not large enough to change 
the conclusion regarding cost-effectiveness of the intervention ;  
++: major positive influence, indicating that increase in the factor would also result in a substantial increase in the cost-utility ratio and the impact was large enough to 
change the conclusion regarding cost-effectiveness of the intervention;  
-: minor negative influence, indicating that increase in the factor would result in minor decrease in cost-utility ratio but the impact was not large enough to change the 
conclusion regarding cost-effectiveness of the intervention ;  
--: major negative influence, indicating that increase in the factor would result in a substantial decrease in cost-utility ratio and the impact of the factor was large enough to 
change the conclusion regarding cost-effectiveness of the intervention;  
N.A.: Not available (magnitude of the impact was not presented in the publication).  
Unless indicated in the study, the threshold of cost-effectiveness was USD 50,000/QALY in this review. 
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3.3.3.3 Patient-related factors 
        Incorporating patient-specific characteristics or performing subgroup analysis in 
CUA studies have been increasingly advocated, because such information would 
improve the validity and comparability of results across different studies or 
populations (Van Hout et al., 1999; Arneson and Trommald, 2005; Gudex et al., 1997). 
Age (N=6), gender (N=2), compliance/adherence (N=2), race/ethnicity (N=1) were 
identified as patient-related influential factors as shown in Table 3.3. 
 
       According to a literature review by Russel and Sisk (2000), they found that age 
had been incorporated into several CUA due to its profound impact on life expectancy, 
risk level, incidence and prevalence rates, and treatment efficacy, which would 
ultimately influence both cost and utility components of CUA. It was interesting to 
note that the direction and magnitude of influence was not congruent in the findings, 
which was dependent on how age affected other QALY- and cost-related variables. 
For example, when the incidence rate declined with age, the pneumococcal conjugate 
heptavalent vaccine became far less cost-effective when covering all children less 
than 60-months of age, compared with those less than 24-months of age (Schleinitz  
and Heidenreich, 2005). On the contrary, when incidence rate of mild thyroid failure 
was expected to increase with age, the cost-effectiveness became more favorable 
when age at first screening was increased (Danese et al., 1996).  
 
       However, it was also noted that many studies had not modeled age differences in 
sufficient detail to ensure that differences in cost-utility ratios by age were accurate. 
As the influence of age on CUA would also be dependent on both the disease type 
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(chronic or acute) and treatment type (preventive, curative or palliative), it was 
suggested that more complete age-specific data should be incorporated to ensure a 
sound basis for decisions (Richards and Irving, 1996).  
 
       Apart from age, gender and race/ethnicity were the other two demographic 
parameters shown to impact on cost-utility ratios of patients with heart diseases 
(Kupersmith et al., 1995) and HIV (Johnson-Masotti et al., 2000).  Again, there was 
no definitive conclusion about the direction of impact on cost-utility ratio by these 
two factors, as it would also be potentially relied on how gender or ethnicity affected 
other disease-, treatment- or even cost-related variables. Although not explicitly 
studied in CUA, some of other sociodemographic parameters (e.g. education level, 
marital status, family support, etc) might indirectly impact on cost-utility ratio due to 
their influence on health preferences elicited from patients (Goold and Vijan, 1998).  
 
 Compliance with treatment was identified to be the other critical parameter in the 
cost-effectiveness of interventions. It was shown to be the most sensitive parameter in 
the CUA on patients with depression (Revicki et al., 1997) and diabetes (Clark et al., 
2000). For instance, a CUA of an Angiotensin-Converting Enzyme (ACE) inhibitor 
therapy for diabetic nephropathy, changes in the compliance rate from 67% to 51% 
could result in a swing from a savings of $899 to an expenditure of more than $1 
million per additional QALY (Van Hout et al., 1999). 
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Table 3.3 Patient-related factors that affect cost-utility ratio 
Factor  Disease Reference Magnitude of impact on cost–
utility ratio* 
Hypothesis or justification provided by 
author(s), if any  
Age      
 Intestinal failure Richards and Irving, 1996 ++ Subgroup analysis for different age groups 
 Diabetes Goold and Vijan, 1998  N.A. It is likely the cost and benefits will be based on 
the age of patient.  
 Non-ST-segment elevation 
acute coronary syndrome 
Latour-Pérez, 2004 ++ Uncertainty about the age effect.  
 Pneumococcal conjugate 
immunization 
Ess et al., 2003  ++ Uncertainty about the age effect  
 Mild thyroid failure Danese et al., 1996 - Uncertainty about the age effect ; Potential 
correlation between age and incidence rate  
 N/A (review)  Russel and Sisk, 2000 N.A.  It is not known how well studies model the risks 
and costs associated with age. 
Gender     
 HIV Johnson-Masotti et al., 2000 Major impact (all three 
interventions were cost-effective 
for men, but only single-session 
was cost-effective for woman)  
  
Uncertainty about the gender impact  
 Mild thyroid failure Danese et al., 1996 Moderate impact (more favorable 
towards woman) 
Uncertainty about the gender effect ; Potential 
correlation between gender and incidence rate  
Race/ethnicity     
 Diabetes Goold and Vijan, 1998  N.A.  Potential impact of ethnicity gap on the cost and 
effectiveness of treatment  
Compliance      
 Diabetic nephropathy Clark et al., 2000 -- Uncertainty about the compliance rate  
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Table3.3 (Continued) 
Factor  Disease Reference Magnitude of impact on cost–
utility ratio* 
Hypothesis or justification provided by 
author(s), if any  
Compliance     
 Depression Revicki et al., 1997  - Uncertainty about the compliance rate 
*:  
+: minor positive influence, indicating that increase in the factor would also result in  minor increase in the cost-utility ratio but the impact was not large enough to 
change the conclusion regarding cost-effectiveness of the intervention ;  
++: major positive influence, indicating that increase in the factor would also result in a substantial increase in the cost-utility ratio and the impact was large enough 
to change the conclusion regarding cost-effectiveness of the intervention;  
-: minor negative influence, indicating that increase in the factor would result in minor decrease in cost-utility ratio but the impact was not large enough to change 
the conclusion regarding cost-effectiveness of the intervention ;  
--: major negative influence, indicating that increase in the factor would result in a substantial decrease in cost-utility ratio and the impact of the factor was large 
enough to change the conclusion regarding cost-effectiveness of the intervention;  
N.A.: Not available (magnitude of the impact was not presented in the publication).  
Unless indicated in the study, the threshold of cost-effectiveness was USD 50,000/QALY in this review. 
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3.3.3.4 Cost-related factors  
       Treatment cost (N=17), incorporation of indirect cost (N=3) were identified to be 
the two cost-related factors influencing outcomes of CUA as shown in Table 3.4.  
 
       Treatment cost was found to be the most frequently identified cost-related 
parameter in this review. Variations in treatment cost were assumed in different 
scenarios, such as mere increase or decrease in price/cost of the same drug/device, 
incorporation of other drugs/devices to treat side effects or complications and changes 
in the frequencies/doses of the intervention (Van Hout et al., 1999; Earle et al., 2004; 
Dranitsaris and Hsu, 1999; Stolk et al., 2000).  
 
       In some cases, different types of changes in cost were studied both independently 
and in combination. For example, in a CUA of second-line irinotecan for metastatic 
colon carcinoma in a multi-center, open-label phase III clinical trial (Earle et al., 
2004), it was found that cost-utility ratio was very sensitive to the cost of irinotecan 
with a base-case ratio of $78627/QALY. If cost of irinotecan was decreased to around 
80% of the current cost, then the every-3-week regimen became more attractive than 
the weekly regimen. Hospitalization, mostly due to admissions for toxicity, was more 
likely in the weekly regimen. If such excess of hospital costs were removed, then the 
cost-utility ratio would rise to $108,438/ QALY. A multivariate sensitivity analysis 
eliminating all other cost offsets indicated a maximum cost-utility ratio of 
$267,287/QALY. Fifty-five percent of patients in the every-3-week arm started 
irinotecan at 300 mg/m2. However, if the intended starting dose were reduced to 300 
mg/m2 among all patients while achieving the same outcomes, then the cost-utility 
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ratio would decrease slightly to $72,761/QALY.  
         
       Recent studies based on lifetime utility maximization models suggest that CUA 
should account for all future costs, not only direct and non-direct medical cost, but 
also indirect cost. Especially for CUA from a societal perspective, whether indirect 
cost is incorporated is a major concern (Liljas, 1998). The magnitude of indirect cost 
has been shown to substantially alter both the absolute and relative cost-effectiveness 
of medical interventions, particularly when an intervention would increase length of 
life more than quality of life. For example, the inclusion of indirect cost significantly 
reduced the incremental cost-utility ratio. This further demonstrated the cost-
effectiveness of intensive medical interventions that decreased mortality among 
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Table 3.4 Cost-related factors that affect cost-utility ratio 
Factor  Disease Reference Magnitude of impact on cost–
utility ratio* 
Hypothesis or justification provided by 
author(s), if any  
Treatment cost     
 Diabetes Kiberd and Larson, 2000 ++ Uncertainty about the pancreas 
transplantation cost  
 Orbital foreign body  Seidenwurm et al., 2000 ++ Uncertainty about the screening cost  
 Chronic arthritis Spiegel et al., 2003  ++ Uncertainty about the price of drug  
 Colon Carcinoma  Earle et al., 2004  ++ Uncertainty about the price of the drug  
 Refractory epilepsy Forbes et al., 2003  + Uncertainty about the cost of device  
 Progressive relapsing Touchette et al., 2003 + Uncertainty about the acquisition and 
administration cost of therapy  
 Inguinal hernia Stylopoulos et al., 2003 ++ Uncertainty about the ambulatory facility 
cost  
 Meningeal signs Oostenbrink et al., 2002 + Uncertainty about the treatment cost  
 Hemophilia Miners et al., 2001  ++ Uncertainty about the clotting factor unit 
cost 
 Heart burn Heudebert et al., 2000  + Uncertainty about the medication cost  
 Breast cancer Hayman et al., 2000 + Uncertainty about the treatment cost 
  Hutton et al., 1996 + Uncertainty about the treatment cost 
  Verma and Rocch, 2003 + Uncertainty about the treatment cost 
 Mild thyroid failure    
 Renal transplantation Keown et al., 2001  ++ Uncertainty about the length of 
hospitalization  
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Table 3.4 (Continued) 
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided by author(s), if 
any  
Treatment cost     
 Groin hernia repair Medical Research Council 
Laparoscopic Groin Hernia 
Trial Group, 2001 
++ Uncertainty about the cost of laparoscopic hernia repair, 
which might be due to theatre time and increased 
equipment and sterilization costs 
 Parenteral nutrition program Detsky et al., 1986  + Uncertainty about the cost of alternative treatment  
 Chronic myeloid leukemia Gordois et al., 2003  + Hypothesis about the drug price (10% to 50% discount) 
 Lung cancer  Lievens et al., 2005  + Uncertainty about the cost of Continuous 
Hyperfractionated Accelerated Radiotherapy  
(CHART) 
Incorporation of 
indirect cost  
Not applicable (review)  Meltzer D, 1997 N.A.  Uncertainty about the magnitude of future indirect cost 
 Diabetes  Meltzer D et al., 2000 + Uncertainty about the magnitude of indirect costs 
 Gallstone disease Cook et al., 1994  + Uncertainty about the impact of indirect cost  
*:  
+: minor positive influence, indicating that increase in the factor would also result in  minor increase in the cost-utility ratio but the impact was not large enough to change 
the conclusion regarding cost-effectiveness of the intervention ;  
++: major positive influence, indicating that increase in the factor would also result in a substantial increase in the cost-utility ratio and the impact was large enough to 
change the conclusion regarding cost-effectiveness of the intervention;  
-: minor negative influence, indicating that increase in the factor would result in minor decrease in cost-utility ratio but the impact was not large enough to change the 
conclusion regarding cost-effectiveness of the intervention ;  
--: major negative influence, indicating that increase in the factor would result in a substantial decrease in cost-utility ratio and the impact of the factor was large enough to 
change the conclusion regarding cost-effectiveness of the intervention;  
N.A.: Not available (magnitude of the impact was not presented in the publication).  
Unless indicated in the study, the threshold of cost-effectiveness was USD 50,000/QALY in this review.
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3.3.3.5 Methodology-related factors 
       Cost-utility ratio was also affected by other methodology-related factors, such as 
discount rate (N=6), QALY elicitation method (N=2), statistical uncertainly (N=1), 
handling of confounding variables (N=1) and uncertainty about data source (N=1) 
(Table 3.5).  
 
        Discounting has been recommended as a standard practice in CUA to account for 
the time preference between now and future of both costs and benefits. According to 
the recommendations by the Panel of Cost-effectiveness in Health and Medicine, 
values in the future were suggested to be devalued by a constant annual percentage, 
equal for costs and effects (Siegel et al., 1996). Variations in discount rate have been 
shown to cause negative impacts on cost-utility ratios for both prevention programs 
and treatment interventions, the magnitude of which ranged from minor to major as 
shown in table 3.5 (Bonneux and Birnie, 2001; Seidenwurm et al., 2000; Brown et al., 
2002).  For example, in a hypothesized modeling study conducted by Bonneux and 
Birnie (2001), it was reported that an intervention eliminating cardiovascular disease 
cost 71,100 Euro/QALY with no discount. Applying different discount rates of 3% 
and 6%, the same intervention would cost 8,100 Euro/QALY (8.8 times less) and 
1,100 Euro/QALY (65 times less), respectively. Moreover, in the meantime, the 
assumption of equally discounting cost and benefit has been much argued among 
various schools of thought and no consensus has been reached yet, which might also 
influence results of CUA (Mankiw, 2001; Viscusi, 1996; Cohen, 2003). 
           
         One of the most important components in CUA is the assessment of utilities. 
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QALY can be elicited using preference-based methods such as direct elicitation 
methods (time trade-off, standard gamble and rating scale) or by indirect methods 
using utility-based generic instruments (EQ-5D, SF-6D, etc) (Cook et al., 2001; 
Bravata et al., 2005). Although not directly proven by empirical studies, review 
articles focusing on QALY elicitation methods reported that different methods had 
resulted in different QALY values. It was commented that such difference would 
make results incomparable and may influence the magnitude and direction of results 
for evaluations (Richardson and Manca, 2004). In addition, Arneson and Trommald 
(2005) further proposed that other factors (e.g. age, gender, employment, etc) should 
also be taken into consideration even when comparing QALY values from the same 
method.  
 
       Uncertainties about Markov modeling have triggered heated discussions over 
recent years. In two sequential articles published by Nuijten et al. (2003; 2004), the 
authors generated the concern that cost-utility ratios produced by Markov modeling 
could be severely biased in the potential presence of statistical uncertainty (e.g. 
selection of p-value, type of estimation error), other potential confounding variables 
(e.g. covariance for time relationship between health state and the other explanatory 
variable, covariance between efficacy of the study drug and the other explanatory 
variable) or uncertainty about the data source (e.g. inclusion criteria, 
representativeness of the study population and source of the data whether from 
medical records, meta-analysis or others). However, such methodological thinking 
was strongly criticized by O’Hagan et al. (2005), that it might mislead and violate the 
current practices in handling uncertainties in modeling studies.  In response to this, 
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Nuijten (2005) clarified that these concerns did exist, and more empirical studies 
should be conducted to verify such problems to further improve the current practices.   
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Table 3.5 Methodology-related factors that affect cost-utility ratio 
 
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided 
by author(s), if any  
Discount rate     
 Severe hemophilia Miners et al., 2001 -- Different assumptions about the 
discount rate 
 Visual loss Brown et al., 2002  - Different assumptions about the 
discount rate 
 Cardiovascular disease Bonneux and Birnie, 2001 -- Different assumptions about the 
discount rate  
 Orbital foreign body 
screening 
Seidenwurm et al., 2000  -- Different assumptions about the 
discount rate 
 Orthoptic screening König and Barry, 2004 - Different assumptions about the 
discount rate 





    
 Not applicable (review) Arnesen and Trommald, 2005 N.A  Uncertainty caused by different values 
elicited from different QALY values  
Data source     
 Not applicable (review) Nuijten, 2004 N.A.  Uncertainty about the impact of data 
sources 
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Table 3.5 (Continued)  
Factor  Disease Reference Magnitude of 
impact on cost–
utility ratio* 
Hypothesis or justification provided 




    
 Not applicable (review) Nuijten, 2004 N.A. Uncertainty about the impact of 
confounding variables  
Statistical 
uncertainty 
Parkinson’s disease Nuijten, 2004 N.A. Variation caused by of statistical 
uncertainty  
*:  
+: minor positive influence, indicating that increase in the factor would also result in  minor increase in the cost-utility ratio but the impact was not large enough to 
change the conclusion regarding cost-effectiveness of the intervention ;  
++: major positive influence, indicating that increase in the factor would also result in a substantial increase in the cost-utility ratio and the impact was large enough 
to change the conclusion regarding cost-effectiveness of the intervention;  
-: minor negative influence, indicating that increase in the factor would result in minor decrease in cost-utility ratio but the impact was not large enough to change 
the conclusion regarding cost-effectiveness of the intervention ;  
--: major negative influence, indicating that increase in the factor would result in a substantial decrease in cost-utility ratio and the impact of the factor was large 
enough to change the conclusion regarding cost-effectiveness of the intervention;  
N.A.: Not available (magnitude of the impact was not presented in the publication).  
Unless indicated in the study, the threshold of cost-effectiveness was USD 50,000/QALY in this review.  
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3.4 Discussions  
         In this qualitative literature review, altogether 20 factors were identified that 
have shown to influence CUA results. They could be further grouped into five 
categories as treatment-related (duration, efficacy, and frequency of treatment), 
disease-related (severity level, risk level, incidence rate, prevalence rate, disease 
progression rate and survival length), patient-related (age, gender, race/ethnicity and 
compliance), cost-related (treatment cost, incorporation of indirect cost), and 
methodology-related factors (discount rate, QALY elicitation method, statistical 
uncertainty, handling of confounding variables and reliability of data source). 
Although most of the CUA studies included in the literature review were conducted in 
Western countries, yet it is highly possible that those 20 factors could potentially 
affect the CUA results in Asia.   
 
        To the best of our knowledge, this review article was the very first dedicated to 
identify all the influential factors of CUA in a qualitative and systematic way. The 
findings provide important implications and suggestions to further improve the 
robustness of CUA in the following perspectives:  
 
       First, the current list of 20 factors provides a comprehensive (yet definitely 
incomplete) checklist based on the current literature for both healthcare researchers 
and decisions-makers when conducting and interpreting CUA results. It is worth 
noting that the selection and investigation of influential factors should be adjusted 
according to the real scenario of the intervention and study population.  In some cases, 
there might be no uncertainty about a few of the factors, while in other cases, there 
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could be other factors beyond the current list that might impose potential influence on 
CUA results. Hence, the current checklist is recommended to be used as a basic 
framework while allowing for further modifications. 
 
        Second, our results further emphasize the importance of conducting and 
reporting high quality sensitivity analysis; failure of which has actually been 
identified in a substantial proportion of CUA literatures (Schakman et al., 2004). As 
found in this review, cost-utility ratio may be subject to drastic changes in the 
presence of uncertainties induced by various parameters. Therefore, it is of great 
importance to identify all the sources of uncertainties in the first place. Then, as a 
good practice, extensive sensitivity analysis should be performed accordingly to well 
explore the impact of uncertainties to increase robustness of the results. If the 
uncertainty could not be investigated due to any restrictions, it should also be well 
recognized and documented to raise full awareness. 
 
       Last but not least, we would like to further point out that the factors in the current 
checklist might not be mutually independent. For example, efficacy of treatment was 
reported to be influenced by ethnicity, which could also influence other disease-
related factors like incidence rate, risk level, prevalence rate etc (Kumar et al., 2006;  
G.ryskiewicz et al., 2006; Claudio et al., 2006; Kanuha, 2000).  Therefore, due to such 
potential inter-correlations among various variables, the exploration of collective 
impact of these factors would be better off studied using multi-way sensitivity 
analysis to control for confounding effects in future studies.   
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       In the meantime, some potential limitations of this literature review should also 
be recognized. First, although the current literature review was based on extensive 
search among several most comprehensive health-economics-related databases and 
top journals, it was possible that some other qualified articles published in other 
sources might not be retrieved. Second, the magnitude of minor or major impact as 
defined in the current review might not be accurate enough. For illustration purposes, 
we used a threshold of USD 50,000/QALY to differentiate whether the intervention 
was cost-effective for most of the cases, unless another specific threshold was 
mentioned in the publication. As such cut-off point is still in debate across countries 
or diseases, we suggested interpreting the magnitudes as presented in tables with 
caution.   
 
3.5 Conclusion 
        The current list of factors could be used as a basic checklist when identifying 
sources of uncertainties and performing sensitivity analysis in CUA. Further empirical 
and theoretical studies were suggested to continuously provide better understanding of 
other potential influential factors so as to improve the robustness of CUA in medical 
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4.1 Introduction  
       In the disease management value chain, patients should not be merely recognized 
as recipients, who will get the estimated value of outcomes based on a certain amount 
of resource input. In fact, patients should be regarded as stakeholders, whose active 
participation in the disease management program would make a positive difference in 
the overall cost-effectiveness of the program and ensure the long-term optimization of 
the healthcare delivery process.  
        Such active participation has been commonly referred to as "patient 
empowerment", which emphasized the point that patient should assume their 
responsibility for their own disease and treatment; by incorporating a series of 
attitudinal and behavioral changes, these "empowered" patients would be more 
knowledgeable about, satisfied with and more committed to the treatment to achieve 
the best possible outcomes (Steele et al., 1987).   
        In the current chapter, we would focus on one of the most sought-after patient 
empowerment strategies, that is, disease knowledge and use diabetes population as an 
illustrative example.  
       Several published studies have shown that diabetes knowledge was positively 
associated with more frequently performed self-care behaviors (van den Arend et al., 
2000) and better metabolic control (Beeney and Dunn et al., 1990; Nicolucci et al., 
2000; Persell et al., 2004). It has also been reported that better metabolic control was 
associated with better Health-related Quality of Life (HRQoL) of diabetic patients 
(Vanelli et al., 2003; Mortensen et al., 2002; Hoey et al., 2001). However, relatively 
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little is known regarding the impact of diabetes knowledge on HRQoL. Furthermore, 
the impact of diabetes knowledge on health utility scores has not been explored either, 
the results from which would provide further rationale of whether disease knowledge 
should be incorporated as an influential factor when assessing the efficiency of 
disease management programs with  cost-utility analysis. 
        Hence, in this preliminary study, our primary objective was to investigate the 
correlation between diabetes knowledge with health utility scores. In the mean time, 
we would also present the findings of the association between diabetes knowledge and 
HRQoL as a secondary objective.  
4.2 Methods  
4.2.1 Subjects and study design 
         The cross-sectional study was undertaken at the World Diabetes Day 2004 
commemorative event organized by Diabetic Society of Singapore (DSS) at the 
exhibition hall of a major shopping center in Singapore on October 17, 2004. The aim 
of the event was to enhance people’s knowledge of diabetes, preventive methods and 
other disease-related information as well as to provide free screening tests of 
cholesterol, blood pressure, body fat, HbA1c etc. Participants were approached by 
research assistants to identify whether they were eligible for the current study. 
Inclusion criteria were English-speaking diabetic patients aged 21 and above, who 
were able to complete questionnaires in English without any assistance. The purpose 
of the study was explained to potential subjects by the research assistants. All subjects 
who agreed to participate in the study were asked to sign a written informed consent.  
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       Subjects were then asked to complete a booklet containing a background 
datasheet, diabetes knowledge test sheet, and pages of health utility and HRQoL 
measures. The background datasheet collected information on patient information 
including socioeconomic variables (age, gender, ethnicity, years of education, 
dwelling type, and working status) and related medical conditions (smoking history, 
presence of acute medical conditions in the past 4 weeks, presence of other chronic 
medical conditions and presence of diabetes complications). Patients’ knowledge was 
tested by the General Diabetes Knowledge Test (GDKT). Their health utility scores 
were assessed by two generic preference-based utility measures, namely, EQ-5D and 
SF-6D. The disease-specific HRQoL measure, namely, the Audit of Diabetes-
dependent Quality of life (ADDQoL) was used to assess patients' HRQoL.  
 
4.2.2 Instruments  
4.2.2.1 The General Diabetes Knowledge Test  
       General Diabetes Knowledge Test (Wee et al., 2005) is a 36-item questionnaire 
covering 6 content areas in diabetes prevention and control, namely, general 
knowledge of diabetes, risk factors of diabetes, symptoms of diabetes, complications 
of diabetes, treatment and management of diabetes and monitoring of diabetes (as 
shown in Appendix 4.1). It was a newly developed questionnaire by our research 
group with the aim to evaluate outcomes of diabetes education among general public 
including patients and non-patients, as such tool was lacking before. It has proven to 
be a valid and reliable measure. Internal consistency of GDKT was high (Kuder-
Richardson Formula 20 or KRF20=0.9289). Item difficulty ranged from 0.59 to 0.97 
and was significantly different between subjects with and without diabetes for 8 items 
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(p<0.05). Test-retest reliability was moderate (Intra-correlation coefficient, or 
ICC=0.54). Construct validity was demonstrated using a known-group approach 
where subjects with diabetes were expected to have better knowledge of diabetes (i.e. 
higher GDKT scores) than subjects without diabetes. Here, any response of “yes” is 
regarded as a correct answer and marked as 1 point, “no” or “unsure” is regarded as 
wrong answer and marked as 0. A raw score is obtained based on the sum of correct 
responses. Then it is converted to a final score of 0-100 according to percentage. A 
higher score indicates better general knowledge of diabetes. 
  
4.2.2.2  EQ-5D  
 Please refer to Section 2.2.3.2 for a detailed description of EQ-5D. 
 
4.2.2.3   SF-6D 
 Please refer to Section 2.2.3.3 for a detailed description of SF-6D. 
 
4.2.2.4   ADDQoL 
 Please refer to Section 2.2.3.1 for a detailed description of ADDQoL. 
 
4.2.3 Statistical Analysis  
         Data were entered into an Excel spreadsheet (Microsoft Corporation, Redmond, 
Washington) and analyzed using the Statistical Package for the Social Sciences, 
version 12.0 (SPSS Inc, Chicago, Ill). Subjects with ≥10 missing values in GDKT or 
≥6 missing items in ADDQoL or ≥ 1 missing value in EQ-5D were excluded from all 
analyses. Data with a normal distribution were reported as mean (standard deviation 
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or SD). Otherwise, the median (interquartile range or IQR) was reported. Descriptive 
analysis was used to characterize sociodemographics (age, gender, ethnicity, 
education level, smoking status, work status and dwelling type), medical information 
[type of diabetes, presence of acute disease(s) and co-morbidities and diabetes-related 
complications,] and scores of GDKT, EQ-5D, SF-6D and ADDQoL. 
 
        Relationships between various external variables and utility scores and HRQoL 
were explored by univariate analyses using Mann-Whitney or Kruskal-Wallis tests for 
categorical independent variables, or Spearman’s correlation for continuous 
independent variables. Correlations between GDKT score and utility and HRQoL 
scores were studied in two steps, first with bivariate Spearman’s correlation and then 
with partial correlation after adjustment for other potentially significant variables in 
the univariate analysis (p<0.1). Magnitude of correlation was interpreted according to 
the criteria proposed by Guyatt et al. (1999): less than 0.2 as very weak, over 0.2 but 
less than 0.35 as weak, over 0.35 but less than 0.5 as moderate, and over 0.5 as strong. 
If there was a statistically significant correlation (p<0.05), two-step multiple 
regression models were also constructed to further study the potential impact of 
disease knowledge on HRQoL or utility scores. In all the models, utility or HRQoL 
score was analyzed as the dependent variable. In the first step, disease knowledge was 
included as the only independent variable. In the second step, the impact of disease 
knowledge was studied after adjustment for potential confounding external variables 




4.3 Results  
4.3.1 Characteristics of the subjects 
 Altogether 458 eligible subjects were approached at the event, however most of 
them declined to participate in the study. Thus 56 subjects participated in the study 
(response rate=12.2%), of which 14 were dropped due to incomplete responses as 
defined previously, leaving 42 subjects with complete responses for analysis. 90% of 
the eligible subjects had more than six years of education. Apart from diabetes, 64.3% 
had at least one other chronic medical condition, with 40.5% suffered from at least 
one diabetes complication.  
 
 In the current study, patients were reported with high level of diabetes knowledge 
based on the GDKT, with a median (IQR) of 94 (89, 100). Health utility values as 
generated by SF-6D and EQ-5D were at the higher end [Median (IQR) of SF-6D: 0.80 
(0.70, 0.95); Median (IQR) of EQ-5D: 1.00 (0.80, 1.00)]. However, the HRQoL as 
measured by the disease-specific ADDQoL indicated that most of the patients were in 




















Table 4.1: Characteristics of study subjects and scores of diabetes knowledge, health 
utility and HRQoL  
Subject characteristics (N=42) 
 
N (%) unless specified 
otherwise 
Age (years) [Mean (SD)] 53.5(9.64) 
  
Female  18(45.0) 
  
Ethnicity   
   Chinese 36(85.7) 
   Indian 5 (11.9) 
  
Types of diabetes mellitus   
   Type I 13(31.0) 
   Type II 29(69.0)  
  
Dwelling type   
   Public housing 33(78.6) 
   Private housing  9(21.4) 
  
Years of education   
≤ 6  4(10.0) 
7-12 18(45.0) 






Presence of acute medical conditions* 23(54.8)  
  
Presence of other co-morbidities†  27(64.3) 
  
Prevalence of diabetes complications‡ 17(40.5) 
  
Median (interquartile range) General Diabetes Knowledge Test scores§ 94 (89,100) 
  
Median (interquartile range) EQ-5D scores 1.00 (0.81, 1.00) 
  
Median (interquartile range) SF-6D scores 0.80 (0.70, 0.95) 
  
Median (interquartile range) ADDQoL scores|| 49.57(38.53, 64.67) 
* Having had at least one of the acute disease(s) in the following five categories: a running nose/ sore 
throat/ cough, vomiting/diarrhea, a headache lasting more than one day, sleeping disorder, body injury 
in the past four weeks.  
†: Having had at least one of the chronic disease(s) in the following nine categories, other than their 
primary diagnosis of diabetes: hypertension, heart disease, stroke, asthma or other lung disease, cancer, 
rheumatism or back pain or other bone or muscle illness, mental illness, other chronic diseases.  
‡:Having had at least one of the diabetes-related complication (s) in the following seven categories: eye 
disease, foot problems, kidney disease, heart disease, stroke, erectile dysfunction, neuropathy.  
§:A 36-item diabetes knowledge test, with a score standardized to 0-100; The higher the score, the 
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better the knowledge level.  
||: A 19-item diabetes-specific HRQoL measure, with a score standardized to 0-100; The higher the 
score, the better the HRQoL.  
 
4.3.2 Correlation of diabetes knowledge with health utility values and HRQoL 
       Table 4.2 presents both the unadjusted and adjusted correlation coefficients 
between scores of GDKT and health utility and HRQoL. It was found that none of the 
unadjusted correlation between GDKT with EQ-5D, SF-6D, or ADDQoL was 
statistically significant. The unadjusted correlation coefficients were 0.02 (p=0.881) 
with EQ-5D, 0.05 (p=0.760) with SF-6D, and 0.20 (p=0.203) with ADDQoL.  
 
       In the univariate analysis, after adjusting for the parameter(s) that may potentially 
confound the correlation between diabetes knowledge and utility values and HRQoL 
(p<0.1), the respective correlation coefficients were 0.01 (p=0.936) with EQ-5D, 0.07 
(p=0.715) with SF-6D, and 0.30 (p=0.081) with ADDQoL. Although the correlation 
coefficients between diabetes knowledge with SF-6D and ADDQoL were increased 
after the adjustment, neither of the relationship was statistically significant in the 
current study. 
  
4.3.3 Exploration on the impact of diabetes knowledge on the ADDQoL score  
        Although in the partial correlation analysis, the correlation between diabetes 
knowledge and ADDQoL score was not statistically significant, yet a trend of 
correlation was observed (p=0.081). Such lack of significance level could be due to 
the potential impact of small sample size on the statistical level; therefore, we decided 
to carry on the exploration the impact of diabetes knowledge on the ADDQoL score 
for further verifications.  
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       It was found that in the first regression model with GDKT score as the only 
independent variable, it explained up to 5.0 % of the variances in ADDQoL score 
(p=0.084). However, in the second step, after adjusting for the other confounding 
variables as found in the univariate analysis, it was found that GDKT no longer added 
any more to the explanative power of the other three external variables (adjusted R 
square=0.13, p=0.059), namely, education level, presence of chronic disease(s) and 
presence of diabetes-related complication(s).  
 











EQ-5D 0.02 0.881 0.01 0.936 
SF-6D 0.05 0.760 0.07 0.715 
ADDQoL  0.20 0.203 0.30 0.081 
*; Diabetes knowledge is measured by the Generic Diabetes Knowledge Test (GDKT, score 
range 0-100)  
†: In the partial correlation analysis, variables that are adjusted based on the univariate 
analysis (p<0.1) are as follows:  
EQ-5D: Education level (p=0.05) 
SF-6D: Education level (p=0.09), presence of chronic disease(s) (p=0.02), Age (p=0.05) 
ADDQoL: Education level (p=0.01), presence of chronic disease(s) (p=0.09), presence of 
diabetes-related complication(s) (p=0.09)  
 
4.4 Discussion 
 In this preliminary study among English-speaking diabetic patients, we found that 
the correlation between diabetes knowledge (measured by GDKT) and health utility 
values (measured by generic health utility instruments as EQ-5D and SF-6D) was 
rather minimal, suggesting the impact of diabetes knowledge on the health utility 
values was lacking. Although not statistically significant, diabetes knowledge was 
found to be weakly correlated with disease-specific HRQoL score as measured by 
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ADDQoL. However, after adjusting for other variables, diabetes knowledge had no 
further impact on ADDQoL scores. Albeit preliminary, our findings could help to 
raise or address the following important issues regarding diabetes knowledge, health 
utility and HRQoL assessment:      
 
First, if EQ-5D and SF-6D are taken as two generic health utility measures, then 
the lack of correlation between diabetes knowledge and EQ-5D and SF-6D scores 
suggest that diabetes knowledge might not be an influential factor on the utility values 
in cost-utility analysis when utilities are indirectly elicited from utility-weighted 
generic health status measures. Hence, it seemed rational and justifiable not to spend 
extra time and efforts to examine patients' knowledge during the data collection for 
cost-utility analysis.  
 
However, if we take EQ-5D and SF-6D as the generic HRQol measure (Coons et 
al., 2000), then it is interesting and important to note from HRQoL scores that generic 
HRQoL measures might not be as sensitive and responsive as the disease-specific 
instrument (ADDQoL as in the study), which further reinforces the advantage and 
need of using disease-specific instrument to measure HRQoL of those patients. 
Furthermore, it suggested that utilities directly generated from disease-specific health 
states might be more accurate to evaluate the effectiveness of the disease management 
programs compared with generic health states.  
 
 Second, although the adjusted correlation between diabetes knowledge and 
ADDQoL was weak and insignificant, it suggested that the increase in diabetes 
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knowledge still have a role to play in improving HRQoL. Moreover, apart from the 
usual aim of increasing disease knowledge, patient education programs could also 
incorporate other elements of patient empowerment strategies such as communicating 
effectively with healthcare professionals, cultivating a positive attitude towards the 
disease management, etc (Aujoulat et al., 2007).   
 
       In the mean time, several limitations of this preliminary study also need to be 
pointed out. First, as this study was a cross-sectional study by convenience sampling 
at just one event on the same day, substantial number of patients could not be 
recruited and this might have led to the insignificant relationship as analyzed.  Further 
studies utilizing larger sample size by purposive sampling would be required to 
confirm the findings.  Second, in the current study, patients were reported to have a 
quite high level of disease knowledge, which could be due to the fact that GDKT was 
developed based on the findings of a public survey on general diabetes knowledge 
and was aimed to be used among the general population (Wee et al., 2002; Wee et al., 
2005). Hence, its power to assess more specific diabetes knowledge might not be 
strong enough and a more comprehensive diabetes knowledge test like the one 
developed and validated by Michigan Diabetes Research and Training Center 
(Fitzgerald et al., 1998) is suggested to be used to validate the current findings. Third, 
future studies incorporating the measurement of clinical endpoints to measure 
diabetes control (e.g. HbA1c) would help bridge the theoretical link between diabetes 




4.5 Conclusion  
This preliminary study showed that diabetes knowledge did not impact generic 
health utility values or generic HRQoL scores. Yet there was a weak yet insignificant 
correlation between diabetes knowledge and disease-specific HRQoL score. Further 













































Chapter Five  
 
 
Exploring the Impact of Health Literacy on Utility 
Assessment and Health-Related Quality of Life 
(HRQoL) among Patients with Rheumatic Diseases 
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5. 1 Introduction  
        In general, health literacy is defined by the American Medical Association 
(AMA), as “a constellation of skills, including the ability to perform basic reading and 
numerical tasks required to function in the healthcare environment.” (AMA, 1999). It 
has been regarded as a better endpoint to measure patients’ literacy capabilities in a 
medical setting as compared with general literacy (Villaire and Mayer, 2007). With 
the emerging emphasis on patient empowerment strategies in disease management, 
adequate health literacy has become an increasingly important factor in ensuring the 
effectiveness of health education programs and the quality of communication between 
patients and physicians (Safeer and Keenan, 2005; Speros, 2005). Inadequate health 
literacy has shown to be associated with lower treatment compliance rates, poorer 
biomedical and functional outcomes, and increased burden of illness, especially 
among patients with chronic diseases including diabetes, asthma, etc (Andrus and 
Roth, 2002; Schillinger et al., 2002; Wolf et al., 2005; Howard et al., 2005). 
 
        Since the emergence of health literacy studies in the medical literature in the 
early 1990s, the problem of inadequate health literacy has been reported among 
patients with rheumatic diseases including rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE). Patients with rheumatic diseases with limited health 
literacy were more likely to misinterpret prescription labels, have poorer disease 
knowledge and more hospital visits (Larson and Schumacher, 1992; Gordon et al., 
2002; Buchbinder et al., 2000; Hearth-Holmes et al., 1997). However, as highlighted 
in a recent review by Rudd et al. (2007), most of the studies on health literacy in 
Rheumatology have focused on the assessment of readability of health education 
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materials, health literacy levels of patients with rheumatic diseases, or the suitability 
of health education materials for the intended study population. That is, little is known 
about the potential impact of health literacy on the health-related outcomes of patients 
with rheumatic diseases.  
 
       In spite of biological or physiological differences among different types of 
rheumatic diseases, patients with these diseases share some common outcomes, 
specifically disabilities in their physical, mental and social functioning (Wright, 1990; 
Brand et al., 1992; Wolfe, 1999; Allaire, 2001). As biomedical measures sometimes 
may not sensitively indicate the improvement in symptoms and health status, Health-
related Quality of Life (HRQoL) has been increasingly incorporated as a 
complementary and essential outcome measure to assess changes in the physical, 
psychological, social and somatic functioning and well-being of these  patients (Ward, 
2004; Brunner and Giannini, 2003).  
 
       Given the perceived challenge of inadequate health literacy in the self-
management skills of rheumatic diseases, it is important to explore whether health 
literacy influences HRQoL as an outcome among patients with rheumatic diseases 
(Ramos-Remus et al., 2000). Moreover, health utility scores generated from generic, 
preference-based HRQoL measures such as EQ-5D and SF-6D have been widely used 
in cost-utility analyses to determine the cost-effectiveness of pharmacological and 
surgical interventions in rheumatology for approval and subsidy decisions (Kobelt, 
2006; Kavanaugh, 2007). Therefore, the exploration of the impact of health literacy on 
utility assessment would also be of great interest in determining if it is necessary to 
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incorporate health literacy as a potential factor influencing the results of cost-utility 
analysis of disease management programs among these patients. To address these 
issues and to help bridge the gap between health literacy and outcomes research in 
patients with rheumatic diseases, the current study aimed to explore the impact of 
health literacy on the utility assessment and HRQoL among patients with rheumatic 
diseases.  
 
5.2 Methods  
5.2.1 Subjects and study design  
       Consenting English-speaking patients with rheumatic diseases without cognitive 
problems who were over 18 years old and seen at a tertiary referral centre in 
Singapore were recruited by purposive sampling in this Institutional Review Board 
(IRB) approved study. Eligible patients were first asked to read out the 66 medical 
terms in the Rapid Estimate of Adult Literacy in Medicine (REALM) to the 
interviewer. Patients were next asked to self-complete two generic health utility 
measures (EQ-5D and SF-6D), a generic HRQoL measure (SF-36) and a pre-tested 
questionnaire to obtain information on patient’s characteristics (including age, gender, 
ethnicity, education level, working status, dwelling type, presence of acute disease(s) 
and co-morbidities, primary diagnosis, disease activity and severity based on 10 cm 
horizontal visual analogue scales scored by the patient’s rheumatologist). If the 
eligible patient reported that he or she was illiterate, he/she was be given a REALM 
score of 0, and HRQoL and subject characteristics were obtained through an interview 
– however, all subjects studied had some degree of literacy.  
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5.2.2 Measures  
5.2.2.1 REALM  
       REALM is a 66-item word recognition test to assess the ability of an adult patient 
to read common medical words and lay terms relating to body parts and illnesses (See 
appendix 5.1). It was designed to assist medical professionals in estimating a patient’s 
literacy level so that oral instructions and written education materials could be 
appropriately provided. REALM takes about two to three minutes to administer and 
score. According to the scoring scheme (range 0-66), results of REALM should be 
categorized and interpreted as follows: (1) 0-18: Will not be able to read most low 
literacy materials; will need repeated oral instructions, materials composed primarily 
of illustrations, or audio or video tapes; (2) 19-44: Will need low literacy materials; 
may not be able to read prescription labels; (3) 45-60: Will struggle with most patient 
education materials; and (4) 61-66: Will be able to read most patient education 
materials. (Davis et al., 1991) Correspondingly, in this study, patients were 
categorized into two groups as low health literacy (0-60) or adequate health literacy 
(61-66) to reflect their ability to read materials below or above ninth grade level.   
 
5.2.2.2 SF-36  
       The SF-36 is a multi-purpose, short-form generic HRQoL measure with 36 
questions on eight subscales, namely, physical function (PF), role-physical (RP), 
bodily pain (BP), general health (GH), vitality (VT), social function (SF), role-
emotional (RE),  and mental health (MH), with higher scores (range 0–100) reflecting 
better perceived health. The validity of SF-36 has been demonstrated in the English-
speaking population in Singapore (Thumboo et al., 2001).   
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5.2.2.3 SF-6D  
 Please refer to Section 2.2.3.3 for a more detailed description of SF-6D 
 
5.2.2.4 EQ-5D 
  Please refer to Section 2.2.3.2 for a more detailed description of EQ-5D. 
 
5.2.3 Statistical analysis  
         Data were entered into a Microsoft Excel spreadsheet (Microsoft Corporation, 
Redmond, WA) and analyzed using SPSS 12.0 (SPSS Inc., Chicago, IL). All tests 
were two-tailed and conducted at a significance level of 0.05. Data with a normal 
distribution were reported as mean (standard deviation or SD). Otherwise, the median 
(interquartile range or IQR) was reported. Descriptive analysis was used to 
characterize sociodemographics (age, gender, ethnicity, education level, work status 
and dwelling type), medical information [presence of acute disease(s) and co-
morbidities, primary diagnosis, activity and severity of the diagnosis] and scores of 
REALM, EQ-5D and SF-6D, and SF-36. The sociodemographic and other 
characteristics of patients with adequate and inadequate health literacy were compared 
using Student’s t-test for continuous variables with a normal distribution, Mann-
Whitney U non-parametric test for variables without a normal distribution, and the 
chi-square test for categorical variables. 
 
       Relationships between various external variables and utility scores and HRQoL 
were explored by univariate analyses using Mann-Whitney or Kruskal-Wallis tests for 
categorical independent variables, or Spearman’s correlation for continuous 
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independent variables. Correlations between health literacy level and health utility 
and HRQoL scores were studied in two steps, first with bivariate Spearman’s 
correlation and then with partial correlation after adjustment for other potentially 
significant variables in the univariate analysis (p<0.1). Magnitude of correlation was 
interpreted according to the criteria proposed by Guyatt et al. (1999): less than 0.2 as 
very weak, over 0.2 but less than 0.35 as weak, over 0.35 but less than 0.5 as 
moderate, and over 0.5 as strong. If there was a statistically significant correlation 
(p<0.05), two-step multiple regression models were also constructed to further study 
the potential impact of health literacy on utility or HRQoL scores.  In all the models, 
utility or HRQoL score was analyzed as the dependent variable. In the first step, 
health literacy level was included as the only independent variable. In the second step, 
the impact of health literacy level was studied after adjustment for potential 
confounding external variables identified in the univariate analysis (p<0.1). Statistical 
significance level was set at p<0.05.  
 
5.3 Results 
5.3.1 Subject characteristics 
       Of 220 eligible subjects, 90.5% (n=199) participated. The majority of the patients 
were female Chinese with more than 10 years of education [70.5% female, 74.0% 
Chinese and 79.5% with at least 10 years education]. The commonest primary 
diagnoses among participants were Rheumatoid Arthritis (21.0%), Osteoarthritis 
(17.5%), Systemic Lupus Erythematosus (11.5%) or a Spondyloarthropathy (11.5%), 
with 47% of patients having at least one co-morbidities.  
 
  103
       Based on REALM scores, 112 patients (56.3%) were categorized as having 
adequate health literacy and 87 patients as having low health literacy. Table 5.1 shows 
the comparison of subject characteristics between the two groups. As compared with 
low health literacy subjects, subjects with adequate health literacy were older, had 
more years of education and a higher chance of living in private housing. 
 
5.3.2 Comparison of health utility and HRQoL scores in patients with rheumatic 
diseases by health literacy levels  
       No statistically significant difference in either EQ-5D or SF-6D utility scores was 
found between patients with adequate health literacy and those with inadequate health 
literacy. As for HRQoL, the physical functioning score (PF) of patients with adequate 
health literacy was significantly higher than those with inadequate health literacy 
[Median (IQR) of PF: 80 (60, 90) vs. 70 (45, 85) respectively, p=0.006]. Table 5.2 
shows that apart from the difference in PF scores between these groups, there were no 



















Table 5.1: Subject Characteristics 
 Median (interquartile range),  unless otherwise specified
（N=199） 






P value  
 
Age (years) [Mean (SD)] 48.5 (14.7) 43.7 (14.0) 0.044 
Ethnicity (N, %)   0.805 
  Chinese 82 (73.2) 65 (74.7)  
  Malay 11(9.8) 10 (11.5)  
  Indian 16 (14.3) 10 (11.5)  
Female (N, %) 76 (67.9) 64 (73.6) 0.383 
Education (N, %)   0.010 
  ≤6 years  4 (3.6) 8 (9.2)  
  7-12 years 46 (41.1) 49 (56.3)  
  >12 years 61 (54.5) 30 (34.5)  
Working (N, %) 66 (58.9) 54 (62.1) 0.654 
Housing (N, %)   0.001 
  Private  51 (45.5) 20 (23.0)  
  Public (i.e. Government 
subsidised) 
61 (54.5) 67 (77.0)  
Presence of acute medical 
conditions * (N, %) 
79 (70.5) 64 (73.6) 0.638 
Presence of co-morbidities † (N, 
%) 
54 (48.2) 38 (43.7) 0.525 
Primary diagnosis (N, %)    0.462 
  Osteoarthritis ‡ 23 (20.5) 11 (12.6)  
Rheumatoid Arthritis‡ 20 (17.9) 22 (25.3)  
Systemic Lupus  
Erythematosus‡ 
12 (10.7) 11 (12.6)  
  Spondyloarthropathy§ 13 (11.6) 10 (11.5)  
  Others || 40 (35.7) 30 (34.5)  
Activity of primary diagnosis ¶ 0.50 (0.20, 0.65) 0.50 (0.20, 1.00) 0.050 
REALM score†† 64 (63, 65) 57 (51, 60) 0.000 
* Having had at least one of the acute disease(s) in the following five categories: a running 
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nose/ sore throat/ cough, vomiting/diarrhea, a headache lasting more than one day, sleeping 
disorder, and body injury in the past four weeks.  
†: Having had at least one of the chronic disease(s) in the following nine categories, other than 
their primary diagnosis of the rheumatic disease: diabetes, hypertension, heart disease, stroke, 
asthma or other lung disease, cancer, rheumatism or back pain or other bone or muscle illness, 
mental illness, other chronic diseases.  
‡ : Based on the American College of Rheumatology (ACR) classification criteria 
§: Based on the European Spondylarthropathy Study Group (ESSG) criteria 
||: Other diagnosis ncluded hypermobility syndrome, osteoporosis, other forms or arthritis (e.g. 
gout, reactive arthritis), soft tissue rheumatism, fibromyalgia, other connective tissues 
diseases (e.g. myositis, Sjögren's syndrome) and systemic vasculitis,  
¶: Measured on a 10 cm horizontal visual analogue scale, from “inactive” (scored as 0) to 
“very active” (scored as 10)   
**: Measured on a 10 cm horizontal visual analogue scale, from “mild” (scored as 0) to “very 
severe” (scored as 10)    
††: The 66-item Rapid Estimate of Adult Literacy in Medicine (REALM) is scored based on 
the correct number of answers, from 0 to 66.  
  
Table 5.2: Comparison of health utility and HRQoL scores of patients with rheumatic 
diseases by health literacy levels 
Instrument Health utility or HRQoL scores of patients by health literacy levels  
Median (interquartile range) (N=199) * 
 Adequate health literacy  
(N=112)  
Low health literacy  
(N=87) 
P value  
 
EQ-5D  0.80 (0.73, 1.00) 0.80 (0.73, 1.00) 0.645 
SF-6D 0.80 (0.70, 0.88) 0.76 (0.66, 0.89) 0.160 
SF-36†    
 PF 80.00 (60.00,90.00) 70.00 (45.00,85.00) 0.006 
 RP 75.00 (0.00,100.00) 75.00 (0.00,100.00) 0.705 
 BP 62.00 (51.00,84.00) 62.00 (41.00,74.00) 0.323 
 GH 67.00 (47.00,77.00) 62.00 (45.00,72.00) 0.300 
 VT 65.00 (55.00,75.00) 65.00 (50.00,75.00) 0.252 
 SF 81.25 (60.50,100.00) 87.50 (62.50,100.00) 0.895 
 RE 100.00 (66.67, 100.00) 100.00 (66.67,100.00) 0.808 
 MH 80.00 (68.00,88.00) 76.00 (60.00,88.00) 0.497 
*: Based on the scoring scheme of REALM, scores between 0 and 60 (less than 9th grade) are 
categorized under “low literacy” and scores between 61 and 66 (over 9th grade) are under 
“adequate literacy”.  
†: PF (physical function), RP (role physical), BP (bodily pain), GH (general health), VT 




5.3.3 Correlation between health literacy levels and health utility and HRQoL 
scores 
       Utility scores as measured by SF-6D and EQ-5D scores were not significantly 
correlated with health literacy in either bivariate or partial correlations which adjusted 
for the respective significant external variables identified in the separate univariate 
analysis (Table 5.3).  
 
        In the exploration of correlation between health literacy level with HRQoL score 
as measured by SF-36, it was found that in univariate analysis, health literacy level 
was significantly correlated with PF; however this correlation was considered weak 
(Spearman’s correlation coefficient=0.20, p=0.006). Other variables significantly 
associated with PF scores in univariate analyses were age, education level, working 
status, presence of co-morbidities and activity of the primary diagnosis. After 
adjustment for these five external variables in the partial correlation between the 
health literacy level and PF, the Spearman’s correlation coefficient was 0.22 
(p=0.002). This suggests that patients with rheumatic diseases with inadequate health 
literacy were more prone to worse physical functioning after adjusting for the 
influence of these other variables. However, as for the remaining SF-36 domains, no 










Table 5.3 Correlation between health literacy level and HRQoL and utility scores of 









P value  
EQ-5D  0.03 0.645 0.02 0.771 
SF-6D 0.10 0.160 0.08 0.259 
SF-36‡     
 PF 0.20 0.006 0.22 0.002 
 RP 0.03 0.705 0.03 0.714 
 BP 0.07 0.323 0.04 0.554 
 GH 0.07 0.300 0.04 0.548 
 VT 0.08 0.252 -0.01 0.887 
 SF 0.10 0.895 -0.04 0.580 
 RE 0.02 0.808 0.02 0.832 
 MH 0.05 0.497 -0.01 0.900 
*: Based on the Rapid Estimate of Adult Literacy in Medicine (score range: 0-66), health 
literacy levels are categorized into “low health literacy” (0-60) and “adequate health literacy” 
(61-66).  
†: In the partial correlation analysis, variables that are significantly associated with SF-36 and 
utility scores are adjusted as follows:  
EQ-5D: ethnicity, presence of co-morbidities, presence of acute disease, severity of the 
primary diagnosis, age, working status;  
SF-6D: presence of acute disease, activity of the primary diagnosis, severity of the primary 
diagnosis, working status  
PF: age, education level, working status, presence of co-morbidities and activity of the 
primary diagnosis are adjusted. 
RP: presence of acute disease, activity of the primary diagnosis, severity of the primary 
diagnosis; 
BP: presence of co-morbidities, activity of the primary diagnosis, severity of the primary 
diagnosis, working status; 
GH: presence of co-morbidities, presence of acute disease 
VT: age, presence of acute disease, activity of the primary diagnosis 
SF: gender, presence of acute disease, activity of the primary diagnosis, severity of the 
primary diagnosis 
RE: severity of the primary diagnosis, working status 
MH: presence of acute disease, age, housing 
‡ : PF (physical function), RP (role physical), BP (bodily pain), GH (general health);, VT 




5.3.4 Impact of health literacy level on Physical function 
        As health literacy level was found to be only significantly associated with PF, 
further exploration of the impact of health literacy on PF was performed using 
multiple linear regression (MLR) models (Table 5.4). When health literacy level was 
the only independent variable (Step 1), it explained up to 3.6% of the variance in PF. 
When the five potential influential external variables (age, education level, working 
status, presence of co-morbidities and activity of the primary diagnosis) significantly 
associated with PF were adjusted for (Step 2), health literacy level was found to 
independently and significantly explain up to 3.7% of the variance in PF, with the 
other five external variables explaining up to 20.3% and the total of six variables 
explaining up to 24.0% of the variance in PF. Furthermore, based on the regression 
coefficient, it was also found that patients who were younger, working, having lower 
disease activity and with adequate health literacy were more likely to have better 















Table 5.4 Impact of health literacy level on the physical functioning of patients with 
rheumatic diseases using multiple linear regression models 

























 Age (per year) -0.18  
(-0.28, -0.08) 
-0.26 0.001 
 Working  3.14 
(0.47, 5.81) 
0.16 0.022 





 Disease activity† -3.31  
(-4.87, -1.75) 
-0.30 0.000 
 Education     
   >12 years 1.45 
(-3.80, 6.69) 
0.07 0.587 
   7-12 years -0.57  
(-5.96, 4.82) 
-0.03 0.835 
   ≤6 years‡ 0 0  
*: Based on the Rapid Estimate of Adult Literacy in Medicine (score range: 0-66), health 
literacy levels are categorized into “low health literacy” (0-60) and “adequate health literacy” 
(61-66).  
†: Measured on a 10 cm horizontal visual analogue scale, from “inactive” (scored as 0) to 
“very active” (scored as 10).   








       In this cross-sectional study among patients with rheumatic diseases, we found 
that health literacy level did not impact health utility scores measured using either SF-
6D or EQ-5D. Furthermore, it was also found that health literacy level did not 
influence HRQoL in general. Although there was a statistically significant correlation 
between health literacy level and physical functioning which persisted after adjusting 
for other variables, the strength of this correlation was weak and had an explanatory 
power of less than 4%. No significant impact of health literacy was found on the 
remaining 7 SF-36 domains.  To the best of our knowledge, this is among the first 
studies exploring the impact of health literacy on health utility and HRQoL 
assessment in patients with rheumatic diseases. Our findings may provide useful 
information and important implications for the health literacy issues on patients with 
rheumatic diseases in several ways, detailed below.  
 
      First, it would be of special interest to the medical decision makers to know that 
health literacy level was not an influential factor of the final utility scores of patients 
with rheumatic diseases measured by EQ-5D and SF-6D. Utility scores elicited from 
patients with rheumatic diseases have been used to determine the effectiveness or the 
further cost-effectiveness of different interventions for the purposes of treatment 
selection and intervention reimbursement (Homik and Suarez-Almazor, 2004). Our 
results are reassuring in this regard as they suggest that health literacy does not 
influence utility scores in patients with rheumatic diseases. Thus there is unlikely to 
be a need to intentionally stratify recruitment of subjects on the basis of their health 
literacy.   
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       Second, the weak yet significantly positive association between health literacy 
and physical functioning raises potential concerns over the problem of inadequate 
health literacy for various stakeholders in the management of rheumatic diseases. As 
preservation of the physical function is among the top priorities in the long-term care 
of patients with rheumatic diseases, our results suggest that physicians need to make 
extra efforts to effectively convey medical instructions to those with limited health 
literacy and ensure their compliance and proper execution on a regular basis (Simon, 
2004; Sutcliffe et al., 1999). Similarly, health education materials for such patients 
need to be developed in such a way that they are well comprehended by patients with 
inadequate health literacy to optimize their positive impact on physical functioning in 
such patients. From a patients’ perspective, those with inadequate health literacy 
could be encouraged take a more active role in communicating with their health care 
providers to maximize the possibility of improving their health status. It was also 
interesting to note that the correlation between health literacy and HRQoL outcomes 
detected in the current study was actually much higher than those found in other 
studies on patients with other chronic diseases like cancer (no association), depression 
(no association) and asthma (r=-0.02, p<0.01) (Hahn et al., 2007; Lincoln et al., 2006; 
Mankuso et al., 2006).  
 
      Last but not least, the high prevalence (44%) of patients with inadequate health 
literacy as identified by REALM in the current study further contributes to the 
increase in awareness of health literacy problems in patients with rheumatic diseases. 
According to the earlier cross-sectional studies on patients with SLE or RA, the 
percentage of inadequate health literacy ranged from 10% to 48% (Larson and 
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Schumaker, 1992; Buchbinder et al., 2000; Buchbinder et al., 2006). Therefore, the 
administration of a health literacy test could be recommended as a one-time screening 
test in routine healthcare settings to identify patients with rheumatic diseases with 
limited health literacy so as to deliver more tailored consultation and education.(e.g. 
further explaining medical terms in layman’s language and designing special written 
materials for patients with low health literacy). 
 
        Finally, we recognize several limitations of this study. First, because the current 
study population included patients belonging to different categories of rheumatic 
diseases, no disease-specific preference-based health utility or HRQoL measure was 
used. Although the SF-36 appears to be the best available generic measure to evaluate 
health status of patients with rheumatic diseases, it might not be as sensitive as some 
other disease-specific HRQoL measures to capture small but meaningful differences 
in certain domains of HRQoL affected by a given disease. Besides, there is ongoing 
debate regarding the accuracy and sensitivity of using REALM, a word recognition 
test, to evaluate the comprehension capability, that is, the functional health literacy 
level of patients (Friedman and Hoffman-Goetz, 2006). These could possibly account 
for the weak (yet statistically significant) correlation between health literacy level and 
physical functioning. Future research could investigate the magnitude of such 
relationships using a disease-specific HRQoL measure. For example, in osteoarthritis, 
the Western Ontario MacMaster questionnaire (WOMAC) could be administered 
(Bellamy et al., 1988). Second, some characteristics of the study population may 
potentially mask the correlation between health literacy level with other domains of 
HRQoL. Because the study population in our study was mainly composed of those 
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with mild severity and disease activity, their mental health and other HRQoL 
functioning might be less affected than patients with more severe conditions. 
Therefore, in order to verify the lack of correlation between health literacy and other 
HRQoL functioning, it would be helpful to conduct the similar study on patients with 
more diversified levels of disease activity and severity.  Apart from clinical endpoints 
such as disease activity and severity, incorporating the measurement of compliance 
level would also help bridge the theoretical link between health literacy and 
HRQoL/health utility and further verify our findings.  
 
5.5 Conclusion  
        This study showed that health literacy did not impact generic health utility scores 
or HRQoL in general, but had a weak impact on the physical functioning of patients 
with rheumatic diseases. In order to confirm and expand the results of the current 
study, it is suggested that further studies be conducted on patients with specific 
































Development and Validation of a generic functional 




6.1 Introduction  
        Compared with the general definition of "health literacy" by the American 
Medical Association (AMA) as mentioned at the beginning of last chapter, "functional 
health literacy" is a more specific term referring to the ability of understanding and 
capability of acting on health information (Andrus and Roth, 2002). With the 
increasing emphasis on patient-oriented disease management and preventive medicine, 
patients as well as the general public need to achieve an adequate functional health 
literacy level to perform corresponding tasks in order to improve their clinical 
outcomes.  
 
         In health care settings, patients have to be functionally literate to be able to read 
and comprehend prescription labels, interpret appointment slips, follow instructions 
for diagnostic tests, complete medical documents, etc (Parker et al., 1995; Baker, 
1995; Speros, 2005; Marrow et al., 2006). Inadequate functional health literacy has 
been shown to be related with poorer health status, lower compliance rates, prolonged 
hospitalization and increased health care costs (Guerra et al., 2005; Howard et al., 
2005; Rutherford et al., 2006; Schillinger et al., 2006).  
 
        Similarly, the general public should also demonstrate relatively sufficient health 
literacy levels to comprehend various health education materials in order to 
continuously improve their health-related quality of life (HRQoL), strengthen their 
disease prevention capabilities and achieve the cost-effectiveness of those programs. 
Due to the poor correlation between functional health literacy and highest education 
level, it is not possible to reliably predict one’s functional health literacy level simply 
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from his or her education achievement (Weiss, 2001; Kleinpeter, 2003).  
 
        As for the measurement of functional health literacy, it has been debated that the 
widely used word recognition test, the 66-item Rapid Estimate of Adult Literacy in 
Medicine (REALM) might not be accurate and sensitive enough to measure 
functional health literacy levels (Friedman and Hoffman-Goetz, 2006). It is because 
the REALM only asks respondents to pronounce words rather than test 
comprehension of the words, which may sometimes lead to either under-estimation or 
over-estimation of the actual functional health literacy level.  
 
Based on the literature search in PubMed (up till March 2007), there were 
altogether three validated functional health literacy tests for use in primary health care 
settings, namely, the Newest Vital Sign (NVS), the Test of Functional Health Literacy 
among Adults (TOFHLA) and the Test of Functional Health Literacy in Dentistry 
(TOFHLiD) (Parker et al., 1995; Weiss et al., 2005; Gong et al., 2007). A brief 
description of these three tests is provided as follows: The NVS is based on a nutrition 
label that is accompanied by 6 questions and requires 3 minutes for administration, 
which was recommended by the authors for use as a quick screening test for limited 
literacy in primary health care settings (Weiss et al., 2005). The TOFHLA is based on 
actual hospital materials used in the United States, which consists of a 50-item 
reading comprehension and 17-item numerical ability test, taking up to 22 minutes to 
administer (Parker et al., 1995).   Using TOFHLA as a template, the TOFHLiD is to 
measure functional oral health literacy, with a 48-item reading comprehension and a 




However, none of these three tests was shown to be readily applicable for use 
among the general public for the following reasons. It has been highlighted that NVS 
was indistinguishable from a standard adult literacy test used in the National Adult 
literacy survey (NALS). That is, NVS was not specially developed to test the 
functional health literacy. Besides, NVS tended to assess quite a high proportion of 
mental mathematical skills, which may not be used that often by the general public in 
routine health education programs (King, 2005; Bennet, 2005). According to the 
discussions of TOFHLiD by its own developers, TOFHLiD was not recommended to 
be used among the general public or patients in primary health care settings other than 
those in dentistry (Gong et al., 2007). 
 
Compared with NVS and TOFHLiD, TOFHLA was considered as a gold 
standard for measuring functional health literacy. Yet some of its drawbacks could not 
be ignored. Its incorporation of “Medicaid” (a unique health insurance system in USA) 
as one reading comprehension passage in both TOFHLA and S-TOFHLA (an 
abbreviated version of TOFHLA) made it lack of face validity when applied to other 
English-speaking populations (Baker et al., 1999). Besides, its relatively long 
completion time of 20 minutes prevented it from being administered as a screening 
test, especially in a busy clinic setting.  
 
As none of the functional health literacy tests demonstrated appropriateness for 
use among general public of English-speaking populations around the world, a new 
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functional health literacy test should be developed and validated to fill this need. The 
primary objective of the current study was to develop and validate a generic 
functional health literacy test (GFHLT) for use among the English-speaking general 
public. A secondary objective of the current study was to further test the reliability 
and validity of GFHLT among English-speaking rheumatic patients in Singapore, as 
an example of its application and usefulness in a real-life health care setting. 
 
The recruitment of English-speaking Singaporeans in the current study for the 
development and testing of the GFHLT has its unique advantages. Singapore has an 
education system based on the UK model which incorporates elements of the USA 
model, and English is the administrative language of government and the language of 
instruction at the local educational institutes, providing great potentials of adapting 
the current GFHLT to be used among other populations who are educated in English 
as well. Another advantage is that English health education programs developed in 
Singapore have been usually served as good examples within the Asian region, 
suggesting further potentials of administering GFHLT to the other English-speaking 
populations.  
 
6.2 Methods  
6.2.1 Study design and subjects 
 The whole study was divided into two phases: GFHLT development and 
GFHLT validation. The study was approved by the Institutional Review Board of the 
National University of Singapore and the Singapore General Hospital. 
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6.2.1.1 GFHLT development  
        As measured by the Flesch-Kincaid grade level index, a readability level of ninth 
grade was preset for the testing material of GFHLT, because the ninth grade had been 
shown to be the minimum functional health literacy level for patients to comprehend 
the majority of the health education materials (Davis et al., 1991; Eysenbach et al., 
2002; Davis and Wolf, 2004; Aldridge, 2004; National Center for Education Statistics, 
2007).  An extensive review of health education materials published in Singapore by 
the same index also revealed that the readability levels ranged from sixth to twelfth 
grade level, with an average of around the ninth grade.  
 
Due to the demonstrated simplicity and reliability to test reading comprehension 
in the education settings, the Maze procedure (a modified cloze test procedure) was 
adopted as the guideline to develop GFHLT (Rye, 1982). To increase the content 
validity, the 138-word passage was selected from a health education material called 
“Guidelines on Taking Medicines”, which was published by the Singapore Health 
Promotion Board (Guidelines on Taking Medicines, 2007). According to the Maze 
procedure, every fifth word was taken out and replaced with a multiple choice item, 
which consisted of the correct word, a semantically incorrect distracter and a 
syntactically incorrect distracter. Hence, the GFHLT is a 21-item self-administered 
test to assess the functional health literacy level of respondents (See Appendix 6.1 for 
the GFHLT). Each of the 21 items was scored as either “0” for incorrect or “1” for 
correct, resulting in a range from “0” to “21” for the final score of GFHLT. As a rule 
of thumb in the interpretations of maze test suggested by Rye (1982), percentage of 
correctness was converted and assigned into categories of 0%-59% (frustrational 
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reading level), 60%-79% (instructional reading level) and 80%-100% (independent 
reading level).  
 
When the preliminary version was ready, GFHLT was reviewed by two linguistic 
experts in English (researchers from the Center for English Language 
Communications with Ph D qualifications, National University of Singapore) and two 
pharmacists (from the National University of Singapore) to check the content validity. 
A pilot test of interviews with 55 respondents aged over 18 was then carried out by 
convenient sampling within the National University of Singapore to assess face 
validity, content validity and time of completion of GFHLT. Further suggestions on 
potential modifications of the GFHLT were also gathered from the respondents.  
 
6.2.1.2 GFHLT validation 
         After any necessary amendments, the finalized questionnaires were distributed 
by research assistants to a convenience sample of 200 eligible Singaporeans at local 
neighborhoods and community centers, and a purposive sample of 200 eligible 
Singaporean patients with rheumatic diseases at a rheumatology outpatient clinic from 
a local tertiary hospital. Eligible respondents should be English-speaking subjects 
aged over 18 and with proper eyesight to read the questionnaire. Retests of the 
GFHLT were posted to contactable respondents at the second week and were required 
to be completed and posted back within one month after the first test.   
 
6.2.2 Measures  
       During the validation stage, TOFHLA was not included, due to its drawbacks 
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such as being too time-consuming and lack of content validity among Singaporeans. 
Despite the lack of sufficient accuracy in measuring functional health literacy, the 
Rapid Estimate of Adult Literacy in Medicine (REALM) (Davis et al., 1991) was 
incorporated so as to study the construct validity of the GFHLT, as REALM shares the 
general construct with GFHLT as being a health literacy test. In addition, during the 
validation phase, sociodemographic and medical related information, such as age, 
gender, education level, working status, dwelling type, presence of chronic disease(s), 
was collected. At the same time, generic HRQoL of the participating subjects was 
measured by EQ-5D.  
 
6.2.2.1 REALM  
Please refer to Section 5.2.2.1 for a more detailed description of REALM.  
  
6.2.2.2 EQ-5D 
Please refer to Chapter 2, Section 2.2.3.2 for a more detailed description of EQ-5D.. 
 
6.2.3 Statistical analysis  
 Data were entered into a Microsoft Excel spreadsheet (Microsoft Corporation, 
Redmond, WA) and analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL). All tests 
were two-tailed and conducted at a significance level of 0.01. Mean (standard 
deviation or SD) was reported for data with normal distribution, otherwise median 
(interquartile range or IQR) would be shown. Descriptive analysis was used to 
summarize sociodemographics (age, gender, education level, working status and 
housing type), the presence of chronic disease(s), EQ-5D and REALM scores of the 
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respondents.  
Item difficulty was calculated based on the formula of:   
D (item difficulty) = C (number of correct answers)/ N (number of respondents).  
      The item difficulty index has a range between 0.0 (most difficult) to 1.0 (least 
difficult). Item discrimination was analyzed by the corrected item-total correlation 
coefficient (range from 0.0 (least discriminative) to 1.0 (most discriminative) with a 
figure of being equal to or above 0.4 indicating adequate item discrimination 
(Cronbach, 1951). A statistical comparison by Student's t test was also performed to 
explore the potential differences in item difficulties between the samples of general 
public and the patients with rheumatic diseases. Average completion time of GFHLT 
was also calculated to evaluate any potential response burden.  
 
      Comparisons were made by Student’s t test for continuous variables or Chi-square 
tests for categorical variables. EQ-5D, REALM and GFHLT scores were compared by 
Wilcoxon rank test. Reliability of GFHLT was assessed in terms of internal 
consistency by Cronbach’s alpha, of which 0.7 was regarded as adequate reliability 
(Cronbach, 1951). After adjustment for significantly different external variables 
between the two populations, construct validity was studied by the partial correlation 
coefficients to evaluate the convergent validity between GFHLT and REALM scores, 
and the divergent validity between GFHLT score and education level. Test-retest 
reliability was assessed by intraclass correlation coefficient between the two 
measurements taken at baseline and at one-month post-test. Magnitude of correlation 
was interpreted according to the criteria proposed by Guyatt et al. (1999): less than 
0.2 as very weak, over 0.2 but less than 0.35 as weak, over 0.35 but less than 0.5 as 
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moderate, and over 0.5 as strong. 
 
6.3 Results  
6.3.1 Scale development  
       GFHLT was judged as content valid by the two linguistic experts and two 
pharmacists. During the interview with a total of 55 respondents in the pilot test, face 
validity and content validity of GFHLT were recognized as well. Only one minor 
change was made based on suggestions from 10 respondents that the items should be 
numbered and bolded to prevent any missing answer (Appendix 6.1). The average 
completion time of GFHLT was 3 (2, 5) [Median (IQR)] minutes.  
 
6.3.2 Scale validation  
6.3.2.1 Subject characteristics 
       Altogether 223 respondents from the general public and 200 rheumatic patients 
participated in the validation study of GFHLT. Table 6.1 presents the subject 
characteristics. The mean (SD) age of the two groups were 43.8 (14.2) of the general 
public and 46.6 (14.7) of the rheumatic patients, respectively. The two groups were 
not significantly different in terms of education level, with about half of the 
respondents had more than 12 years of education.  
 
       However, compared with the general public, the sample of rheumatic patients had 
significantly higher proportion of female respondents (70.5% vs. 49.3%, p<0.01), but 
fewer working population (60% vs. 70.9%, p=0.02) and worse HRQoL as measured 
using EQ-5D [Median (IQR): 0.80 (0.73, 1.00) vs. 1.00 (0.81, 1.00), p<0.01]. 
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Interestingly, it was found that the health literacy level of rheumatic patients were 
significantly higher than that of the general public [Median (IQR): 62 (58, 64) vs. 56 
(50, 62) by REALM, p<0.01; and 19 (18, 20) vs. 19 (16, 20) by GFHLT, p<0.01].  
Table 6. 1: Subject Characteristics 
 Median (Interquartile range), unless otherwise 
specified  






Age (years) [Mean (SD)] 43.8 (14.2) 46.6 (14.7)  0.054 
Female (N, %) 110 (49.3) 141 (70.5) <0.01 
Education (N, %)   0.581 
≤6 years  25 (11.2) 12 (6.0)  
7-9 years 30 (13.5) 28 (14.0)  
10-12 years 66 (29.6) 68 (34.0)  
>12 years 102 (45.7) 91 (45.5)  
Working (N, %) 158 (70.9) 120 (60.0) 0.019 
Housing (N, %)   0.349 
Private  89 (39.9) 72 (36.0)  
Public 131 (58.7) 128 (64.0)  
Presence of chronic medical 
conditions* (N, %) 
102 (45.7) 93 (46.5) 0.876 
EQ-5D score 1.00 (0.81,1.00) 0.80 (0.73, 1.00) <0.01 
REALM score† 56 (50,62) 62 (58,64) <0.01 
GFHLT score ‡    
   Baseline score 19 (16,20) 19 (18,20) <0.01 
   Scoring categories (N, %)      
     0%-59% 15 (6.1) 3 (1.5)  
     60%-79% 47 (21.1) 19 (9.5)  
     80%-100% 161 (72.8) 78 (89)  
   1-month retest score Not applicable 19 (18,20)  
Completion time of GFHLT 3 (2, 5) 3 (3, 4) 0.460 
 
*: Having had at least one of the chronic disease(s) in the following 9 categories: diabetes, 
hypertension, heart disease, stroke, asthma or other lung disease, cancer, rheumatism or back 
pain or other bone or muscle illness, mental illness, other chronic diseases.  
†: The 66-item Rapid Estimate of Adult Literacy in Medicine (REALM) is scored based on the 
correct number of answers, from 0 to 66. Each item is scored as either “0” for incorrect 
answer or “1” for correct answer.  
‡: The 21-item Generic Functional Health Literacy Test (GFHLT) is scored based on the 
correct number of answers, from 0 to 21. Each of the items is scored as either “0” for 
incorrect answer or “1” for correct answer.  
 
 
6.3.2.2 Item difficulty, item discrimination and response burden 
Table 6.2 shows item difficulty and item discrimination of GFHLT. The item 
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difficulty ranged from 0.7 to 0.9 of the general public and 0.5 to 0.9 of the rheumatic 
patients. Item nine [Directions (to/for/and) use] and item ten [Any activity, food and 
(others/ other / which) medicines to be avoided] were shown to be the comparatively 
most difficult items in both populations. In terms of differences in the item difficulty 
between the two populations, the majority of the items were not significantly different, 
except for item nine [Directions (to/for/and) use], item 11 [(How/ Any / An) side 
effects] and item 13 [Be sure you (track/ follow / ignore) the instructions] with a small 
yet significant difference ranging from 0.1 to 0.2.  
 
Based on the corrected Pearson item-total correlation coefficient, it was found that 
except for item one [Listen carefully to the (speech / instructions / then)], all the other 
items have reached adequate item discrimination power with coefficients of being 
equal to or above 0.4. The average completion time of the GFHLT in median was 
three minutes for both populations, suggesting its appropriateness of being used as a 
















             Table 6.2 Item difficulty and item discrimination of the GFHLT*  















1 Instructions 0.9 0.9 0.77 0.3 0.2 
2 Label 0.9 0.9 0.45 0.4 0.4 
3 Ask 0.9 0.9 0.56 0.4 0.4 
4 Understand 0.9 0.9 0.46 0.4 0.4 
5 They 0.8 0.8 0.07 0.4 0.4 
6 Should 0.8 0.8 0.12 0.4 0.4 
7 And 0.8 0.9 0.04 0.4 0.4 
8 Purpose 0.8 0.9 0.15 0.5 0.4 
9 For 0.7 0.5 <0.01 0.5 0.4 
10 Other 0.7 0.7 0.19 0.5 0.4 
11 Any 0.8 0.9 <0.01 0.4 0.4 
12 Out 0.8 0.9 0.14 0.5 0.4 
13 Follow 0.8 0.9 <0.01 0.4 0.4 
14 Exceed 0.9 0.9 0.12 0.4 0.4 
15 Treatment 0.8 0.9 0.02 0.4 0.4 
16 Prescribed 0.8 0.8 0.88 0.4 0.5 
17 Complete 0.9 0.9 0.56 0.5 0.5 
18 Medicines 0.9 0.9 0.05 0.4 0.5 
19 Longer 0.9 0.9 0.41 0.4 0.5 
20 Check 0.8 0.9 0.01 0.5 0.4 
21 Taking 0.9 0.9 0.04 0.4 0.5 
 
*: The 21-item Generic Functional Health Literacy Test (GFHLT) is scored based on the 
correct number of answers, from 0 to 21. Each item is scored as either “0” for incorrect 
answer or “1” for correct answer.  
†: Item difficulty is calculated based on the formula: D = C/N, where D= item difficulty, 
C=number of correct answers and N=number of respondents (range: 0.0 (most difficult) to 1.0 
(least difficult) ; 
‡: Item discrimination is calculated as the corrected item-total correlation coefficient (range: 
0.0 (least discriminative) to 1.0 (most discriminative) with a figure of being equal to or above 
0.4 indicating adequate discrimination.  
 
 
6.3.2.3 Reliability and construct validity  
       Cronbach’s alpha of GFHLT was 0.72 of the general public and 0.68 of the 
rheumatic patients, suggesting adequate reliability as a generic functional health 
literacy test. Based on a retest sample of 112 rheumatic patients (representing a 
response rate of 56%), the test-retest reliability of GFHLT was shown to be high, with 
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an intraclass correlation coefficient of 0.95. As the response rate of the general public 
was too low (9%), the test-rest reliability was not calculated for such population.  
 
After adjustment for significantly different external variables such as gender, 
working status and HRQoL score, the convergent validity of GFHLT was shown by 
the strong partial correlation between scores of GFHLT and REALM [0.59 (p<0.01) 
of the general public, 0.72 (p<0.01) of the rheumatic patients]. Similarly, after 
adjustment for the same set of external variables, the divergent validity was 
demonstrated by the weak correlation between GFHLT score and education level 
[0.33 (p<0.01) of the general public, 0.28 (p<0.01) of the rheumatic patients]. 
 
6.4 Discussions   
       To the best of our knowledge, the 21-item GFHLT is the first test specially 
developed to screen the functional health literacy level of the general public. The face 
validity and content validity of GFHLT were well recognized by linguistic experts and 
pharmacists during the expert judgment and by another 55 eligible respondents from 
the general public during interviews. At the validation stage, GFHLT has further 
demonstrated its adequate reliability, good construct validities and sufficient item 
discrimination power in both study populations, the general public (N=223) and 
rheumatic patients (N=200) in Singapore. Furthermore, as GFHLT could be 
completed in about three minutes, it has great potential to be used as a screening test 
of functional health literacy in health education and clinical settings. Besides, GFHLT 
could also be incorporated into other disease management evaluation studies to assess 
the functional health literacy either as a dependent or as an independent variable with 
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minimal response burdens. 
 
       Apart from the key results, some of the other findings are also worth mentioning 
for a variety of interests. First, the results from our study support the observation that 
highest education level should not be used as a proxy for functional health literacy 
level due to their weak correlations. Second, we found that item difficulty of the 
majority of items was skewed towards easier items, with indices of over 0.5. Although 
such result could be explained by the similarly high-end skewed literacy levels of the 
respondents measured by both REALM and GFHLT, further refinement of the 
distracters in choices could be made to increase the difficulty levels to the 
recommended range of 0.3 to 0.7 or to an optimal of 0.5, if possible. The further 
improvement in the item difficulty would also be expected to increase the reliability 
level of the GFHLT (Aiken, 1997). Third, as the readability level of GFHLT was 
preset at the ninth grade, we suggested the ninth grade to be used as a reference point 
when categorizing respondent’s functional health literacy capabilities into 
frustrational, instructional and independent levels.  
 
      We recognize several limitations of this study, which lead to suggestions for future 
studies and are thus presented together. Due to the poor response rate of the general 
public at retest, the test-retest reliability was not known on such population. Hence, 
this would need to be ascertained with further studies, and we suggest that tokens for 
respondents could be given out to increase response rate of the retest to prove the test-
retest reliability of the GFHLT among the general public. Besides, due to practical 
constraints which did not allow implementation of probability sampling strategies, the 
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current sample included only a handful of respondents with very low literacy levels. It 
could be possibly due to the shyness and reluctance of them to participate in surveys 
as found in other studies (Dowse and Ehlers, 2005; Miller et al., 2007). Therefore, we 
would suggest more efforts to be made for recruitment of such respondents by 
purposive sampling in both the general public and rheumatic patients to explore the 
sensitivity of GFHLT in identifying respondents with frustrational functional literacy 
levels.  
 
       Despite the limitations, it is expected that the availability of GFHLT would help 
health care educators and practitioners develop more proper health education 
programs at compatible health literacy levels so as to enhance the overall cost-
effectiveness of those disease management programs. Potential studies may include 
but are not limited to the exploration of impact of functional health literacy on a 
variety of outcomes such as compliance, health-related quality of life, cost-
effectiveness of the programs, etc. Consequently, better health education outcomes 
would contribute to the increasing health care awareness, improved HRQoL and more 
empowered disease management capabilities of the populations (Hoffmann and 
Worrall, 2004;.Kleinbeck, 2005).  
 
6.5 Conclusion  
       In conclusion, our results demonstrated that the 21-item GFHLT is a reliable and 
valid screening test to measure functional health literacy levels of the general public 
as well as patients in a health care setting. The availability of GFHLT would 
contribute to the more accurate assessment of the functional health literacy and further 
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An Exploratory Study of Response Shift in Health-
Related Quality of Life (HRQoL) and Utility 
Assessment among Patients with Osteoarthritis 












7.1 Introduction  
       Originating from self-report evaluation studies on organizational and educational 
psychology, a phenomenon termed “response shift” has been increasingly reported in 
patient-reported outcomes (PROs) assessment among chronically or terminally ill 
patients over the last decade (Golembiewski et al., 1976; Zwiebel, 1987; Postulart and  
Adang, 2000). 
 
       In the healthcare arena, response shift has been regarded as an instinctive 
psychological mechanism of patients to adapt to the changes caused by illness or 
treatment (Wilson, 1999). Sprangers and Schwartz (1999) have defined response shift 
as a change in the meaning of one’s self-evaluation of a target construct as a result of: 
(a) a change in the respondent’s internal standards of measurement (scale 
recalibration); (b) a change in the respondent’s values (scale reprioritization); or (c) a 
redefinition of the target construct (reconceptualization).” Although distinguished as 
three types of response shift, reconceptualization, scale recalibration and 
reprioritization are thought to occur in combination (Ahmed et al., 2005). 
 
        Health-related quality of life (HRQoL) measurement may be affected by 
response shift because it quantifies patient perceptions, which may change with time 
due to response shift. Paradoxes such as overestimation of health status or 
underestimation of treatment effects measured by HRQoL outcomes have been found 
across various patient groups including cancer (Breetvelt and Van Dam, 1991), stroke 
(Ahmed et al., 2005), mental illness (Schweickhardt et al., 2005), etc. A theoretical 
model has been built to illustrate the relationship between response shift and HRQoL, 
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in which “changes in an individual’s health status may prompt behavioral, cognitive 
and affective processes necessary for accommodating illness, which may be 
influenced by antecedents (e.g. sociodemographics, personalities, expectations, etc) of 
the individual; these processes have the potential to change an individual’s standards, 
values and conceptualization of HRQoL.”(Breetvelt and Van Dam, 1991). The 
presence of response shift calls into question the assumption that patients would 
perceive and value a self-reported item with entirely the same internal standards 
during longitudinal research. In other words, there may be situations where true 
change measured by HRQoL instruments may not be simply calculated as the 
difference between respective pre- and post-intervention test scores (Howard et al., 
1979; Ahmed et al., 2004).  
 
         In various evaluations of disease management programs, pre- and post- 
intervention comparisons of HRQoL have been used as a standard method to evaluate 
patients’ improvement in both generic and disease-specific health status, and 
consequently to determine cost-effectiveness of the interventions (Bernhard et al., 
2001; Fetterrolf et al., 2004). Due to the potential impact of response shift on such 
pre-post comparison outcomes, it is thus necessary to explore the presence of 
response shift and the magnitude of it in either HRQoL or utility assessment. In the 
current thesis, our study would use total knee replacement (TKR), a surgical 
intervention for managing the end-stage knee osteoporosis, as an illustrative example.      
 
       The exploration of response shift has become an emerging area in HRQoL 
research of surgical interventions (Thompson-Fawcett et al., 2000; Oort et al., 2005; 
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Roos et al., 2004). There is however limited information currently available on the 
impact of response shift in subjects undergoing TKR, with only one recent publication 
showing that response shift significantly affected postoperative function six months 
after TKR when measured using a disease-specific HRQoL questionnaire, the 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
(Razmjou et al., 2006). However, the impact of response shift on generic HRQoL 
instruments, including preference based HRQoL instruments (e.g. the EQ-5D or SF-
6D) is not known.  If present, this may lead to inaccurate or even invalid results when 
these instruments are used in utility assessment in this situation. Additionally, 
evidence of its influence on TKR patients over a follow-up period longer than six 
months is also lacking. Neither is it clear whether response shift also affects 
comparisons between two postoperative time points for recovery assessment.   
 
       To address these gaps in the literature, the primary objective of the current study 
was to explore and compare the impact of response shift on HRQoL and utility scores 
measured by generic HRQoL instruments at baseline and six months after TKR when 
assessed 18-months after TKR. It was hypothesized that response shift at baseline 
would be larger than that at six months post TKR, given that there was no major 
intervention between six months and 18 months postoperatively. If response shift 
were demonstrated, potential demographic and health-related factors associated with 
response shift at that time point would be investigated. In addition, the agreement 
between SF-6D and EQ-5D in detecting response shift would also be explored. Based 
on a comparison study of EQ-5D and SF-6D across seven patient groups including 
osteoarthritis, it was hypothesized that correlation of response shift between the two 
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measures would be moderate as categorized by Cohen’s criteria (a correlation 
coefficient within the range of 0.3-0.5) (Brazier et al., 2004; Cohen, 1988).  
 
7.2 Methods  
7.2.1 Subjects and study design 
       By purposive sampling, contactable consenting TKR patients without cognitive 
problems who underwent the TKR at the orthopedic surgery department a tertiary 
referral centre in Singapore in 2005 (the most established orthopedic surgery 
department in the country) were recruited in this Institutional Review Board (IRB) 
approved study. Due to difficulties in communication during the telephone survey (the 
third phase as mentioned below), dialect-speaking patients who could not speak either 
English or Mandarin Chinese (N=19) were excluded. In addition, patients undergoing 
any additional surgery during the study period would also be excluded to obviate any 
confounding physical and psychological impact caused by this additional surgery.  
 
       This IRB approved prospective study was carried out in three phases. Data for the 
first two phases were retrieved from an earlier IRB approved study, in which generic 
HRQoL and utility scores were determined by an interviewer using the SF-6D and 
EQ-5D at baseline before the surgery (pre-test 1), and using the SF-6D  six months 
after surgery (pre-test 2) (Xie et al., 2007). Response shift was studied using the 
“then-test” approach in the third phase, in which eligible Mandarin- or English-
speaking patients were interviewed through the telephone 18 months after their 
surgery. In this telephone interview, patients were asked to give their HRQoL scores 
for their current health status using both the SF-6D and EQ-5D (i.e. post-test scores). 
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They were also asked to give their HRQoL scores at baseline (i.e. then-test 1 scores) 
and six months after TKR (i.e. then-test 2 scores). The rationale of the then-test 
approach is that at post-test using the same measure, respondents will provide their 
retrospective judgment of the health status at baseline and six months using the same 
internal standard (Sprangers and Schwartz, 1999). In the scoring scheme of the then-
test approach, response shift is calculated as the difference between pre-test and then-
test scores for each time point assessed, in this case at baseline and six months after 
TKR. True change or adjusted treatment effect is calculated as the difference between 
respective post-test and then-test scores. The difference between respective post-test 
and pre-test scores was considered the observed change or unadjusted treatment effect 
(Brossart et al., 2002). 
 
        Additional data collected during the telephone survey included demographics 
(age, gender, education level, work status, dwelling type), medical information 
(presence of acute or chronic illnesses, past knee surgery, number of knees operated) 
and general satisfaction with knee surgery (on a 0-10 Likert scale, with 0 means "not 
satisfied at all" and 10 means "totally satisfied").  
 
7.2.2 HRQoL Measures  
7.2.2.1 SF-6D  
 Please refer to section 2.2.3.3 for a more detailed description of SF-6D. 
 
7.2.2.2 EQ-5D  
 Please refer to Section 2.2.3.2  for a more detailed description of EQ-5D. 
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7.2.3 Statistical analysis 
         Data were entered into a Microsoft Excel spreadsheet (Microsoft Corporation, 
Redmond, WA) and analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL). All tests 
were two-tailed and conducted at a significance level of 0.01 to reduce the possibility 
of spurious tests of significance due to multiple comparisons. Descriptive analyses 
were used to characterize demographics (age, gender, education level, work status, 
dwelling type), medical information (presence of acute or chronic illness, past knee 
surgery, number of knees operated) and general satisfaction with knee surgery (on a 0-
10 Likert scale). Data with a normal distribution were reported as mean (standard 
deviation or SD). Otherwise, medians (interquantile range or IQR) were reported.  
Mann-Whitney tests were used to investigate whether there were any statistically 
significant differences between the respondent group and non-respondent group in 
terms of demographics, medical information and health status at baseline and six 
months after the surgery. Wilcoxon Signed Rank tests were used to assess the 
significance of differences between pre- and then-test scores, between true change and 
observed change at baseline and six months after surgery, between magnitude of 
response shift and between changes in levels of SF-6D domains of response shift at 
baseline and six months after surgery.  
 
       Relationships between response shift and external variables were investigated by 
univariate analyses using Mann-Whitney or Kruskal-Wallis tests for categorical 
independent variables, or Spearman’s correlation for continuous independent 
variables. Independent variables with p < 0.10 in univariable analyses were then 
entered into respective multiple linear regression (MLR) models to explore factors 
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potentially impacting response shift. The dependent variable for each MLR was 
response shift at baseline or at six month after TKR, respectively. Due to the small 
number of subjects, we considered the results of MLR analysis as exploratory. The 
agreement between SF-6D and EQ-5D in detecting response shift was explored by 
Spearman’s correlation and Bland-Altman plots.  
 
7.3 Results 
7.3.1 Response rate and subject characteristics  
       It was noted that none of the 117 identified patients underwent additional surgery 
during the study period. The response rate of in this 18-month follow up study was 
63% (74 of 117 patients). Altogether 43 patients were not recruited for the following 
reasons: dialect-speaking (N=19), uncontactable (N=10), declined participation (N=5), 
cognitive problems (N=4), overseas residence (N=2), admission into hospital (N=1), 
deafness (N=1) and death (N=1). There was no statistically significant differences 
between responders and non-responders in terms of demographics (age, gender, 
education level, work status, dwelling type), medical information (presence of acute 
or chronic illness, past knee surgery, number of knees operated), and health status at 
baseline and six months after the surgery.  
 
       The majority of respondents were elderly women with few years of education and 
with chronic disease(s) [median (IQR) age: 68 (63, 76) years, 81% female, 92% with 
less than 12 years of education, 68% with at least one chronic disease]. Patients’ 
satisfaction with the TKR was high, with a median (IQR) score of 8 (8, 9)]. More 
detailed subject characteristics are presented in Table 7.1.  
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Table 7.1: Subject Characteristics 
 Median (interquantile range), unless otherwise specified 
（N=74） 
Age (years) 68 (63,76) 
Ethnicity (N, %)  
  Chinese 66 (89.2) 
  Malay 3 (4.1) 
  Indian 4 (5.4) 
Female (N, %) 60 (81.1) 
Education (N, %)  
  ≤6 years  49 (66.2) 
  7-12 years 19 (25.7) 
  >12 years 6 (8.1) 
Working (N, %) 10 (13.5) 
Housing (N, %)  
  Private  15 (20.3) 
  Public 59 (79.7) 
Presence of acute 
disease(s) * (N, %) 
53 (71.6) 
Presence of chronic 
disease(s)† (N, %) 
50 (67.6) 
Past knee surgery 
(N, %) 
7 (9.7) 
Number of knee(s) 
operated on at 
baseline(N, %) 
 
  1 knee  59 (79.7) 
  2 knees 15 (20.3)  
Satisfaction with 
the operation(s) ‡ 
8 (8,9) 
SF-6D index for 
current health 
status at 18 months 
0.77 (0.66, 0.90) 
EQ-5D index for 
current health 
status at 18 months 
0.87 (0.71,1.00) 
*: Having had at least one of the acute disease(s) in the following 5 categories: a running 
nose/ sore throat/ cough, vomiting/diarrhea, a headache lasting more than 1 day, sleeping 
disorder, body injury in the past four weeks.  
†: Having had at least one of the chronic disease(s) in the following 9 categories: diabetes, 
hypertension, heart disease, stroke, asthma or other lung disease, cancer, rheumatism or 
back pain or other bone or muscle illness, mental illness, other chronic diseases.  
‡: Self-reported satisfaction with the total knee replacement was measured on a 11-point 
Likert Scale from 0 (totally unsatisfied) to 10 (totally satisfied).  
 
7.3.2 Presence and impact of response shift 
 As seen in Table 7.2, median (IQR) SF-6D scores of then-tests at baseline 
[0.48 (0.42, 0.49)] and six months after TKR [0.72 (0.66, 0.79)] were significantly 
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different from the respective pre-test scores [0.61 (0.58, 0.68) at baseline, p<0.001; 
0.69 (0.63, 0.72) at six months after TKR, p<0.001], indicating the presence of 
response shift at both time points. Interestingly, response shift at baseline [0.14 (0.08, 
0.20)] was not only significantly larger than that at six months after TKR [-0.05 (-0.14, 
0.00), p<0.001], but also in opposite directions. When measured by EQ-5D, 
significant difference was also detected between pre-test and then-test scores at 
baseline [0.69 (0.17, 0.73) for pre-test vs. -0.18 (-0.23, 0.00) for then-test, p<0.001].  
 
 Thus when response shift was considered in studying the impact of TKR, the 
adjusted improvement in health status became significantly greater between the pre- 
and six-month postoperative period [true change of 0.30 (0.18, 0.39) by SF-6D and 
0.72 (0.22, 0.91) by EQ-5D, p<0.001]. On the contrary, after adjustment, the 
treatment effect between the periods of six months and 18 months after surgery 
became quite minimal, though statistically significant [true change of 0.03 (0.00, 0.09) 
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               Table 7.2.  Horizontal comparisons between pre- and then-test, and between true change and observed  
                                                      change at baseline and six months after total knee replacement *  
 
Baseline           
 N  Pre-test 1† Then-test1 ‡ Magnitude of 
Response 
Shift§ 







































At 6 Months 

































*: Data are reported as Median (interquantile range). 
†:Pre-test 1: measure taken at baseline, just prior to the TKR surgery. 
‡: Then-test1: retrospective measure of baseline score taken at 18 months after the TKR surgery 
§: Magnitude of response shift= respective (pre-test score- then-test score). 
Please note that the result was based on the statistical analysis of response shift of 74 patients, so it might be slightly different from the result of a 
simple subtraction. 
||: Observed change= respective (post-test score - pre-test score). 
¶: True change=respective (post-test score - Then-test score). 
**:Pre-test 2: measure taken at six months after the TKR surgery. 
††: Then-test 2: retrospective measure of score of six-month postoperative score taken at 18 months after the TKR surgery. 
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      Similarly, when the magnitude of response shift was further studied using 
individual SF-6D items [Table 7.3], it was found that the degree of impairment in all 
six domains (each measured by one item) as were rated as more severe during the 
then-test at baseline. A similar situation was also found in the then-test six months 
after TKR, except for the domain of “vitality” where the direction of response shift 
was towards less severe reduction, in contrast with that observed for the other 
domains. 
        
      Interestingly, contrary to the quantitative data showing the presence of response 
shift provided by patients, these same subjects generally did think that their then-test 
and pre-test ratings were similar. At the end of the telephone survey, when asked 
whether their then-test ratings were different from pre-test ratings, 70 out of 74 
patients thought that these would be similar for both time points assessed (i.e. at 
baseline and six month postoperatively). At baseline, the magnitude of response shift 
of patients who thought their scores were similar (N=70) [by EQ-5D: 0.72 (0.25, 
0.90); by SF-6D: 0.15 (0.08, 0.20)] was slightly larger than patients who were actually 
aware of the difference (N=4) [by EQ-5D: 0.57 (0.04, 1.02); by SF-6D: 0.12 (0.07, 
0.25)]. However, there seemed to be no obvious difference between the two groups 
regarding response shift at six months after TKR [SF-6D scores of -0.05 (-0.14, -0.00) 










Table 7.3 Response shift in domains of SF-6D at baseline and six months after total knee 
replacement *  
 
Median (Interquantile) SF-6D domains† 
0-month 6-month 
P value  















Pain (6 levels) -1.00 
(-2.00, 0.00) 
0.00  
(-1.00, 0.00 ) 
<0.001 










*: Response shift= Pre-test level - Then-test level. 
†: Each domain is measured by numeric levels from “1” onwards, with higher number 




 7.3.3 Influence of external variables on response shift  
        Univariate analysis indicated that response shift at baseline measured using the 
SF-6D was significantly influenced by education level (p=0.042), working status 
(p=0.050) and presence of chronic disease(s) (p=0.037). Interestingly, patients with 
less education and chronic disease(s) who were not working experienced a larger 
degree of response shift, compared with those having higher education level and a job 
but no chronic disease. However, the six-month postoperative response shift measured 
using the SF-6D was only significantly influenced by education level (p=0.004). In 
contrast with the findings at baseline, patients with more education experienced a 
larger degree of response shift. No further variables were incorporated into either 
regression model, as their respective p values in the univariate analysis were all more 
than 0.1.  
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       The exploratory MLR analysis (Table 7.4) suggested that the combination of 
education level, working status and presence of chronic disease accounted for 8% of 
the variance in baseline response shift (p=0.05). At six-months postoperatively, 
educational level was the only external variable incorporated, accounting for 16% of 
the variance (p<0.01). 
 
Table 7.4 Influence of external variables on respective response shift at baseline and six 
months after total knee replacement  
 
MLR on baseline response shift * 
Independent variable(s) † Regression coefficient  
(95% confidence 
interval) 
P value  Adjusted R 
square  
   Education level ‡   
           7-12 years -0.04 (-0.10, 0.02) 0.179 
           >12 years -0.08 (-0.17, 0.00) 0.068 
   Working status ‡ -0.02 (-0.10, 0.06) 0.608 




    
MLR on response shift at six months after total knee replacement 
Independent variable † Regression coefficient  
(95% confidence 
interval) 
P value  Adjusted R 
square 
   Education level ‡   
           7-12 years -0.05 (-0.10, 0.00) 0.055 
           >12 years -0.12 (-0.20, -0.05) 0.001 
 
0.16 
*: Multiple Linear Regression Model;  
   Response shift in the table was measured by SF-6D.  
†: Only external variable(s) with p < 0.05 in univariable analyses were incorporated into 
(MLR) models as independent variable (s).  No further external variables had p value <0.1.  
‡: Reference categories of education level, working status and presence of chronic disease(s) 
were ≤6 years of education, not working, and with no chronic disease(s), respectively.  
 
7.3.4 Systematic difference between SF-6D and EQ-5D of detecting response shift 
         In the current study, the EQ-5D was found to have a significantly larger 
magnitude of response shift at baseline [0.72 (0.22, 0.91)], as compared to the SF-6D 
[0.14 (0.08, 0.20)]. A moderate correlation [Spearman’s correlation coefficient of 0.43 
(p<0.001)] in response shift at baseline for these two measures was found as 
hypothesized. Further comparison of the degree of response shift using a Bland-
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Altman plot (Figure 7.1) also showed moderate agreement between the two measures, 
with most of the data points falling in between the lower and upper 95% limit of 
agreement. A systematic difference in response shift between SF-6D and EQ-5D was 
also detected in the plot, demonstrated by the presence of a linear relationship 
between EQ-5D and SF-6D scores.  The mean difference between the two measures 
(EQ-5D minus SF-6D) was 0.43 [SD: 0.40, 95% CI: (-0.36, 1.22)], suggesting that 
response shift detected by EQ-5D was generally larger than that detected by the SF-
6D.    
 








       In this 18-month follow-up study of patients undergoing TKR, we detected the 
presence of response shift and quantified its impact on both HRQoL and utility 
assessment using the then-test approach. We found that response shift was present at 
both baseline and six months after TKR, and significantly influenced HRQoL scores. 
This may have an impact on the use of conventional pre- and post-test methods to 
assess improvement in HRQoL and utility scores in longitudinal studies. It also 
suggests that treatment effect may be masked by response shift, due to gradual 
adaptation to an improving health status of patients (Timmerman et al., 2003; Ring et 
al., 2005). To the best of our knowledge, this was one of the very few pioneering 
studies to explore impact of response shift in utility assessment of disease 
management programs. Besides, it was also the first study exploring response shift 
among TKR patients using generic measures and over a prolonged 18-month 
postoperative period. Given that there is great paucity in the published literature on 
impact of response shift in utility assessment and given that TKR is a commonly 
performed procedure to manage end-stage osteoporosis, our findings are important in 
several ways as detailed in the following paragraphs. 
 
         First, our results further suggested that response shift did present in the 
longitudinal HRQoL and utility assessment, especially when a major intervention 
occurred in between. Though measured with the Western Ontario and Mc Master 
Universities Osteoarthritis questionnaire (WOMAC) and SF-36, the magnitude and 
direction of response shift (rating at then-test being worse than the pre-test) at 
baseline as reported by Razmjou et al. (2006, 2009) in patients undergoing Total knee 
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arthroplasty were similar to our results. The authors also suggested that the response 
shift phenomenon can obscure the measurement of the effectiveness and potentially 
the cost-effectiveness of the surgical intervention.  An earlier exploratory study by 
Bernhard et al., (2001) also detected similar direction of  response shift affected utility 
evaluations of the same health states by cancer patients who undergone chemotherapy 
or surgical interventions.  
 
        Our study further raised concerns over the accuracy of generating utility 
differences in the conventional post- and pre-test manner to evaluate the effectiveness 
or cost-effectiveness of an intervention or to make comparisons between several 
interventions. The substantial changes caused by response shift may also have 
clinically important implications on drug subsidy or technology assessment, as 
illustrated below.  
 
        In addressing the clinical implications of response shift, the minimal important 
difference (MID) for a HRQoL or utility score needs to be considered. The MID is 
defined as the smallest difference in score which patients perceive as beneficial 
(Jaeschke et al., 1989). The MID of the SF-6D and EQ-5D have been reported as 
0.041 and 0.074, respectively (Walters and Brazier, 2005).  Based on our results, the 
quantum of response shift as a percentage of MID changed substantially over time 
[response shift at baseline: 341% by SF-6D and 97% by EQ-5D; response shift at six 
months after TKR: 122% by SF-6D]. With regards to economic impact, after 
adjustment for the response shift observed in this study, the cost-utility ratio would be 
decreased by almost two-fold, suggesting a substantial increase in the cost-
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effectiveness of TKR.  For example, when a hypothetical value of USD 10,000 is 
assigned to account for direct and indirect costs of TKR over 18 months, the impact of 
response shift in SF-6D scores on cost-utility ratio is as high as USD 29,167/QALY, 
changing the unadjusted ratio of USD 62,500/QALY, which would be considered not 
cost-effective (based on a commonly used cut-off point of USD 50,000/QALY) to 
USD 33,333/QALY, which would be considered cost-effective (Brauer et al., 2005).  
 
      Therefore, the impact of response shift could potentially topple the decisions on 
the approval and subsidy of interventions, especially for cases whose cost-utility 
ratios are close to the cut-off point before adjusting for response shift.  Furthermore, 
the presence and impact of response shift could also potentially influence 
comparisons across different studies, if response shift were not fully assessed and 
adjusted for. Interestingly, although we have shown that response shift generated from 
SF-6D and EQ-5D differed systematically, it is of note that the impact of response 
shift on cost-utility ratio in the above example if measured by the EQ-5D would be 
USD 26,511 /QALY, close to that of the SF-6D.  
 
         Second, in terms of contribution to the TKR outcomes research, our data 
complemented and extended the findings of that the previously reported six-month 
longitudinal study on another group of patients undergoing TKR using WOMAC, 
further supporting the idea of incorporating measurement of response shift to more 
accurately measure treatment effects (Razmjou et al., 2006). 
 
        Third, by extending the study period beyond six months, we had the opportunity 
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to further characterize the nature of response shift and its influence on health status 
both at baseline and six months after TKR. We found that during the first six-month 
recovery period, patients may have experienced a larger degree of response shift due 
to a comparatively faster pace of recovery; subsequently, a plateau in health status 
could have been reached and maintained, leading to much lesser degree of response 
shift. Such evidence was also supported by clinical impressions and comments from 
most of the patients during the telephone survey, who generally expressed a view that 
their health status had not improved substantially between six and 18 months after 
TKR (Ethgen et al., 2004). The differing magnitude of response shift at baseline and 
six months also suggests that recall bias was not a major factor influencing the results 
of this study, given that a similar magnitude of response shift would be expected if 
recall bias was present. 
 
        Four, the interview during telephone survey at 18 months also provided some 
other important information for study design and interpretation of results. The 
discrepancies between quantitative and qualitative assessment of response shift 
further suggested that patients experienced response shift in an unconscious manner. 
Therefore, it is necessary to determine both pre- and then-test scores for reference 
purposes. It was also found that SF-6D was preferred over EQ-5D by 51 patients to 
assess health status, as the three-level EQ-5D items were felt by subjects to be less 
accurate a description of their health state when compared to the SF-6D, which had 
five  to six levels for various items.  Such information could partially explain the 
discrepancies between the two measures in detecting response shift at baseline.  
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         Last but not least, the moderate agreement between the SF-6D and EQ-5D in 
measuring response shift suggested that it was feasible to detect response shift with 
both measures. However, the systematic difference between the two measures raises a 
note of caution regarding accurate quantification of response shift in HRQoL and 
utility assessment.  
 
        We also recognize some limitations of the current study. First, the small sample 
size (N=74) prevented us from generalizing our results to all patients undergoing 
TKR in Singapore. Further studies by extending the purposive sampling to more 
cohorts or more TKR centers in Singapore are suggested to confirm the findings from 
this study. For the same reason, the factors identified in MLR analyses should be 
considered as exploratory rather than confirmatory. Second, as the EQ-5D pre-test 
data at six months were not available, we were not able to study the agreement 
between two measures for this time point to provide more robust results.  
 
 
7.5 Conclusion  
       In conclusion, response shift was present and impacted HRQoL and utility 
assessment among patients undergoing TKR both just prior to and six months after 
surgery. This suggests that HRQoL and utility evaluations should be performed 
































8.1 Introduction  
       Since last decade, “health preferences” has become a buzzword due to its 
fundamental role in developing several widely used preference-based Health-related 
Quality of Life (HRQoL) measures such as EQ-5D and SF-6D. More significantly, 
the utility scores generated from health preferences have been incorporated in cost-
utility analysis for decision-making in health care resource allocations (Petitti, 
1994). Studies have shown that health preferences elicited from the same 
instrument varied across different health states and populations (Dion et al., 2002; 
Koh et al., 2003; Shah et al., 2004; Cardarelli et al., 2006; Winkelmayer et al., 
2006). Yet, no study has explored the underlying factors systematically, perhaps it is 
because researchers tried to explain differences from demographic, medical or 
socio-cultural perspectives in a post-hoc way (Franic and Pathak, 2003; Wildi et al., 
2004; Byrne et al., 2004;  Chan et al., 2006). Hence, it is of great significance to 
study health preferences in a prospective manner to elicit a framework of candidate 
factors. With such structure in mind, both researchers and decision-makers could 
interpret utility-score based results more rationally.  
 
        Actually, if traced back to its origin, health preference was categorized as an 
attitude in health psychology (Eagly and Chaiken, 1993). Accordingly, “health 
preference” should be defined as people’s attitude towards a particular health state 
in terms of satisfaction, distress or desirability (Eagly and Chaiken, 1993; Glaz et 
al., 2002). In real world practices, “health preferences” are more widely studied, 
because each respondent is often asked about attitudes on more than one health 
state or treatment scenario for setting benchmark scores or generating treatment 
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priorities (Winkelmayer et al., 2006; King et al., 2003).   
 
        The most established model to predict attitude in a formulated way is the 
expectancy-value model (EVM), which provides a popular framework for 
describing how beliefs are combined to form attitudes (Eagly and Chaiken, 1993). 
The model proposes that an attitude (interpreted as the evaluation of an attitude 
object) is a function of the sum of the expected values of the attributes ascribed to 
the attitude object. The expectancy associated with an attribute is one’s subjective 
probability that the attitude object has the attribute, and the value of an attribute is 
one’s evaluation of it. The expectancy and value associated with each attribute are 
multiplied together, and these products are then summed to evaluate the overall 
attitude towards that health state (Fishbein and Raven, 1962; Fishbein and Ajzen, 
1975). Yet, as attitudes do not derive exclusively from beliefs that people hold about 
attitude objects, external variables (like demographic variables, personal traits 
and/or other variables that are not in the initial EVM) have been introduced to 
compensate for its inadequacy (Eagly and Chaiken, 1993). Based on 
aforementioned theory and systematic structure of EVM, we aimed to explore its 
usefulness in explaining variances in health preference(s) and investigate factors 
that may influence health preference(s).  
 
8.2 Methods  
8.2.1 Study design and subjects  
      The study was conducted in two phases. Within the first phase, preliminary 
interviews were carried out to select altogether 5 health states to indicate best health, 
  154
worst health, and health with minor or moderate or major problem(s). These 5 
health states were aimed to be used as examples to generate health preferences at 
different levels, rather than as exact representative of each severity level. Hence, 
final decision of the 5 health states was based on agreement among the majority of 
respondents and logical concerns of the health states. Due to the wide application of 
EQ-5D in utility studies and its relative simplicity, it was used as the reference to 
describe 5 health states. Accordingly, each of the health state incorporates 5 
dimensions of mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression, with a level to indicate no problem (coded as 1), some problems 
(coded as 2) and extreme problems (coded as 3) in that particular dimension 
(EuroQol Group, 1990; Dolan, 1997).  
 
        After finalization of the selection, focus group discussions were then carried 
out on the same subjects to identify major and common attitudinal attributes 
towards those 5 health states. The main reason for excluding other insignificant 
attitudinal attributes was to reduce response burden, as each additional attribute 
would generate 10 more questions (5 sets of questions for “expectancy” and “value” 
for 5 health states). 
 
       Eligible participants of the first phase were English-speaking Singaporeans 
across the three major local ethnic groups (namely, Chinese, Malay and Indian) and 
aged between 16 and 65 years old. In accordance with rules of thumb, a sample of 3 
to 4 groups with 7 people each was planned initially. The final number of groups 
was determined at the point when information elicited from various groups reached 
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a “saturation point”, that is, no more new information could be obtained (Holly, 
1999; Fern, 2001). Respondents were asked to discuss about any potential 
attitudinal attributes that may influence health preferences towards the 5 given 
health states. Besides, relative impacts of elicited attitudinal attributes were ranked 
at the end of each focus group discussion to identify the most common and 
important attitudinal attributes. Discussions were audio-recorded and transcribed 
for content analysis using ATLAS.ti 5.0 Demo (ATLAS.ti Scientific Software 
Development GmBh, Berlin, 2003-2006). Based on such results, major and 
common attitudinal attributes were incorporated and developed for EVM questions 
accordingly. The survey questionnaire was comprised of Visual Analogue Scales 
(VAS) to measure health preferences (VAS) and EVM items (including external 
variables and expectancy-value questions of attitudinal attributes). The 
questionnaire was then assessed for face validity by another 10 respondents. After 
any necessary amendments, questionnaire was finalized for use in survey.  
 
         At the second phase, the self-administered questionnaire was distributed by 
convenience sampling to eligible respondents, who should be over 16 years old and 
able to complete the English questionnaire without any assistance. Four trained 
research assistants were assigned to approach and recruit eligible respondents. 
Results obtained at this stage were used to explore usefulness of EVM in explaining 
health preferences and identifying underlying factors.  
 
8.2.2 Measures  
        Health preferences for each EQ-5D health state were measured with a 0-1 VAS, 
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of which 0 represents the worst imaginable state and 1 represents the best 
imaginable state. Appendix 8.1 shows an example of a complete set of questions 
and answers for both “expectancy” and “value” of one health state. The same set of 
questions and answers were used to study both “expectancy” and “value” of all the 
other health states selected in the study. For each of the question, 7-point bipolar 
Likert scales (range from -3 to +3) were applied to measure “expectancy” [from    
“-3” (extremely unlikely) to “+3” (extremely likely)] and “value” [from “-3” 
(extremely bad) to “+3” (extremely good)] respectively. Such bipolar numbering 
system and the 7-point Likert scales have the advantage of capturing bipolar 
answers of various respondents in a wide range, compared with monopolar 
numbering system and 5-point Likert scales.  
 
        External variables included demographic information (age, gender, religion, 
housing, education level, working status, and marital status) and health status (acute 
disease occurrence in the past month, current chronic disease status and EQ-5D 
index for health status of the day) (Kind, 1996). Besides, potential psychological 
influence by others suffering from severe diseases was also incorporated and 
measured with a 0-10 Likert scale (from “not influenced at all” to “extremely 
influenced).  
 
8.2.3 Statistical analysis  
    Health preferences of 5 health states were analyzed both in combination and 
separately. Student’s t-test, analysis of variance (ANOVA) and Post Hoc Tukey test, 
where applicable, were applied to explore potential external variables that caused 
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significant differences in health preferences, which would be further included into 
EVM. Bivariate correlation analysis was performed to study the correlation 
between health preferences and external variables in the EVM. Pearson partial 
correlation coefficients were calculated to investigate the relationship between 
health preferences with the sum of attitudinal attributes and individual attribute 
respectively, when all the external variables in the EVM were controlled. Cohen’s 
criteria were adopted as a reference for the magnitude of the correlations. Thus, a 
correlation coefficient of 0.10-0.29 is considered weak, 0.30-0.49 moderate and 
0.50 and above as strong (Van et al., 2002). 
   
        For each of the 5 health state, multiple linear regression (MLR) analysis was 
used to explore the explanatory power of EVM for health preferences by examining 
the sum of attitudinal attributes and external variables separately or in combination. 
Besides, MLR was further used to examine the explanatory power of each 
attitudinal attribute in EVM for health preferences as well. When the explanatory 
power of EVM for health preferences was studied across 5 health states in a mixed 
scenario, an ordinary least squares (OLS) model was used to account for intra-
person correlations. It was because that there might be potential correlations among 
the health preferences elicited from a same person in such scenario. Adjusted R 
squares were reported for both of the MLRs and OLS to indicate the variances 
explained by EVM in health preferences in different scenarios. For all data analysis, 




8.3 Results  
8.3.1 Selection of the 5 health states 
       All of the 28 respondents agreed to use “11111” and “33333” (see the following 
paragraph for detailed description of the health states) to indicate full health and 
worst imaginable health. “Moderate pain or discomfort” was agreed by most of the 
participants (n=21) to represent minor problem. Similarly, the choice of “21221” 
and “32323” was also based on agreement among the majority of the respondents 
and logical concerns to describe rationale health states.  
 
        The detailed description of the 5 health states were as follows: (1) Full health: 
coded as 11111, indicating no problems in mobility, self-care, usual activities, no 
pain/discomfort, and no anxiety/depression; (2) Minor problem in health: coded as 
11121, indicating no problems in mobility, self-care, usual activities, no 
anxiety/depression, yet moderate pain/discomfort; (3) Moderate problems in health: 
coded as 21221, indicating no problems in self-care and no anxiety/depression, yet 
some problems in mobility, usual activities and moderate pain/discomfort; (4) 
Major problems in health: coded as 32323, indicating some problems in self-care, 
moderate pain/discomfort, extreme problems in mobility, usual activities and 
anxiety/depression; (5) Worst possible health: extreme problems in mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression.  
 
8.3.2 Generation of attitudinal attributes  
 Four focus groups with a total number of 28 participants were shown to be 
adequate for generating attitudinal attributes. Based on the content analysis, 
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altogether 10 attitudinal attributes were identified, namely, "worsening your quality 
of life in terms of health", "adding a burden to your family", "making you less 
independent", "making you unable to work or study", "making you depressed", 
"making you unable to enjoy social life", "making you unable to have a close 
relationship with family or friends", "making you losing dignity", "making you less 
confident" and "making you unable to support your family". Based on the 
frequency and importance of these attributes as mentioned by the focus group 
respondents, four following attitudinal attributes were identified as the most 
important and common ones to influence health preferences of the 5 given health 
states, namely, “worsening your quality of life in terms of health” (WQoL) (N=28), 
“adding a burden to your family” (BTF) (N=25), “making you less independent” 
(MLI) (N=20) and “making you unable to work or study” (UWS) (N=20).  
 
8.3.3 Characteristics and health preferences of survey respondents 
        Table 8.1 shows health preferences and characteristics of the 232 eligible 
respondents. ANOVA demonstrated that health preferences varied significantly 
among the 5 states, ranging from 0.12 for “33333” (worst possible health) to 0.97 
for “11111” (full health). Besides, it was found that respondents who are not 
religious had significantly higher preferences [N=51, VAS score=0.77 (0.17), 
p<0.05] for health state “11121” (minor problem in health) than religious 
respondents [N=181, VAS score=0.68 (0.22), p<0.05]. As for health state “21221” 
(moderate problem in health), health preferences of those with over 6 years of 
education [N=218, VAS score=0.47 (0.17), p<0.05] were significantly higher than 
those with 6 or less years of education [N=12, VAS score=0.35 (0.19), p<0.05]. 
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Furthermore, respondents who were not working elicited higher preferences on 
“32323” (major problem in health) [N=18, VAS score=0.40 (0.27), p<0.05], 
compared with the working population [N=214, VAS score=0.25 (0.17), p<0.05]. 
























            Table 8.1. Characteristics and health preferences of 232 survey respondents 
 N (%) unless stated   
Age [Mean (SD)] 27.7 (15.07)  
Female 114 (49.1) 
Ethnicity   
  Chinese 153 (65.9) 
  Malay  36 (15.5) 
  Indian 40 (17.2) 
Years of Education  
  ≤ 6 years 12 (5.2) 
  7-12 years 165 (71.1) 
  ≥ 13 years  54 (23.3)  
Housing   
   Public housing 189 (81.5)  
   Private housing  39 (16.8)  
Working  214 (92.2)  
Married  73 (31.5) 
Religious * 181 (78.0) 
Presence of acute medical conditions in the past month † 157 (67.7) 
Presence of chronic medical conditions ‡ 87 (37.5)  
Past experience with people suffering from severe diseases  132 (57.6) 
Potential psychological influence by others suffering from severe 
diseases §[Mean (SD)] 
7.43 (2.66)  
EQ-5D index [Mean (SD)] 0.96 (0.55)  
Health preferences [Mean (SD)]  
       11111 0.97 (0.09)  
       11121 0.70 (0.21)  
21221 0.48 (0.18)  
32323 0.26 (0.19)  
33333 0.12 (0.21)  
*: Religions included Buddhism, Taoism (Chinese traditional beliefs), Islam, Hinduism, Sikhism, 
Catholicism, Christianity and others etc.  
†: Acute medical conditions included running a nose, sore throat or cough, vomiting or diarrhea, 
headache lasting more than one day, sleeping problems and body injuries. 
‡: Chronic medical conditions included diabetes, hypertension, heart disease, stroke, asthma or 
other lung disease, rheumatism, back pain or other bone or muscle illness, mental illness and 
kidney problems on dialysis.  
§: potential psychological influence by others suffering from severe diseases was also 
incorporated and measured with a 0-10 Likert scale (from “not influenced at all” to “extremely 
influenced). 
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8.3.4 Correlation between various components of EVM and health preferences 
        In the bivariate analysis, none of the external variables in the EVM was shown 
to be significantly correlated with health preferences. Table 8.2 shows partial 
correlation coefficients between health preference(s) and attitudinal attributes in 
terms of the sum of attitudinal attributes and individual attributes, when all the 
external variables in the EVM are controlled.  
 
       When data were analyzed across all 5 health states with control over all 
external variables and subjects, correlation between the sum of attitudinal attributes 
and health preferences was as strong as 0.78 (p<0.01). Besides, all four attitudinal 
attributes demonstrated strong correlation with health preferences, ranging from 
0.68 to 0.73 (p<0.01). Comparatively, when further control over health state was 
added to remove the impact of severity level, correlation coefficients between 
attitudinal attributes and health preferences ranged from 0.25 to 0.35 (p<0.01).  As 
for the data analysis of each individual health state, except for “MLI” in health state 
“11111”, significant correlations between attitudinal attributes and health 
preferences were found with correlation coefficients ranging from 0.14 to 0.42 
(p<0.01).   
 
       Furthermore, a trend was observed. As severity of health state increased, scores 
of attitudinal attributes (shown in Table 8.3) and health preferences decreased, 






Table 8.2 Correlation between health values and attitudinal attributes* 
 
Health value(s) by 
health state(s) 
Attitudinal attributes  
  SUM WQoL  BTF MLI UWS 
5 health states mixed 
(1)†  0.78¶ 0.69¶ 0.71¶ 0.68¶ 0.73¶ 
5 health states mixed 
(2)‡  
0.35¶ 0.28¶ 0.25¶ 0.28¶ 0.29¶ 
By individual health 
state  
     
11111  0.27¶ 0.31¶ 0.15¶ 0.10¶ 0.25¶ 
11121  0.42¶ 0.26¶ 0.27¶ 0.37¶ 0.30¶ 
21221  0.31¶ 0.26¶ 0.25¶ 0.21¶ 0.28¶ 
32323  0.31¶ 0.26¶ 0.25¶ 0.21¶ 0.28¶ 
33333  0.20¶ 0.20¶ 0.16¶ 0.17¶ 0.14¶ 
*The following external variables were controlled in the partial correlation analysis: age, sex, 
religion, housing, education level, working status, and marital status, and health status 
(presence of acute disease occurrence in the past month, presence of current chronic disease 
status, and EuroQol Five-Dimension (EQ-5D) index for health status of the day) and potential 
psychological influence by others suffering from severe diseases. 
†With additional control over subjects. 
‡With additional control over subjects and health states. 
¶P < 0.01. 
BTF, adding a burden to your family; MLI, making you less independent; SUM, sum of 
products of the four additional attributes as WQoL, BTF, MLI, and UWS;UWS, making you 






Table 8.3  Score distribution of attitudinal attributes of Expectancy-Value Model by 

























































Data were shown as Mean (SD)  
SUM: sum of products of the four additional attributes as WQoL, BTF, MLI and UWS 
WQoL: worsening your quality of life in terms of health 
BTF: adding a burden to your family  
MLI: making you less independent 
UWS: making you unable to work or study  
 
8.3.5 Explanatory power of EVM  
      When 5 health states were mixed, EVM explained up to 62% of the variances in 
health preferences. When EVM was applied to each individual health state, the 
explanatory power of EVM was reduced to a range between 8% and 23%. Despite 
such, results showed that compared with models only incorporating external variables, 
EVMs had much higher and significant explanatory powers (Shown as Table 8.4).  
 
       Table 8.5 presents the contribution of each attitudinal attributes to explaining 
health preference(s), when all the external variables are controlled. As for the mixed 
health states, UWS, BTF and WQoL had larger influence on health preference than 
MLI. “WQoL” had significant and dominant impacts on preferences towards 
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“11111”, “11121” and “21221”. “UWS” and “BTF” were the two major influential 
attributes on preferences of “32323”, compared with the other 2 attributes. As for 
the worst state “33333”, “MLI” generated significantly larger impact on health 
preferences.  
 
Table 8.4: Comparison of explanatory power of expectancy-value model versus external 
variables only* 
Health State  Regression model (N=232) 
 expectancy-value model † External variables only  
5 Health states mixed 0.62‡ -0.004  
By Health State   
11111 0.08 ‡ 0.02 
11121 0.15 ‡ 0.05§   
21221 0.08 ‡ 0.02  
32323 0.13 ‡ 0.04  
33333 0.23 ‡ 0.03 
*: Data presented as adjusted R square  
†: Expectancy-Value Model included the sum of attitudinal attributes and external 
variables (including age, gender, religion, housing, education level, working status, and 
marital status, acute disease occurrence in the past month, current chronic disease status 
and EQ-5D index for health status of the day and potential psychological influence by 
others suffering from severe diseases). For the mixed scenario of 5 health states, ordinary 

















Table 8.5: Contribution of each attitudinal attribute to explaining health 
preferences * 
Health State  Attitudinal attributes of the Expectancy-Value Model 
(N=232) † 
 WQoL  BTF  MLI  UWS 
5 health states 
mixed 
0.22 ** 0.24 ** 0.13 ** 0.28 ** 
By Health State     
11111 0.28 ** 0.01 -0.06 0.14 
11121 0.15 ** 0.07 0.04 0.14 
21221 0.12 0.05 0.01 0.08 
32323 0.09 0.14 0.04 0.15 
33333 0.09 ** 0.12 0.27 ** 0.14 
*: Standardized coefficients (beta) 
†:The following external variables were controlled in the multiple liner regression: age, sex, 
religion, housing, education level, working status, and marital status, and health status 
(presence of acute disease occurrence in the past month, presence of current chronic 
disease status, and EuroQol Five-Dimension (EQ-5D) index for health status of the day) 
and potential psychological influence by others suffering from severe diseases. 
‡: P < 0.01. 
BTF, adding a burden to your family; MLI, making you less independent; UWS, making 
you unable to work or study; WQoL, worsening your quality of life in terms of health. 
 
8.4 Discussions 
       In this exploratory study to investigate the power of EVM in explaining health 
preferences, we found that compared with models that only incorporated external 
variables, EVM that incorporated both external variables and attitudinal attributes 
could explain a much larger proportion of the variances in health preferences. 
Besides, EVM could further explore the contributions of each component, either 
attitudinal attribute or external variable, to identify important factors that influence 
results of health preferences and quantify their magnitude by regression analyses. In 
our study, it was interesting to note that the magnitudes of influence of each 
individual attitudinal attribute differed across various health states. Such differences 
were probably related to the differences in health states, which would trigger 
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respondents' different expectancy towards the attitudinal attribute.  
 
        Our results provide important implications in understanding health preferences 
in several ways:   
        Basically, EVM-based utility measure could be used to help explain and 
understand the differences in utility values elicited by patients themselves from the 
same utility measure. Cautions should be taken not to apply EVM to study the results 
generated from different-based utility measures (e.g. time trade-off, standard gamble, 
VAS, etc), as these measures were reported to elicit different scores due to 
methodology concerns (Krabbe et al., 1997). We suggested using EVM as a 
complementary tool when the interest was to understand the differences in preference-
based utility values across different studies or to check why the utility values elicited 
from patients were different from expectations of health care practitioners or decision 
makers during the process of assessing disease management programs.  
  
       The promising explanatory power of EVM for health preferences could also 
potentially help evaluating disease management programs in other ways. It could be 
applied by health care practitioners and decision makers to better understand 
patients’ psychological concerns about the treatment or medication. Based on such 
information, they could partially figure out why certain patients refuse to accept or 
poorly comply with the intervention. For example, Polsky et al. (2002) found that a 
woman’s preference of surgical treatment for breast cancer was largely influenced 
by her perception of its short-term benefits rather than long-term ones. Hence, even 
though the surgical treatment would be a long-term cost-effective measure to 
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improve patients’ treatment outcomes and health-related quality of life, the 
misconceptions from patients might even eventually alter the fact and consequently 
the choice (Polsky et al., 2003). Therefore, it would be useful to put such perception 
into EVM as one of the attitudinal attributes. By doing so, decision makers and 
practitioners could have identified underlying reasons why the elicited utilities do 
not match with their assumptions, which might topple the sequential judgment on 
the cost-effectiveness of the intervention.    
 
       Furthermore, on individual basis, health care practitioners could help patients 
rectify certain wrong perceptions of attitudinal attributes towards treatment, so as to 
improve patient-practitioner communication, treatment compliance which might 
contribute to better treatment outcomes and even the cost-effectiveness of the 
treatment.  Such application could also be expanded to other disease management 
programs, such as health care education on attitudes towards smoking cessation, 
HIV prevention, etc. In such cases, EVM could be used as part of the effectiveness 
assessment to evaluate changes in attitudes.  
 
   However, limitations together with suggestions for future studies should be 
noted in this exploratory study as well:   
 
   First, in general, EVM tends to be less powerful to explain variances in health 
preference of individual health state compared with mixed states. A potential 
contributor of such poor performance for individual health states might be due to 
the limitation of Likert Scale to measure attitudinal attributes accurately. The 7-
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point Likert scale only allowed respondents to rate “expectancy” and “value” with 1 
out of the 7 numbers. However, health preferences were elicited on a continuous 
VAS from “0-1”, which provided infinite choices. Such incompatibility in the 
scaling method could have caused poor differentiation power of EVM when 
variances of health preferences in each state were rather small. Hence, we suggested 
future studies with compatible continuous scales to measure attitudinal attributes be 
carried out first for validation purposes. If validated, further research could be 
focused on the explanatory power of EVM constructed on these new scales.  
 
       Second, the attitudinal attributes generated in the current study may not be 
applicable to other health scenarios or populations due to its potential specificity 
and sociodemographic influences. Hence, it is suggested that the attitudinal 
attributes of the current study should be validated first before its application in a 
different population or a new health scenario. If the validation is failed, exploration 
of the applicable attitudinal attributes should be generated from the scratch. 
Although it would be clearer to have common attributes for comparison studies, 
those specific additional attribute(s) could provide additional useful information to 
explain significant variances.  
 
       Third, the convenience sampling used in this study may potentially hamper the 
generalization of the study results to the general population in Singapore.  Further 
studies using proportional quota sampling are suggested to confirm our study 
findings and also to improve the generalizability of the study results.  
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8.5 Conclusions  
       In summary, our results showed that EVM was useful in explaining variances 
of health preferences. However, its power to predict small variances might be 
restricted due to limitations of current Likert Scale to measure “expectancy” and 
“value” in EVM. With further improvement and validation of a compatible 
continuous scale for more accurate measurement, EVM is expected to explain 
health preferences to a larger extent. Future studies are suggested to explore the 
power of EVM in explaining health preferences towards different health or 
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9.1 Introduction   
        In the current era of disease management, with the increasing emphasis on 
pharmaceutical care, the roles of the pharmacists have been undergoing vigorous 
expansion. Studies have shown that better pharmaceutical care contributed to less 
drug-related morbidity and mortality, improved clinical outcomes and health-related 
quality of life (HRQoL), and lowered medical costs, which may further contribute to 
the cost-effectiveness of disease management programs (Penna, 1990; Benny et al., 
2000; Hermansen and Wilderholt, 2001).  
 
        A key success factor of pharmaceutical care is the quality of patient-pharmacist 
relationship. In such relationship, patients grant authority to pharmacists to manage 
their health and well-being. In turn, pharmacists accept responsibility and do good to 
patients (Penna, 1990; Helper and Strand, 1990). Because of the vulnerability of 
patients and uncertainties of outcomes, patient-pharmacist relationship is largely 
influenced by the level of patients’ trust in pharmacists (Moorman et al., 1993). From 
patients’ perspective, trust in pharmacists could be defined as “patients’ willingness to 
be vulnerable to the actions of pharmacists based on the expectation that pharmacists 
will do what is best for patients, irrespective of patients’ ability to monitor 
pharmacists.” (Mayer et al., 1995).   
 
        Based on the literature search in PubMed (1966 to Oct 2007), there was no 
published scale to measure patients’ trust in pharmacists. In order to assess influence 
of trust on disease management related outcomes (i.e., effectiveness or cost-
effectiveness of the treatment, adherence to drug therapy, satisfaction with the 
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pharmacy service, quality of pharmaceutical care, etc.) as demonstrated in studies on 
other medical practitioners, a reliable and valid instrument to test patients’ trust in 
pharmacists should be developed first, which was actually the primary objective of 
our study (Anderson and Dedrick, 1990; Thom et al., 2004; Piette et al., 2005)  
 
Although practical patterns are different between pharmacists and other 
healthcare practitioners, items and dimensions in trust scales of other medical 
practitioners could still provide reference for the scale development. It was found that 
items in trust scales could be summed into two overarching dimensions as technical 
competence and benevolence (Thom and Campbell, 1997; Leisen and Hyman, 2001).  
Technical competence might include evaluating problems thoroughly, providing 
appropriate and effective treatment, predisposing factors and structural and staffing 
factors. Benevolence dimension might comprise understanding patients’ individual 
experiences, expressing caring, communicating clearly and completely, building 
partnership and sharing power, demonstrating honesty and respect, and keeping 
information confidential (Anderson and Dedrick, 1990; Thom and Campbell, 1997; 
Kao et al., 1998; Swan et al., 1999; Leisen and Hyman, 2001).  
 
Additionally, to test construct validity, it was hypothesized that patients’ trust in 
pharmacists were positively correlated with “satisfaction with pharmacists’ service”, 
“returning for care” and “preference of decision-making patterns” respectively 
(Anderson and Dedrick, 1990; Thom and Campbell, 1997; Kao et al., 1998; Leisen 
and Hyman, 2001; Dugan et al., 2005).  
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9.2 Methods  
9.2.1 Study design and subjects  
      The whole study was divided into two phases: scale development and scale 
validation. 
 
9.2.1.1 Scale development 
      A Literature review on trust scale in other medical professions was performed for 
reference. A focus group approach was then used to determine whether the concept, 
domains and items based on literature review were relevant and to explore any 
potential new domains or items. Eligible participants were recruited from the final-
year pharmacy undergraduates at the National University of Singapore, who had 
consulted and obtained medications from pharmacists during the past six months 
before the study. The rationale to recruit final-year pharmacy undergraduate students 
as focus group participants was that their valuable experience as intern pharmacists 
could add in the perspective from pharmacists as well as third-party observers.  
 
In accordance with rules of thumb, a sample of three to four groups with seven 
people each was planned initially. The exact number of groups was determined by the 
reach of “saturation point” (Hall et al., 1999). Focus group discussions were audio-
recorded and transcribed for content analysis using ATLAS.ti 5.0 Demo (ATLAS.ti 
Scientific Software Development GmBh, Berlin, 2003-2005).  
 
Based on the results of focus group approach and literature review, the candidate 
version of “Trust in Pharmacists Scale” was developed. The scale was structured with 
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both favorably and unfavorably worded items to avoid respondents’ blind agreement 
with statements regardless of the content (Ware, 1978). Answers were formatted with 
a 7-point Likert scale (with -3=totally disagree and 3= totally agree) to improve score 
distribution (MacKeigan and Larson, 1989). Then the questionnaire was evaluated by 
10 other pharmacy graduate students for face validity (the relevance of items to 
measure “patients’ trust in pharmacists”) and clarity of items. An expert panel of three 
experienced pharmacists was asked to assess content validity, that is, how well items 
represented the specific intended domains based on experts’ judgment (Armstrong, 
2005). Pilot testing of the revised version was undertaken by a convenience sample of 
another 77 final-year pharmacy undergraduates, who had not participated in the focus 
group discussion. Time of completion, comments on questionnaire were also collected 
to ensure non-excessive burden on the respondents and to provide further suggestions 
on item modifications.  
 
9.2.1.2 Scale validation  
After necessary amendments, the finalized questionnaire was distributed by 
research assistants to a sample of 1,200 English-speaking Singaporeans at local 
neighbourhoods and community centers using purposive sampling. It was designed 
that study subjects should be across the three major local ethnic groups (Chinese, 
Malay and Indian) from 3 age groups (18-35 yrs; 36-55 yrs; 56 yrs and above) with an 
equal ratio among ethnic groups and 2:2:1 ratio among age groups to explore factor 
structure, reliability and validity of the questionnaire. The uneven ratio of age groups 
was due to the fact that English-speaking elderly population is small in Singapore and 
they might have cognitive dysfunction as well (Singapore census of population, 2005). 
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Eligible respondents should be able to complete English questionnaire without any 
help and have consulted or obtained medications from a pharmacist during the past 
six months.  
 
9.2.2 Measures   
Besides the trust scale, several other measures were included in the finalized 
questionnaire: demographic information (age, gender, ethnicity, housing, education 
level); current chronic disease status, basic information relevant to the scale (time 
period of last visit to a pharmacist; type of pharmacist visited last time); six-item scale 
to assess patients’ satisfaction with the pharmacists’ service; and two items to assess 
the behavior intents [willingness to return for care on the 7-point Likert scale, 
preferred decision-making pattern on medication on a 5-point Likert scale (1=totally 
by myself, 5=totally by pharmacist)] (MacKeigan and Larson, 1989; Davies and Ware, 
1991; Kraetschmer et al., 2004; Singapore census of population, 2005).   
 
9.2.3 Statistical analysis 
9.2.3.1 Scale development 
Item means and standard deviations were assessed to determine whether adequate 
variability and symmetry in score distribution were achieved in the pilot testing 
version.  
 
9.2.3.2 Scale validation 
       Sample characteristics were descriptively analyzed. Response means and standard 
deviation were calculated to determine variability and symmetry in score distributions, 
  177
which indicated discriminatory power. To select candidate items, item analyses were 
done to ensure the corrected item-total correlation coefficients should be greater than 
0.30 for finalized items (Hinton et al., 2004).  Exploratory factor analysis was used to 
determine dimensions of trust. Principal components analysis of the partial correlation 
matrix was used to identify groups of homogeneous items suitable for measuring each 
dimension of trust. The number of factors selected for Varimax rotation was 
determined by a combination of criteria: (1) the roots criterion of selecting factors 
with eigenvalues to be greater than 1; (2) the Scree test to examine a plot of 
eigenvalues and stop factoring at the point where the pot begins to level off; and (3) 
the interpretability and meaningfulness of trial factor rotations. Each factor should 
have two or more loadings above 0.40 to make a rotated factor interpretable. In 
addition, the items loading on one factor should fit together logically (Kim and 
Mueller, 1978; Stewart, 1981; Gorsuch, 1983; Beun, 1996). Tentative scale was then 
composed of those items with factor loading above 0.40 on one factor and lesser 
loadings on other factors to represent each dimension. If an item loaded above 0.40 on 
more than one factor, assignment of the item was to be based on logical fit and 
verification by item analysis (Stewart, 1981; Gorsuch, 1983; Beun, 1996).  
 
As for reliability, internal consistency was assessed by Cronbach’s alpha. 
Construct validity was studied using Pearson’s correlation coefficients to indicate the 
association between “patients’ trust in pharmacists” with “patients’ satisfaction with  
pharmacists’ service”, “willingness to return for care” and “preferred decision-making 
pattern on medication”.(Beun, 1996)  
 
  178
9.3 Results  
9.3.1 Scale development 
       Altogether four focus groups were shown to be adequate for item generation. 
Eighteen items were identified in literature review, focus group discussion and study 
team discussion. (Table 9.1) Because most of the items generated from the focus 
group discussion were the same as those identified in other studies, relevance of those 
items were analyzed based on a 5-point Likert scale (1=least relevant, 5=most 
relevant) (Items 1 to 17 in Table 9.1). Results showed that age, gender, ethnicity of the 
pharmacist might be less relevant to patients’ predisposing trust in pharmacists than 
the rest of the items. There were two brand new items generated from the focus group 
discussion: type of the pharmacist and set-up of the pharmacy counter. Some of the 
participants thought aloud that they preferred hospital pharmacists due to their rich 
experience with various illnesses. Additionally, “a neat and tidy pharmacy counter” 
was regarded as a reflection of professionalism and efficiency of pharmacists. Based 
on literature review, another item on global trust was also included (Item 18 in Table 
9.1) (Leisen and Hyman, 2001). 
 
       The questionnaire was assessed as having face validity by the pharmacy 
postgraduate students and as content valid by the expert panel of pharmacists. In the 
pilot test, the average completion time was 7.4 minutes. Score distribution of 18 items 
was shown to achieve good variability (SD>1.0) and symmetry (means ranged from -
1 to 1). In the open-ended question on readability of the questionnaire, quite a few 
respondents suggested to avoid using negative worded items so as to minimize 
confusion. Except for some minor wording changes, no other problems were raised. 
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After minor revisions, the questionnaire was finalized with 18 items as shown in 


























Table 9.1: Item generated from focus group approach and response analysis  
 Item  Source * Relevance † 
Mean (SD) 
1 Demonstrating up-to-date knowledge  3 4.32 (0.72) 
2.  Evaluating medical problems thoroughly  3 4.36 (0.68) 
3.  Keeping information totally private 
(confidentiality) 
3 4.75 (0.52) 
4. Demonstrating honesty when a mistake is made 3 4.32 (0.77) 
5.  Expressing concern  3 4.43 (0.69) 
6. Communicating clearly and completely 3 4.61 (0.50) 
7. Showing sufficient respect  3 4.57 (0.69) 
8. Providing effective medication at a reasonable 
price 
4 4.82 (0.48) 
9. Allowing shared decision-making pattern when 
there are alternatives.  
2 3.89 (0.69) 
    
Predisposing factors    
10. Age of the pharmacist  3 2.50 (1.28) 
11. Gender of the pharmacist  3 2.25 (1.18) 
12. Ethnicity of the pharmacist 1, 4  2.11 (1.10) 
13. Type of the pharmacist (Hospital, polyclinic, 
community, etc.) 
1 N/A 
14. Past experience with pharmacists 4 4.00 (0.90) 
15. Recommendation by others (friends, neighbors，
relatives, etc.) 
3 3.68 (0.72) 
16. Set-up of the pharmacy counter  1 N/A 
17. Professional appearance  3 4.14 (0.71) 
18.  Global trust in pharmacist  2 N/A  
*: 1= generated from focus group only; 2=generated from literature review only; 3=both 1 
and 2; 4=generated by the study team only  
†: Relevance is scored on a 5-point Likert scale (1=most irrelevant; 2=somewhat irrelevant; 
3=neutral; 4=somewhat relevant; 5=most relevant) from 28 participants. It is presented as 
Mean (SD).  





 Table 9.2: Item analyses of 18 candidate items 




1. I trust a pharmacist who has updated knowledge 1.58 (0.98) 0.39 
2. I trust the pharmacist if he/she evaluates my medical 
problem thoroughly. 
1.59 (0.99) 0.45 
3. I trust the pharmacist who could keep the information we 
discuss totally private. 
1.63 (1.05) 0.43 
4. I trust the pharmacist if he/she tells me about a mistake 
he/she has made on my medication. 
0.95 (1.35) 0.28 
5. I trust the pharmacist if he/she expresses concern and 
talks to me with reassuring and comforting words.  
1.47 (0.99) 0.41 
6. I trust the pharmacist if he/she could communicate with 
me clearly and completely.  
1.79 (0.87) 0.46 
7. I trust a pharmacist who shows sufficient respect for me.  1.75 (0.74) 0.43 
8. I trust the pharmacist if he/she provides me with 
effective medication at a reasonable price to me.  
1.60 (1.03) 0.46 
9. I trust the pharmacist if he/she allows me to make 
decision on which medication to take when there are 
alternatives.  
0.99 (1.19) 0.33 
10. I trust an older pharmacist more than a younger one.  0.44 (1.42) 0.32 
11. I trust a hospital pharmacist more than other types of 
pharmacist (community, polyclinic pharmacist, etc.)  
0.31 (1.41) 0.28 
12. I trust a pharmacist with professional appearance.  1.25 (1.07) 0.46 
13. I will trust other pharmacists if I have had pleasant past 
experience with another pharmacist.   
0.25 (1.48) 0.14 
14. I trust a pharmacist of the same race as myself more 




15. I trust a pharmacist of the same gender as myself more 




16. I trust a pharmacist who has been recommended by 
others (i.e., friends, neighbors or relatives, etc.)  
1.13 (1.06) 0.39 
17. I trust a pharmacist whose set-up of the counter is neat 
and tidy.  
1.19 (0.95) 0.37 
18. I trust a pharmacist so much that I always try to follow 
his/her advice.  
0.84 (1.14) 0.38 





9.3.2 Scale validation 
The finalized questionnaires were distributed to 1,206 eligible respondents. Data 
analysis was based on 1,196 respondents with complete answers on all 18 items of the 
trust scale. Demographic and background information was summarized in Table 9.3.  
 
Item analyses (Table 9.2) showed that five items (Items 4,11,13,14, and 15) were 
below the criteria of 0.3 in item-total correlation (Hinton et al., 2004), so they were 
dropped in the first round. When the 13 candidate items underwent the same analysis 
again, item 10 was found to be below the criteria (coefficient =0.12 <0.3), leaving 12 



















Table 9.3: Demographic and background information of respondents  
 N (%) unless specified otherwise 
Age * 38.6 (14.9) 
Female  617 (51.6) 
Ethnicity   
   Chinese 460 (38.5) 
   Malay  373 (31.2) 
   Indian  363 (30.4) 
Housing   
   Public housing  927 (77.5) 
   Private housing  254 (21.2) 
Presence of chronic medical problems 526 (44.0) 
Education level   
   ≤6 yrs of education  137 (11.5) 
   7 to 10 yrs of education  646 (54.0) 
   ≥11 yrs of education  394 (32.9) 
Last visit to a pharmacist   
   Within 1-3 months  671 (56.1) 
   Within 4-6 months  525 (43.9) 
Type of pharmacist visited last time   
   Hospital  294 (24.6) 
   Polyclinic  388 (32.4) 
   Community  507 (42.4) 
*: Age is presented as Mean (SD).  
 
Based on the criteria of eigenvalue and Scree plot, three factors were identified 
that accounted for 55% of the total variance with the first factor explaining up to 36%. 
Two items (Items 3 and 5) had dual loadings (loadings greater than 0.40 on two 
factors). Scale assignments for them were made on the basis of logical fit with other 
items loading on the two factors under consideration. Table 9.4 lists the factor loading 
and assignment of the 12 items.  
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alpha if item 
deleted  
Factor 1 (benevolence)  3 0.42 0.56 0.81 
 5 0.46 0.52 0.81 
 6 0.68 0.60 0.80 
 7 0.79 0.55 0.81 
 8 0.73 0.53 0.81 
 9 0.53 0.36 0.82 
     
Factor 2 (technical 
competence)  
1 0.84 0.52 0.81 
 2 0.82 0.60 0.80 
     
Factor 3 (global trust)  12 0.62 0.43 0.82 
 16 0.67 0.35 0.82 
 17 0.74 0.43 0.82 
 18 0.59 0.38 0.82 
 
 
 Factors were labeled as follows according to the order of extraction: (1) 
benevolence (including six items: confidentiality, expressing caring, communicating 
clearly and completely, showing sufficient respect, providing effective medication at a 
reasonable price and allowing shared decision-making pattern when there are 
alternatives); (2) technical competence (including two items: demonstrating up-to-
date knowledge and evaluating medical problem thoroughly); and (3) global trust 
including all other aspects that do not exclusively fit in any dimension (including four 
items: blind trust in pharmacists and predisposing factors such as recommendation by 
others, set-up of pharmacy counter and professional appearance) (Anderson and 
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Dedrick, 1990; Thom and Campbell, 1997; Kao et al., 1998; Swan et al., 1999; Leisen 
and Hayman, 2001).  
 
        Due to the observation that the correlation coefficients among three factors via 
Promax rotation were all less than 0.5, discriminatory power was demonstrated and a 
three-dimension scale structure was suggested (Kim and Mueller, 1978). As shown in 
Table 9.4, item-scale correlation coefficients were between 0.35 and 0.60. The 
Cronbach’s alpha was 0.83, indicating high internal consistency (Beun, 1996). 
Construct validity was demonstrated by the finding that, as hypothesized, patients’ 
trust in pharmacists was positively correlated with patients’ satisfaction with 
pharmacists’ service (r=0.54, P<0.001), returning for care (r=0.30, P<0.001) and 
preference of medical decision-making pattern (r=0.16, P<0.001). 
  
9.4. Discussion  
      In the current study, we developed and validated a 12-item scale to measure 
patients' trust in pharmacists. The 12-item scale which demonstrated high reliability 
and good construct validity could be further categorized into 3 factors, namely, 
technical competence, benevolence and global trust. To the best of our knowledge, the 
current study was the first one to develop and validate a scale to measure patients’ 
trust in pharmacists. Our study provided important contributions and implications in 
several ways:  
 
       First, as mentioned in the introduction, pharmacists are not only the key 
personnel to deliver high-quality pharmaceutical care, but they are expected to 
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contribute significantly to disease management due to the increasing prevalence of 
chronic diseases in our rapidly ageing societies and urging request for cost 
containment. Hence, the relationship between pharmacists and patients might directly 
or indirectly affect the final results of whether the disease management program such 
as effectiveness or cost-effectiveness. Therefore, the availability of such scale will 
enable the incorporation of “patients’ trust in pharmacists” as either a dependent or an 
independent variable in pharmacoeconomics and pharmaceutical care studies in 
various healthcare settings. Such evaluations would not only further contribute to the 
determination of the impact of patients' trust in pharmacists on economic analysis, but 
also to the better understanding of the key elements in such trust relationship between 
pharmacists and patients.  
 
Second, the current study served as a good example to show that in the 
application of cost-utility or other quality of life studies in the Asian countries, 
sometimes there is a need to develop and validate a new instrument from scratch. 
Such circumstances might include but are not limited to the universal lack of the 
measure or measures developed in Western countries could not be readily adapted to 
the East due to socio-cultural difference for instance. In such case, a systematic 
approach would be recommended to ensure the robustness of the results. For example, 
in the current study, items were generated by literature review and focus group 
approach, followed by item refinement using panel review and pilot testing; and scale 
validation was conducted by response analysis, reliability and validity tests and 
exploratory factor analysis. 
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Third, interestingly, the scale to measure patients’ trust in pharmacists was shown 
to have similar dimensionalities to the scale to measure patients’ trust in physicians. 
The two common dimensionalities were technical competence and benevolence. This 
implied that patients might tend to trust health care professionals based on similar 
criteria. In other words, technical competence and benevolence were the two most 
sought-after qualities that would help to build up patients' trust in health care 
professionals. If so, it is worthwhile for healthcare providers to put special efforts in 
enhancing technical competence and benevolence to obtain more trust from patients. 
A series of desired outcomes might be consequentially achieved, such as better 
communication between patients and health care professionals, enhanced compliance, 
which might translate into improved clinical outcomes, better health-related quality of 
life, and even positively influence the cost-effectiveness of disease management 
programs (Beun, 1996).  
 
In the mean time, several limitations together with suggestions for future studies 
should also be noted:   
First, since patients’ trust is a changeable psychological trait and not a steady 
state (Bruce, 2001; Thom et al., 2004), retest was not carried out in our study. 
Therefore, test-retest reliability remains unknown for the scale, retest may need to be 
carried out in future studies to explore the feasibility of retest and verify the 
robustness of the scale.   
 
Second, despite potential advantages of thinking of trust in perspectives of both 
patients and pharmacists, final-year pharmacy undergraduates may not well represent 
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pharmacy-visiting patients in the real world. Hence, it is possible that the items 
generated from those undergraduates might be different from patients with diversified 
backgrounds.   
 
Third, respondents of the current study tended to be healthier and better educated 
compared with the average pharmacy-visiting patients, due to use of self-
administration purposive sampling methodology. Such potential bias may lead to 
different emphasis on the items of trust in pharmacists, which may lead to somewhat 
different chosen items. Hence, it is suggested that future study be sampled on a more 
general heterogeneous population to further validate the scale.  
 
9.5 Conclusion 
      The 12-item scale, constructed on three factors, namely, benevolence, technical 
competence and global trust, to measure patients’ trust in pharmacists demonstrated 
high reliability and good construct validity. The availability of such scale would 
enable the incorporation of “patients’ trust in pharmacists” as an independent variable 
in pharmacoeconomic evaluations such as CUA to assess disease management 

























A Recapitulation of Major Findings, Contributions, 










10.1 General Introduction 
        In this last chapter, I would like to take the opportunity to recapitulate those 
major findings made in this thesis and evaluate how adequate have the studies 
performed answered the original questions posed at the beginning of the thesis. At the 
same time, the major contributions and limitations of our studies would also be 
highlighted, followed by some suggestions of future studies that would further 
contribute to the application of CUA in assessing disease management in Asian 
countries.  
 
10.2 Major findings  
        In the section of research questions in the Introduction Chapter (Section 1.5), we 
started off with the following questions in mind: 
(1) Is there any linguistic or cultural barrier in the adaptation of an English HRQoL or 
utility instrument into a non-English version? 
 (2) What are the factors that have been found to influence the application of CUA in 
the published literatures so far? 
 (3) Are there any other new factors that may potentially influence the application of 
CUA of disease management programs in Asia?  
 
        Specific to the three broad questions as mentioned above, individual studies were 
conducted as presented from Chapter 2 to Chapter 9. Major findings from these 




10.2.1 Addressing Research Question 1- impact of linguistic or cultural barrier  
  In Chapter 2, using the translating and adapting the English Audit of Diabetes-
Dependent Quality of life (ADDQoL) into a Chinese version as an illustrative 
example, we detected that minor, potential linguistic and cultural differences did exist 
between the original English version and the translated Chinese version. More 
importantly, to conquer such barriers, we found that the universalist approach was 
essential for the systematic translation and adaptation process. Such approach ensured 
that all important equivalences, namely, conceptual, item, semantic, operational, 
measurement and functional equivalences were investigated in a sequential manner 
and potential issues were picked up and solved throughout the whole process. In the 
end, we demonstrated that all those six types of equivalences were achieved and the 
Chinese ADDQoL was a reliable and valid diabetes-specific HRQoL instrument to be 
used in future studies among Chinese-speaking diabetic patients in Singapore.  
 
10.2.2 Addressing Research Question 2- Factors identified from published 
literature 
 In Chapter 3, by conducting a qualitative literature review to find out factors that 
have been demonstrated to influence CUA application or CUA results, altogether 20 
factors were identified in the published literature. They could be further grouped into 
five categories as treatment-related (duration, efficacy, and frequency of treatment), 
disease-related (severity level, risk level, incidence rate, prevalence rate, disease 
progression rate and survival length), patient-related (age, gender, race/ethnicity and 
compliance), cost-related (treatment cost, incorporation of indirect cost), and 
methodology-related factors (discount rate, QALY elicitation method, statistical 
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uncertainty, handling of confounding variables and reliability of data source). We also 
found that most of the CUA studies included in the literature review were conducted 
in Western countries, suggesting that very few studies in Asia have adequately 
explored the potential influence of those factors on their CUA results. It further 
encouraged us to devote our efforts to enhance the robustness of applying CUA 
studies in Asian countries.  
 
10.2.3 Addressing Research Question 3-Exploring other new factors 
       In the current thesis, we focused our efforts on the exploration of two patient 
empowerment-related factors (namely, disease knowledge and health literacy) and 
three health psychology-related factors (namely, response shift, expectancy-value, and 
trust in pharmacists).  
 
10.2.3.1 Patient-empowerment factors 
        In chapter 4, we used diabetes knowledge as an illustrative example to explore its 
potential impact on health utility values. In this preliminary study among English-
speaking diabetic patients, we found that the correlation between diabetes knowledge 
(measured by GDKT) and health utility values (measured by generic health utility 
instruments as EQ-5D and SF-6D) was rather minimal, suggesting the impact of 
diabetes knowledge on the generic health utility values was lacking. Although not 
statistically significant, diabetes knowledge was found to be weakly correlated with 
disease-specific HRQoL score as measured by ADDQoL. However, after adjusting for 
other variables, diabetes knowledge had no further impact on ADDQoL scores, 
suggesting potential lack of impact on health utilities generated by disease-specific 
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health profile measures.  
 
        With special regards to health literacy, in Chapter 5 we found that in the cross-
sectional study among patients with rheumatic diseases, health literacy level as 
measured by the word recognition test, called the "Rapid Estimate of Adult Literacy 
in Medicine" (REALM) did not impact health utility scores as measured by either SF-
6D or EQ-5D. Furthermore, it was also found that health literacy level did not 
influence HRQoL as measured by SF-36 in general. Although there was a statistically 
significant correlation between health literacy level and physical functioning which 
persisted after adjusting for other variables, the strength of this correlation was weak 
and only had an explanatory power of less than 4%. No significant impact of health 
literacy was found on the remaining seven SF-36 domains.   
 
        However, despite the advantage of convenience in administering REALM, 
researchers have questioned on the accuracy and sensitivity of using REALM to 
reflect actual health literacy levels, as REALM is only a word recognition test.  Hence, 
it might fail to measure patients' comprehension capabilities, that is, functional health 
literacy levels. Besides, there was no functional health literacy test that was readily 
available to be used among general public, who are also the important target audience 
in various disease management programs such as disease education and prevention 
programs. Hence, in chapter 6, we developed and validated a generic functional health 
literacy test (GFHLT) for use among the English-speaking general public. The 21-
item GFHLT demonstrated adequate reliability, good face, content and construct 
validities and sufficient item discrimination power. Besides, the average completion 
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was only about 3 minutes, showing promising feature of a screening test.  
 
10.2.3.2 Health psychology-related factors 
In the 18-month follow up study of patients undergoing TKR (Chapter 7), the 
presence of response shift was detected and its impact on both HRQoL and utility 
assessment was quantified using the then-test approach. We found that response shift 
was present at both baseline and six months after TKR, and significantly influenced 
HRQoL scores. It suggested that treatment effect may be masked by response shift, 
due to gradual adaptation to an improving health status of patients. This may have an 
impact on the use of conventional pre- and post-test methods to assess improvement 
in HRQoL and utility scores, which could generate further impact on CUA evaluation 
of longitudinal disease management programs.    
 
In the application of CUA, patients actually play a very important role as health 
utilities are usually generated by their subjective assessment of different health states. 
Hence, it is necessary to understand the variances in health utility values from a 
psychological perspective. In the exploratory study to investigate the power of 
expectancy-value model (EVM) in explaining health preferences (Chapter 8), we 
found that compared with models that only incorporated external variables, EVM that 
incorporated both external variables and attitudinal attributes could explain a much 
larger proportion of the variances in health preferences. Besides, EVM could further 
explore the contributions of each component, either attitudinal attribute or external 
variable, to identify important factors that influence results of health preferences-
based health utilities and quantify their magnitude as well.  
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Last but not least, we also developed and validated a 12-item scale to measure 
patients' trust in pharmacists, as such factor could influence quite a number of aspects 
(such as treatment outcomes, health-related quality of life, health utilizes, treatment 
cost), which would have a final impact on the CUA results. Based on our results, the 
12-item scale was found to be constructed on three factors, namely, technical 
competence, benevolence and global trust. The scale demonstrated high reliability and 
good construct validity.  
 
10.3 Main contributions  
        In general, the results from the studies performed for this thesis would contribute 
to the improved understanding of both the theoretical and practical issues that affect 
the feasibility, reliability and robustness of applying CUA analysis in assessing 
disease management programs in Asian countries. The main contributions of the 
studies are summarized as follows:  
 
        First and foremost, to the best of our knowledge, we provided a pioneering 
example of using the universalist approach to address how to properly overcome the 
linguistic and cultural barrier in translating and adapting a measure to ensure its 
reliability and validity in a different population. Such approach could be further 
applied by researchers in Asia when they plan to incorporate certain foreign measures 
for data collection on some parameters for cost-utility analyses.  
 
       Second, the factors as identified from the qualitative review served as a 
comprehensive (albeit not complete) reference list to Asian researchers and decision 
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makers when conducting CUA. With this reference list, they could then selectively 
incorporating potentially influential factors in the sensitivity analyses to test the 
robustness of the results based on different scenarios.  This potentially would improve 
the acceptability of CUA for assessment of cost-effectiveness of disease management 
programs by decision makers. 
 
        Third, in this thesis, we also initiated the exploration of other new factors and the 
findings contributed to the further understanding and potential expansion of the 
reference list that we have generated. Although theoretically speaking, factors such as 
disease knowledge and health literacy may affect patients' empowerment capabilities 
in disease management, yet their impact on the final CUA results might be quite 
minimal as such factors are more likely to exert indirect influences. Comparatively, 
health psychology-related factors tended to play a more influential role. Response 
shift was suggested as an important factor to be included into the reference list due to 
its impact on longitudinal assessment that would often be used in CUA of disease 
management programs. Furthermore, we successfully applied the expectancy-value 
model to explain variances in health preferences, which could be used as a 
complementary tool to understand the differences in health utility values that would 
be generated from various individuals or populations.  
 
       Last but not least, we also developed and validated two new scales from scratch, 
such as GFHLT and patients' trust in pharmacists, which built up a new platform for 
further exploration of their impact on CUA or other future studies that require the 
measurement of these two factors.  
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10.4 Main limitations  
       The limitations have been discussed in details in the individual chapters. The 
main limitation we would like to address here is the sampling issue. Due to the 
constraint of project timeline and limited resources, we were not able to apply 
probability sampling or purposive sampling to recruit a more representative sample 
with a substantially larger number of respondents in most of our studies. Hence, it is 
recommended that our results should be considered as preliminary findings. Cautions 
should be taken when generalizing our results to a larger and more diversified study 
population. Besides, due to the lack of knowledge in Malay or Tamil languages and 
limited financial resources, the study subjects we recruited were either Chinese-
speaking or English-speaking Singaporeans. Hence, the findings of the new factors 
might not be readily applicable to those Malay or Tamil-speaking population in Asia 
without further verification.  
 
10.5 Future studies  
        The findings and limitations in the thesis have raised some new concerns and 
research questions that could be further investigated in future studies.  
 
       (1) What are the other factors that will impact the application of CUA in 
assessing disease management in Asia? Based on the two new scales we have 
developed in the thesis, future studies could focus on the exploration of the influence 
of functional health literacy and patients' trust in pharmacists. Besides, any other new 
factor, not restricted to the two categories (namely, patient-empowerment strategies 
and health psychology) as we proposed in the thesis, could be investigated to further 
  198
verify and expand the current reference list of the influential factors.  
       (2)  What would be the impact of the factors (disease knowledge, health literacy, 
response shift, and expectancy-value) as we explored on a different population in Asia? 
Those new results could further verify our findings or lead to the modification of 
findings in that particular population.  
       (3)    It would also be meaningful and interesting to perform actual CUA studies 
to assess disease management programs in Asia, in which magnitude of impact of 
various factors in the reference list would be examined to improve understanding in 
real case scenarios.   
 
       We believe the above studies would further complement the findings in this thesis. 
They would continue to contribute to the emerging and robust application of CUAs to 
assess disease management programs in Asia countries for the sustainability of health 
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Appendix 2.1 The ADDQoL-English version 
 
This questionnaire asks about your quality of life – in other words how good or bad you 
feel your life to be. 
 
Please put a “9” in the box that best indicates your response for each item. 
There are no right or wrong answers. We just want to know how you feel.  
 
1 In general, my present quality of life is: 
        
 excellent very good good neither 
good nor 
bad 
bad very bad extremely 
bad 
 
Now we would like to know how your quality of life is affected by your diabetes, its 
management and any complications you may have.   
2 If I did not have diabetes, my quality of life would be: 
      
 very much 
better 
much  better a little better the same worse 
 
Please respond to the following more specific questions.  For each aspect of life 
described: 
For Part (a):      put an “X” in one box to show how diabetes affects this aspect of your 
life; 
For Part (b): put an “X” in one box to show how important this aspect of your life 
is to your quality of life. 
 
3 Do you have family / relatives? 
 yes  If ‘yes’, please continue with parts (a) and (b) 
 no  If ‘no’, please go to question 10. 
 (a) If I did not have diabetes, my family life would be 
      
 very much 
better 
much better a little better the same worse 
 (b) My family life is: 
     
 very important important somewhat 
important 
not at all important
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4 (a) If I did not have diabetes, my friendships and social life would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) My friendships and social life are: 
     
 very important important somewhat 
important 
not at all important
 
5 Do you have or would you like to have a close personal relationship? 
 yes  If ‘yes’, please continue with parts (a) and (b) 
 no  If ‘no’, please go to question 12. 
 (a) If I did not have diabetes, my closest personal relationship would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) For me, having a close personal relationship is: 
     
 very important important somewhat 
important 
not at all important
 
6 Do you have or would you like a sex life? 
 yes  If ‘yes’, please continue with parts (a) and (b) 
 no  If ‘no’, please go to question 13. 
 (a) If I did not have diabetes, my sex life would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) For me, a sex life is: 
     
 very important important somewhat 
important 
not at all important 
 
7 (a) If I did not have diabetes, my physical appearance would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) My physical appearance is: 
     
 very important important somewhat 
important 




If I did not have diabetes, physically I could do: 
      
 very much 
more 
much more a little more the same less 
 (b) For me, how much I can do physically is: 
     
 very important important somewhat 
important 
not at all important
 
9 Are you currently working, looking for work or would you like to work? 
 yes  If ‘yes’, please continue with parts (a) and (b) 
 no  If ‘no’, please go to question 16. 
 (a) If I did not have diabetes, my working life would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) For me, working life is: 
     
 very important important somewhat 
important 
not at all important 
 
10 Do you ever go on holiday or want to go on holiday? 
 yes  If ‘yes’, please continue with parts (a) and (b) 
 no  If ‘no’, please go to question 17. 
 (a) If I did not have diabetes, my holidays would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) For me, holidays are: 
     
 very important important somewhat 
important 
not at all important 
 
11 (a) If I did not have diabetes, I would enjoy my leisure activities: 
      
 very much 
more 
much more a little more the same less 
 (b) My leisure activities are: 
     
 very important important somewhat 
important 
not at all important
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12 (a) If I did not have diabetes, local or long distance journeys would be: 
      
 very much 
easier  
much easier a little easier the same more difficult 
 (b) For me, local or long distance journeys are: 
     
 very important important somewhat 
important 
not at all important
 
13 (a) If I did not have diabetes, my self-confidence would be: 
      
 very much 
greater 
much greater a little greater the same less 
 (b) My self-confidence is: 
     
 very important important somewhat 
important 
not at all important
 
14 (a) If I did not have diabetes, my motivation would be: 
      
 very much 
greater 
much greater a little greater the same less 
 (b) My motivation is: 
     
 very important important somewhat 
important 
not at all important
 
15 (a) If I did not have diabetes, the way people in general react to me would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) The way people in general react to me is: 
     
 very important important somewhat 
important 
not at all important
16 (a) If I did not have diabetes, my feelings about the future (e.g. worries, hopes) 
would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) My feelings about the future are: 
     
 very important important somewhat 
important 
not at all important
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17 (a) If I did not have diabetes, my financial situation would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) My financial situation is: 
     
 very important important somewhat 
important 
not at all important
 
18 (a) If I did not have diabetes, I would have to depend on others (when I do not 
want to): 
      
 very much less much less a little less the same more 
 (b) For me, not having to depend on others is: 
     
 very important important somewhat 
important 
not at all important
 
19 (a) If I did not have diabetes, my living conditions would be: 
      
 very much 
better 
much better a little better the same worse 
 (b) My living conditions are: 
     
 very important important somewhat 
important 
not at all important
 
20 (a) If I did not have diabetes, my freedom to eat as I wish would be: 
      
 very much 
greater 
much greater a little greater the same less 
 (b) My freedom to eat as I wish is: 
     
 very important important somewhat 
important 
not at all important
21 (a) If I did not have diabetes, my freedom to drink as I wish (e.g. sweetened hot 
and cold drinks, fruit juice, alcohol) would be: 
      
 very much 
greater 
much greater a little greater the same less 
 (b) My freedom to drink as I wish is: 
     
 very important important somewhat 
important 
not at all important
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1 总得来说， 我现在的生活素质是:  
        





2 如果我没有糖尿病,  我的生活素质将会:  
      







 有  如果有,请接着回答(a)和(b)  
 没有  如果没有,请前往第 10题 
 (a) 如果我没有糖尿病,  我的家庭生活将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 我的家庭生活： 
     












4 (a) 如果我没有糖尿病,  我的友谊和社交生活将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 我的友谊和社交生活： 
     
 很重要 重要 有些重要 根本不重要 
5 你有没有或想不想有一个关系亲近的人？ 
 有/ 想  如果有,请接着回答(a)和(b)  
 没有/ 不想  如果没有,请前往第 12题 
 (a) 如果我没有糖尿病,  我和我关系最亲近的人将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 对我来说, 有一个关系亲近的人： 
     
 很重要 重要 有些重要 根本不重要 
 
6 你有没有或想不想有性生活？ 
 有/ 想  如果有,请接着回答(a)和(b)  
 没有/ 不想  如果没有,请前往第 13题 
 (a) 如果我没有糖尿病, 我的性生活将会：  
      
 好特别多 好很多 好一点 一样 更差 
 (b) 对我来说, 拥有性生活： 
     
 很重要 重要 有些重要 根本不重要 
 
7 (a) 如果我没有糖尿病,我的外貌将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 我的外貌： 
     










8 (a) 如果我没有糖尿病,我体能上能做的将会： 
      
 增加特别多 增加很多 增加一点 一样 更少 
 (b) 对我来说,能做多少体能活动： 
     
 很重要 重要 有些重要 根本不重要 
 
9 你目前是否在工作、找工作或想去工作？ 
 是  如果是,请接着回答(a)和(b)  
 否  如果否,请前往第 8题 
 (a) 如果我没有糖尿病,  工作生活将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 对我来说, 拥有工作生活： 
     
 很重要 重要 有些重要 根本不重要 
 
10 你曾经去度假或想去度假吗？ 
 有  如果有,请接着回答(a)和(b)  
 没
有
 如果没有,请前往第 17题 
 (a) 如果我没有糖尿病,  我的假期将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 对我来说,假期： 
     
 很重要 重要 有些重要 根本不重要 
 
11 (a) 如果我没有糖尿病,  我享受消闲活动的乐趣将会： 
      
 增加特别多 增加很多 增加一点 一样 更少 
 (b) 我的消闲活动： 
     









12 (a) 如果我没有糖尿病,  本地或长途旅程将会： 
      
 特别容易多 容易多 容易一点 一样 更难 
 (b) 对我来说, 本地或长途旅程： 
     
 很重要 重要 有些重要 根本不重要 
 
13 (a) 如果我没有糖尿病,  我的自信心将会： 
      
 特别高 很高 高一点 一样 更少 
 (b) 我的自信心： 
     
 很重要 重要 有些重要 根本不重要 
 
14 (a) 如果我没有糖尿病,  我的推动力将会： 
      
 特别多 很多 多一点 一样 更少 
 (b) 我的推动力： 
     
 很重要 重要 有些重要 根本不重要 
 
15 (a) 如果我没有糖尿病,  别人通常对我的反应将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 别人通常对我的反应： 
     
 很重要 重要 有些重要 根本不重要 
 
16 (a) 如果我没有糖尿病,  我对将来的心情 (比如，担心、希望等等) 将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 我对将来的心情： 
     










17 (a) 如果我没有糖尿病,  我的经济情况将会： 
      
 好特别多 好很多 好一点 一样 更差 
 (b) 我的经济情况： 
     
 很重要 重要 有些重要 根本不重要 
 
18 (a) 如果我没有糖尿病,  我必须依赖别人(当我不想依赖别人)时将会： 
      
 少特别多 少很多 少一点 一样 更多 
 (b) 对我来说, 不须依赖别人： 
     
 很重要 重要 有些重要 根本不重要 
 
19 (a) 如果我没有糖尿病,  我的居住状况将会：  
      
 好特别多 好很多 好一点 一样 更差 
 (b) 我的居住状况： 
     
 很重要 重要 有些重要 根本不重要 
 
20  (a) 如果我没有糖尿病,  我想吃什么就吃什么的自由将会： 
      
 增加特别多 增加很多 增加一点 一样 更少 
 (b) 我想吃什么就吃什么的自由： 
     
 很重要 重要 有些重要 根本不重要 
 
21 (a) 如果我没有糖尿病,  我想喝什么就喝什么的自由(比如果汁、酒、冷热甜饮料) 将会： 
      
 增加特别多 增加很多 增加一点 一样 更少 
 (b) 我想喝什么就喝什么的自由(比如果汁、酒、冷热甜饮料)： 
     









Appendix 4.1   
The General Diabetes Knowledge Test 
 
This questionnaire asks about your knowledge of diabetes. Please tick the most appropriate 
answer.  
 
Question Yes No Unsure 
1. General Knowledge of diabetes    
a. Diabetes is a condition of high blood sugar    
b. Type 1 diabetes is a condition of insufficient insulin    
c. Type 2 diabetes is a condition of the body not responding to 
insulin    
d. Diabetes is non-contagious    
e. Diabetes is not curable.     
    
2. Risk factors of diabetes.    
The following are risk factors of diabetes:     
a. Family history of diabetes    
b. Age above 40 years old    
c. Obesity    
    
3. Symptoms of diabetes    
The following are symptoms of diabetes:     
a. Constant feeling of thirst    
b. Frequent urination    
c. Weight loss despite normal appetite    
d. Blurred vision    
e. Slow healing of cuts and wounds    
f. Tiredness and weakness    
    
4. Complications of diabetes    
The following are complications of diabetes:     
a. Decaying limbs that require surgical removal    
b. Eye problems    
c. Kidney problems    
d. High blood pressure    
e. Loss of sensation in arms and legs    
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Question Yes No Unsure 
5. Treatment and management of diabetes.    
a. Insulin injections are available for the control of diabetes    
b. Tablets and capsules are available for the control of diabetes    
c. Diabetics should carry sweets and jelly beans when they are out    
d. Diabetics should exercise regularly    
e. Diabetics should have good weight control    
f. Diabetics should go for regular eye check-up    
g. Diabetics should have a low fat and high fiber diet    
h. Diabetics should care for their toes and feet    
i. Diabetics should not consume alcohol    
j. Diabetics should not donate blood    
k. Diabetics should not smoke    
l. Diabetics should not wear tight shoe    
m. Diabetics should not skip meal when busy    
    
6. Monitoring of diabetes    
a. Diabetics should test for blood glucose    
b. Diabetics should test for sugar in the urine    
c. Diabetics should make regular visits to the eye doctor    
d. Diabetics should go for regular medical check-ups    
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Appendix 5.1  
Rapid Estimate of Adult Literacy in Medicine (REALM) 
REALM score sheet                       
LIST 1 LIST 2 LIST 3 
1) Fat _________ 1) Fatigue ________ 1) Allergic _______ 
2) Flu _________ 2) Pelvic _________ 2) Menstrual ______ 
3) Pill _________ 3) Jaundice _______ 3) Testicle  _______ 
4) Dose ________ 4) Infection _______ 4) Colitis _________ 
5) Eye _________ 5) Exercise ________ 5) Emergency _____ 
6) Stress___________ 6) Behavior ________ 6) Medication _____ 
7) Smear _________ 7) Prescription _____ 7) Occupation _____ 
8) Nerves _________ 8) Notify  _________ 8) Sexually _______ 
9) Germs __________ 9) Gallbladder _____ 9) Alcoholism _____ 
10)Meals __________ 10) Calories _______ 10) Irritation ______ 
11) Disease ________ 11) Depression _____ 11) Constipation____ 
12) Cancer_________ 12) Miscarriage ____ 12) Gonorrhea _____ 
13) Caffeine________ 13) Pregnancy _____ 13) Inflammatory___ 
14) Attack ________ 14) Arthritis _______ 14) Diabetes_______ 
15) Kidney ________ 15) Nutrition ______ 15) Hepatitis_______ 
16) Hormones _____ 16) Menopause ____ 16) Antibiotics _____ 
17) Herpes ________ 17) Appendix ______ 17) Diagnosis ______ 
18) Seizure ________ 18) Abnormal ______ 18) Potassium ______ 
19) Bowel _________ 19) Syphilis ________ 19) Anemia ________ 
20) Asthma ________ 20) Hemorrhoids ___ 20) Obesity _______ 
21) Rectal _________ 21) Nausea ________ 21) Osteoporosis ___ 
22) Incest _________ 22) Directed _______ 22) Impetigo ______ 
# of (+) in list 1:______ # of (+) in list 2:______ # of (+) in list 3:______ 












Appendix 6.1  
Generic Functional Health Literacy Test (GFHLT) 
Instructions for respondents and research assistants:  
1) Please carefully record down your start time and end time! (Research assistant, please help 
respondents fill in the time if necessary). Please note that maximum completion time is 3 
minutes! After 3 minutes, please hand over your answers to the research assistants 
immediately! 
2) The following passage is selected from a health education material published by the 
Singapore Health Promotion Board. Please circle only 1 word you consider as the most 
appropriate from the 3 candidate items.  
 
Guidelines on Taking Medicines 
 
1. When you receive medicine from your pharmacist or doctor, you must understand fully 
how to use your medicine before you leave. Listen carefully to the (speech / instructions 
/ then) and check against the (label / poster / stand) on the medicine container. 
(Wonder/ Ask / Listen) when you do not (read/ understand / play) the instructions or 
when (they/ we / yours) are not clear. You (need/ should / well) know the following:  
Name (thus/ and / or) strength of the medicine, 
(Aim/ Purpose / Right) of the medicine,  
Directions (to / for / and) use,  
Any activity, food and (others/ other / which) medicines to be avoided,  
(How/ Any / An) side effects to look (up/ out/ to) for.  
2.  Be sure you (track/ follow / ignore) the instructions. Do not (overwhelm/ exceed / reach) 
the stated dose or (mass/ treatment/ illness) period.  
3. If you are (eating/ prescribed/ stating) antibiotics, make sure you (complete/ end / stop) 
the prescription.  
4. Discard expired (medicines/ utensils/ drinks) as they may no (shorter/ less/ longer) be 
effective.  
5. Please always (interact/ check / ask) with your pharmacist before (finishing/ taking / 
learning) any over-the-counter medicines. 
 
Instructions of scoring Generic health literacy test (the next page)  
1. Please calculate the time of completion: _______ minutes  



















Appendix 8.1  
A complete set of questions and answers used to study both “expectancy” and “value” 
of health state “11121” as an example.    
 
Instruction: Please answer the following questions by circling ONLY ONE number.  







1a) Do you think that living in this health state for the rest of your life will worsen your 
quality of life in terms of health?  
 
 
1b)   You think that worsening of your quality of life in terms of health is ______. 
 
Extremely 







good  Very good  
Extremely 
good
-3 -2 -1 0 1 2 3 
 
1c) Do you think that living in this health state for the rest of your life will add a burden to 














-3 -2 -1 0 1 2 3 
 
1d) You think that adding a burden to your family is ___________.  
 
Extremely 







good  Very good  
Extremely 
good

















-3 -2 -1 0 1 2 3 
 No problems in walking about  
 No problems in washing or dressing yourself  
 No problems in performing usual activities  
 Moderate pain or discomfort  
 Not anxious or depressed  
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-3 -2 -1 0 1 2 3 
 
1f) You think that making you less independent is ____________.   
 
Extremely 







good  Very good  
Extremely 
good
-3 -2 -1 0 1 2 3 
 
1g) Do you think that living in this health state for the rest of your life will make you not able 














-3 -2 -1 0 1 2 3 
 
1h) You think that making you not being able to work or study is ___________.  
 
Extremely 







good  Very good  
Extremely 
good


















Appendix 9.1  
The 18-item scale to measure patients' trust in pharmacists  
1. I trust the pharmacist who has updated knowledge.  
 
Totally          Strongly      Somewhat      Neutral             Somewhat    Strongly      Totally 
disagree        disagree      disagree                                    agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
2. I trust the pharmacist if he/she evaluates my medical problem thoroughly.  
 
Totally          Strongly      Somewhat      Neutral              Somewhat   Strongly      Totally 
disagree        disagree      disagree                                     agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
3. I trust the pharmacist who could keep the information we discuss totally private. 
  
Totally          Strongly      Somewhat       Neutral              Somewhat   Strongly      Totally 
disagree        disagree      disagree                                       agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
4. I trust the pharmacist if he/she tells me about a mistake he/she has made on my medication.  
 
Totally          Strongly      Somewhat        Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                 agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
5. I trust the pharmacist if he/she expresses concern and talks to me with reassuring  
and comforting words. 
 
Totally          Strongly      Somewhat        Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
6. I trust the pharmacist if he/she could communicate with me clearly and completely.  
 
Totally          Strongly      Somewhat         Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                  agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
7. I trust a pharmacist who shows sufficient respect for me.  
 
Totally          Strongly      Somewhat    Neutral             Somewhat   Strongly      Totally 
disagree        disagree      disagree                                  agree            agree           agree 









8. I trust the pharmacist if he/she provides me with effective medication at a   reasonable price 
to me.  
 
Totally          Strongly      Somewhat            Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                     agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
9. I trust the pharmacist if he/she allows me to make decision on which medication to take 
when there are alternatives.  
 
Totally          Strongly      Somewhat           Neutral          Somewhat   Strongly      Totally 
disagree        disagree      disagree                                      agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
10. I trust an older pharmacist more than a younger one.  
 
Totally          Strongly      Somewhat             Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                     agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
11. I trust a hospital pharmacist more than other types of pharmacist (community pharmacist, 
polyclinic pharmacist, etc.).  
 
Totally          Strongly      Somewhat           Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                    agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
 
12. I trust a pharmacist with professional appearance.  
  
Totally          Strongly      Somewhat              Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                       agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
13. I will not trust other pharmacists again if I have an unpleasant past experience with a 
certain pharmacist.  
 
Totally          Strongly      Somewhat              Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                      agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
14. I trust a pharmacist of the same race as myself more than other races.   
 
Totally          Strongly      Somewhat            Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                    agree            agree           agree 







15. I trust a pharmacist of the same gender as myself more than the opposite gender. 
 
Totally          Strongly      Somewhat            Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                    agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
16. I trust a pharmacist who has been recommended by my friends, neighbors or relatives.  
 
Totally          Strongly      Somewhat            Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                    agree            agree           agree 
-3 -2 -1 0 1 2 3 
17. I trust a pharmacist whose set-up of the counter is neat and tidy.  
 
Totally          Strongly      Somewhat            Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                    agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
18. I trust a pharmacist so much that I always try to follow his/her advice.  
 
Totally          Strongly      Somewhat            Neutral        Somewhat   Strongly      Totally 
disagree        disagree      disagree                                     agree            agree           agree 
-3 -2 -1 0 1 2 3 
 
 
